Explore the complete list of our presses below:
Chronic disease drugs fueling Indian pharma boom! Industry to see double-digit growth with new product launches.
A study reveals nearly 2 million people in England and Scotland suffer from long COVID, impacting daily activities and workforce participation.
AbbVie & Gilgamesh join forces to develop neuroplasticity-based treatments for mood & anxiety disorders.
Infinity Labs doubles down on quality! ISO certification ensures excellence in chemical & microbiological testing.
India's Bharat Biotech & Bilthoven team up to ensure reliable supply of Oral Polio Vaccine (OPV) worldwide.
Breakthrough in liver disease treatment! New collaboration focuses on regenerative therapies for chronic liver disease.
The FDA warned Cardinal Health for distributing unapproved Chinese syringes under the Monoject brand, citing risks to medical device safety and compliance.
Catalent plans to lay off 130 employees in Bloomington, Indiana, as part of its restructuring, despite a $16.5B acquisition offer from Novo Holdings.
Zydus Lifesciences secures US FDA approval for Dapsone Gel 7.5%. An effective acne treatment, it targets bacterial growth and inflammation.
Charles River demonstrates its commitment to environmental responsibility through investments and partnerships.
Cresset establishes its new India headquarters in Bangalore to serve the expanding market for computational drug discovery solutions in Asia Pacific.
NHS patients with PAH to benefit from cutting-edge digital technology - personalized care for a life-threatening condition.
DP007 - a new hope for respiratory patients and the planet! Lowers global warming potential compared to current inhalers.
FDA approves Roche's Lp(a) test - a game-changer for identifying patients who can benefit from innovative cholesterol-lowering treatment.
A child in Ontario has died of measles, marking the first such death in a decade. The child was unvaccinated, highlighting concerns about vaccine hesitancy.
Funding boost for Grey Wolf Therapeutics' innovative approach to fighting cancer and autoimmune diseases.
GSK's depekomab targets eosinophilic asthma, offering new hope for millions struggling with severe asthma.
AstraZeneca admits rare thrombosis with thrombocytopenia syndrome (TTS) risk in its COVID-19 vaccine. Legal acknowledgment may lead to settlements.
Eli Lilly expands Indiana plant with a $9 billion investment, creating hundreds of new jobs and boosting production of key diabetes and obesity drugs.
New technology slashes cell therapy production costs by automating the process, paving the way for wider access.
Nestle introduces Vital Pursuit, a $5 line of frozen pizzas and protein pasta for people on weight-loss drugs Wegovy and Ozempic, packed with nutrients.
NIBRT launched a new advanced therapies facility in Dublin, expanding research and training for innovative biomedicines like gene therapies and vaccines.
Novartis invests $256M in Singapore to expand antibody drug manufacturing, boost efficiency with digital tech, and create 100 skilled jobs.
The global pharmaceutical chemicals market is projected to reach $278.76B by 2029, driven by chronic diseases, personalized medicine, and innovative research.
India’s pharmaceutical sector sees Rs 28,328 crore investment under PLI scheme, with significant growth in bulk drugs and medical devices.
Don't miss Pharma Now's latest offerings! Explore innovations & resources at the PharmaLabChem Expo.
Recce Pharmaceuticals ramps up production of new synthetic antibiotic to combat global health threat.
Promising results from Zerion Pharma's Dispersome® technology suggest it could improve existing cystic fibrosis treatments.
Sartorius and TheWell Bioscience join forces to develop innovative 3D cell models, potentially revolutionizing drug testing.
Schreiner MediPharm's innovative service tailors RFID labels on demand, reducing costs and boosting pharmaceutical supply chain efficiency.
Shweta Munjal becomes Chief Communication & CSR Officer at Glenmark Pharmaceuticals, bringing 20+ years of leadership in communications, marketing, and CSR.
South Korea faces a worsening doctor shortage in small cities, amplified by a 3-month trainee doctor strike against policies to boost medical school admissions.
Strides Pharma’s subsidiary gets USFDA approval for generic Sucralfate Oral Suspension, 1gm/10ml, for treating ulcers and GERD, with a market size of USD 124M.
Sun Pharma acquires the remaining 21.52% of Taro Pharmaceuticals for ₹2,891.76 crore, completing the merger, and Taro's shares will be delisted from NYSE.
The global pharmaceutical chemicals market is projected to reach $278.76B by 2029, driven by chronic diseases, personalized medicine, and innovative research.
Learn about TekniPlex Healthcare's participation in The Pharma Days event, where they will showcase their range of sustainable blister packaging solutions.
The U.S. proposes reclassifying marijuana to Schedule 3 to promote research, easing restrictions for cannabis companies, and enabling stock exchange listings.
Thermo Fisher is to lay off 74 employees at its Carlsbad plasmid DNA facility by May 31, 2024, citing demand fluctuations, per a WARN Act report.
Torbay Pharma appoints new COO and CPO to boost growth in North America, addressing supply chain challenges and rising demand for essential medicines.
TriLink BioTechnologies teams up with Johns Hopkins University to accelerate RNA therapeutics research with CleanScript.
Bayer concludes its joint venture with Zydus Lifesciences, acquiring full ownership of Bayer Zydus Pharma Private Ltd.
UPS Healthcare opens a new logistics facility in Dublin, providing end-to-end solutions and creating 30 new jobs.
New FDA regulations enforce stringent oversight of Laboratory Developed Tests to ensure their safety and effectiveness.
New clinical trial reveals promising outcomes for a personalised liver cancer vaccine, showing significant tumour regression.
Register for the “Sterility Testing in Pharmaceuticals” webinar by MicroVerse on June 9, 2024, featuring expert insights and networking.
British pharmacies cut prices on weight-loss treatments Wegovy and Mounjaro amid high demand and competitive market dynamics.
The World Bank Group commits to extending affordable healthcare access to 1.5 billion individuals by 2030 through innovative strategies and partnerships.
Novo Nordisk's weight-loss drug Wegovy shows promise for obese individuals with specific genetic profiles, aiding targeted weight loss.
Torrent Pharma tackles heartburn! Launches Kabvie, a new drug for GERD in India. Expected to be a game-changer for millions.
Confused about Biosimilars? Get the facts on how they offer same benefits as biologics at a fraction of the cost.
Orano Med's new lab to produce 100,000 lead-212 doses annually, offering a powerful new weapon against cancer.
FDA inspection finds major issues at Hengrui's China facility. Contamination control, cleaning & documentation flagged.
Vetter is expanding its U.S. and Germany operations, moving its facility to Des Plaines, and investing in Saarlouis, creating 2,000 jobs by 2030.
Big news in gut health! Nestlé acquires VOWST, a promising therapy to prevent C. Diff recurrence, expanding its reach in microbiome treatment.
The Pharma Packaging market is on fire! A new report predicts a surge to over $15 billion by 2032, driven by sustainability & automation.
GSK's Blenrep, combined with pomalidomide and dexamethasone, significantly reduces multiple myeloma progression risk by 50%
Wockhardt UK steps up! Secures £20 million funding to modernize facilities & expand vaccine production. Read more about their plans here.
Healthcare logistics on the rise! Market expected to surge by $121 billion by 2028, driven by pharma sales & cold chain advancements.
how BioXcel Therapeutics' AI platform accelerates drug development and promotes sustainability through efficient drug repurposing.
Schneider Electric takes center stage at ACHEMA 2024! EcoStruxure for Life Sciences promises to revolutionize sustainable pharma manufacturing.
Syntegon ups its game! Global leader acquires Telstar, boosting liquid pharma processing & freeze-drying solutions. Read the full story here.
FDA approves trials for Lomonitinib - a promising new drug for FLT3-mutated AML. Learn more about this potential breakthrough.
Cash Offer Alert! Cycle Pharmaceuticals steps up with an $8 per share bid to acquire Vanda. See how this could impact the rare disease market.
Syntegon's new Settle Plate Changer at Achema 2024 revolutionizes aseptic processing with enhanced automation and compliance.
Discover Antares Vision Group's HR600 PHC at ACHEMA 2024, showcasing milligram-level precision and autonomous error detection for ultimate quality control.
TurboFil Packaging Machines and Amneal Pharmaceuticals are partnering to create an automated naloxone vial assembly and filling machine.
Discover survodutide, a dual GLP-1 and glucagon agonist, showing promise in treating fibrosis and obesity with positive trial results.
NRx Pharmaceuticals advances next-gen ketamine therapy for severe depression, offering rapid, safe relief for treatment-resistant mental health disorders.
Explore the $1.6 billion partnership formed between Ipsen and Marengo in 2022 to advance precision immuno-oncology candidates from Marengo’s STAR platform.
Discover the groundbreaking partnership between Incepta Pharmaceuticals and MCRI to combat rotavirus infections in children.
BioXcel Therapeutics uses AI to accelerate drug development, focusing on sustainability and cost-effective drug repurposing.
Recce Pharmaceuticals completes dosing in Phase I/II UTI/Urosepsis trial of RECCE® 327, with data review by an Independent Safety Committee pending.
Lupin partners with OLIC Limited to distribute Nextstellis oral contraceptives in Vietnam and the Philippines, enhancing Lupin's women's health portfolio.
IPA's 9th Global Pharmaceutical Quality Summit in Mumbai on June 27-28 will focus on 'Advances in Manufacturing and Quality – Patient Centricity.'
Biocon appoints Mukesh Kamath as Interim CFO starting June 11, 2024. Kamath brings extensive finance experience from his 20-year tenure at Biocon.
ACG partners with EY-Parthenon to achieve net zero emissions and comply with the EU's CBAM, focusing on sustainability and carbon footprint reduction.
The YpsoMate 1.0 autoinjector simplifies methotrexate injections with a two-step process, safety features, and an ergonomic design for easy, secure use.
94% of pharma execs adapt revenue management for regulatory changes. CMS delays rule on aggregating discounts, seen as positive by Model N's Mendelsohn.
Evotec advances in neuroscience with Bristol Myers Squibb, earning $20M. Pre-clinical progress boosts neurodegenerative disease pipeline.
Delhi-based pharmaceutical firm in talks with PE firms for joint bid on BSV. Mankind Pharma plans fundraising for acquisitions and growth.
Dr. Reddy's secures exclusive US rights for Cyclophosphamide injection from Ingenus Pharmaceuticals, sharing 50% of profits.
Torrent Pharma's Indrad plant faces compliance scrutiny with a Form 483 from USFDA, citing five observations post-inspection.
Krista McKerracher, new Chairperson at Genialis, drives RNA-based biomarkers for personalized medicine, focusing on global patient outcomes in biopharma.
Stefan Doboczky, new Borealis CEO, focuses on advancing innovation, sustainability, and market leadership in the global chemicals sector.
EU Antitrust regulators charged Alchem International with price-fixing in a cartel for SNBB, risking fines up to 10% of global turnover.
BioCina secures exclusive rights to CelluTx's RBPS tech for efficient mcDNA production, enhancing gene therapies and biologics manufacturing.
ABIONYX Pharma completes pre-IND meeting with FDA, plans IND filing for apoA-I-based drug, advancing treatments for sepsis and critical care.
AbbVie and FutureGen collaborate on FG-M701, a promising TL1A antibody for IBD, with a $1.56 billion potential milestone and royalties deal.
The BreAK-CRC study tests STC-1010 cancer vaccine in advanced colorectal cancer across 9 EU/US centers, aiming for improved outcomes in cold tumors.
Suven Pharma to acquire 67.5% of Sapala Organics for Rs 229.5 crore, boosting nucleic acid therapy and ADC technology capabilities.
Takeda and Ascentage partner for global rights (ex-China/Russia/Taiwan/Macau/HK) to olverembatinib, a CML TKI, with $100M option payment and milestones.
Mankind Pharma's #RippleOfChange campaign promotes life-saving blood donations in India on World Blood Donor Day.
Sun Pharma and Moebius Medical's MM-II offers durable knee OA pain relief, paving the way for Phase 3 trials and EU approval.
Lupin's Nagpur facility passes USFDA inspection with no observations, ensuring high-quality standards upheld globally.
Wacker's new mRNA centre in Halle boosts vaccine production capacity, enhancing pandemic preparedness globally
Takeda plans potential $1.3B acquisition of Ascentage Pharma's innovative CML treatment olverembatinib
Enveda Biosciences raises $55M, totaling $119M in Series B funding, to advance AI-driven drug discovery and clinical trials for novel therapies by 2025.
Jagsonpal Pharmaceuticals has revealed that it has acquired businesses of Yash Pharma in India and Bhutan. Read the full news here!
DHL Enhances Pharma Logistics In France, Which Will Ultimately Result In Driving Innovation in Healthcare Supply Chain.
Discover the latest findings on RADICAVA® for ALS presented by Mitsubishi Tanabe Pharma at ENCALS 2024. Learn about new insights and study results.
Johnson & Johnson faces a $150M verdict over allegations of breaching marketing practices for HIV medications, intensifying legal battles.
Elion receives $81M funding to advance antifungal therapy, accelerating development and innovation in treatments.
Fosun Pharma to divest a 5% stake in Gland Pharma, raising $172 million in the transaction. This move is part of Fosun Pharma's strategic portfolio adjustment.
ALPLA Group expands its pharma packaging prowess with the acquisition of Heinlein Plastik-Technik GmbH, improving innovation in pharma packaging solutions.
Alembic Pharma achieves significant milestone as U.S. FDA approves Dabigatran Etexilate Capsules, signalling a breakthrough in pharmaceutical innovation.
Ascidian Therapeutics and Roche partner to advance medical research, aiming for breakthroughs in future treatments, shaping the future of medicine together.
Discover MilliporeSigma's €62M state-of-the-art quality control facility in Germany, setting new standards in life sciences innovation and efficiency.
Indian pharma giant Cipla invests EUR 3 million in German biotech firm Ethris, boosting innovative research and development in mRNA-based therapies.
Thermo Fisher's new clinical research hub in Wisconsin, advancing innovation and healthcare solutions. Read the whole news here!
Alvotech partners with Advanz Pharma to distribute AVT06 and AVT29, biosimilars of Eylea, enhancing access to eye disease treatments across Europe.
Belharra Therapeutic’s strategic alliance with Sanofi, aimed at advancing small molecule treatments for immunological disorders.
FDA approves Pryos Pharmaceuticals' Vigafyde, a new vigabatrin oral solution for infantile spasms in children, marking first new formulation in 15 years.
PCI Pharma Services signs a 25-year lease for an 82,000 sq ft facility in Stamullen, enhancing production and sustainability by Q1 2025.
Corealis Pharma expanded $10M facilities in Laval, boosting R&D and production capabilities, aiming to become a global leader in oral solid dosage formulations.
Zydus Lifesciences defends Biotax 1gm amid Nepal's quality concerns, asserting compliance with standards. Details on Business Standard.
AstraZeneca's Truqap, combined with paclitaxel, failed to meet primary endpoints in a trial for metastatic triple-negative breast cancer.
FDA issues warning letter citing violations in cGMP regulations at Sun Pharma's Dadra unit, impacting stock.
Kotak Alt invests Rs. 1,445 crore in Matrix Pharma’s API business, making it the 2nd largest ARV API player in India, expanding global collaborations.
Sun Pharma partners with Takeda to launch Voltapraz (Vonoprazan) in India, offering innovative treatment for reflux esophagitis and acid-related disorders.
Bora Pharmaceuticals expands its capabilities with the acquisition of Emergent BioSolutions’ sterile manufacturing plant in Baltimore-Camden, Maryland.
Discover Zealand Pharma's Phase 1b trial results on petrelintide for weight management. Learn more about this innovative biotechnology advancement today.
Pharma leader wins major international tenders for vital antibiotics and oncology drugs, enhancing global healthcare and boosting India's export influence.
The European Commission approves Takeda's FRUZAQLA for metastatic colorectal cancer, offering a new, effective treatment option for advanced-stage patients.
Abzena and Argonaut team up to enhance biopharmaceutical development, offering integrated solutions for faster, efficient therapy delivery
Sanofi partners with Biovac to produce polio vaccines in Africa, enhancing local production and healthcare resilience.
GL0034, Sun Pharma's latest drug for obesity treatment, demonstrates significant weight loss and improved metabolic health in Phase 1 trials.
Lupin’s New Jersey facility earns a positive FDA report, enhancing its compliance reputation in the pharmaceutical industry.
Phio Pharmaceuticals secures a South Korean patent for RXI-185, targeting UV-induced aging and enhancing its skin care and cancer treatment portfolio.
FDA initiates surprise inspection at Sun Pharma's Mohali plant after finding manufacturing violations at Halol site.
Biocon Biologics gets EMA nod to produce Bevacizumab in Bengaluru, renews GMP certifications for facilities in India & Malaysia, ensuring top-quality standards.
Teva Pharmaceuticals to acquire Labrys Biologics for over $800M, expanding its migraine treatment lineup with promising drug LBR-101.
KDDF funds CHA Biotech's CBT101 R&D for two years, advancing NK cell therapy for recurrent glioblastoma to phase 2 trials and aiming for IND approval.
Lupin and Aurobindo Pharma recall products from the US market due to FDA alerts on manufacturing issues.
Biocon's API facility in Visakhapatnam, Andhra Pradesh, receives four observations from US FDA following inspection. Read more on the regulatory update.
Bharat Biotech includes ICMR as co-owner of Covid-19 vaccine patent, affirming commitment to collaboration and timely vaccine development.
Discover GSK's latest milestone, Omjjara (momelotinib) approved by Japan's MHLW for myelofibrosis treatment, offering hope to patients worldwide.
GSK's application to expand Jemperli with chemotherapy for all advanced or recurrent endometrial cancer patients is accepted by EMA.
Novo Nordisk announces a $4.1 billion investment in Clayton, NC, doubling production capacity for injectable treatments, creating 1,000 jobs.
Xellia's latest layoffs follow the sale of its assets to Hikma, impacting roles at its Bedford facility in the U.S.
ANI acquires Alimera, advancing their Rare Disease portfolio in ophthalmology. Expect enhanced patient care and strategic synergies.
Wacker and CordenPharma enter pandemic-ready state, poised to produce 80 million vaccine doses annually in response to future outbreaks. Learn more.
Silence Therapeutics receives a $2M milestone payment from Hansoh Pharma, advancing their mRNAi GOLD platform to tackle genetic diseases.
ProBio Inc. launches a new 128,000 sq ft facility in Hopewell, NJ, boosting plasmid DNA and viral vector production for cell and gene therapy in North America.
Parse Biosciences partners with Gencell Pharma to expand single-cell sequencing solutions in South America, enhancing research capabilities.
Glenmark Pharmaceuticals recalls 114 batches of 750mg potassium chloride capsules due to dissolution issues, posing hyperkalemia risks.
CSPC Pharmaceutical Group advances with China's approval for mRNA-based cancer cell therapy trial, setting new standards in medical innovation.
CatSci Ltd acquires Reach Separations, enhancing chromatography services from discovery to manufacturing with support from Keensight Capital.
Discover Thermo Fisher's IntelliStack Incubator & CO2 Incubator Shakers—revolutionizing growth environments with precision and reliability for life sciences.
Haelium pioneers pharmaceutical innovation with high-purity solutions and advanced drug delivery products, ensuring global health advancements.
Haleon divests Nicotinell business to Dr. Reddy's, enhancing strategic focus while expanding consumer healthcare capabilities globally.
FDA approves Verona Pharma's Ohtuvayre for COPD. First non-steroidal inhaled treatment, boosting lung function.
Bora Pharmaceuticals acquires Emergent BioSolutions' Camden facility, boosting U.S. presence and sterile manufacturing capabilities.
Nxera Pharma hits a $10M milestone in neurological disease R&D with AbbVie, advancing novel GPCR targets. Potential $1.2B in milestones ahead!
Read how Rhenopharma Group enhances its global pharmaceutical services with the acquisition of Konapharma AG, a leading Swiss contract manufacturer.
Veranova invests $30M to expand its Devens facility, enhancing capabilities in ADC and potent compound development to meet growing US demand.
Jagsonpal acquires Yash Pharma, expanding into dermatology and pediatrics, enhancing market position.
Stay updated on CDSCO's risk-based inspections and new initiatives to enhance drug quality in India's pharmaceutical industry.
Aurobindo Pharma announces US inspection results, partnership with Merck Sharp & Dohme, and strong Q4 FY24 financial performance.
Rocket Pharmaceuticals' shares drop 12% as FDA delays approval of their gene therapy for a rare pediatric disorder, seeking more process information.
Lupin Ltd acquires Gavis Pharmaceuticals LLC and Novel Laboratories Inc. for $880 million, enhancing US market presence with expanded generics pipeline.
Alembic Pharmaceuticals' latest FDA-approved Doxycycline Capsules, 40 mg, for treating rosacea, propel stock surge and market growth.
A milestone in Wockhardt’s clinical trials as Zaynich, an investigational drug, effectively treated a young cancer patient with compromised immunity in the US.
Discover Alembic Pharmaceuticals' latest achievement as their Gujarat oncology facility secures US FDA's Establishment Inspection Report (EIR).
Discover Eisai's new dementia treatment targeting tau protein, aiming for U.S. launch by 2030. Leqembi also set for China debut.
A judge dismissed cancer victims' bid to block Johnson & Johnson's $6.48B talc settlement, stating potential harm was hypothetical. Voting deadline is July 26.
Biogen secures Tecfidera patents after U.S. board rules in its favor, ending royalty dispute with Forward Pharma, impacting stock prices.
President Bola Ahmed Tinubu signs Executive Order to reduce drug prices in Nigeria, eliminating tariffs and VAT on healthcare equipment and raw materials.
ARS Pharma's needle-free nasal spray, EURneffy, gets EMA's nod. Awaiting FDA approval by October 2. Positive results and advocacy groups' support add momentum.
Regeneron Pharma receives CHMP's positive opinion for odronextamab, targeting relapsed/refractory follicular & diffuse large B-cell lymphomas in Europe.
Alembic Pharmaceuticals receives USFDA tentative approval for Bosutinib Tablets, used to treat chronic myelogenous leukemia. Market size estimated at US$ 275M.
Kanvas Biosciences, a full-stack spatial biology company, has raised $12.5 million in additional funding. This brings Kanvas's total funding to $29.5 million.
AstraZeneca has announced that the EU drug regulator has accepted a market authorisation app for Sipavibart, under an accelerated assessment.
With the Union Budget 2024 approaching, the pharma industry is hoping to get better incentives for R&D and grow market size to $120-$130 billion.
Cassava Sciences, a Texas-based pharmaceutical company, will form a committee to evaluate new probes by U.S. regulators and investigate two senior employees.
TauRx Pharma has applied to the UK Medicines and Healthcare Products Regulatory Agency for approval of hydromethylthionine mesylate to treat Alzheimer's disease
Alcon acquires BELKIN Vision for $81M, enhancing glaucoma treatment with DSLT technology, aiming for US market entry.
MBK Partners to acquire Japan's Alinamin Pharmaceutical for 350B yen, boosting its presence in the Asian pharma market.
Media partnership announcement between Pharma Now and the Indian Pharmaceutical Congress for the IPC Expo in Hyderabad.
Pharma Now announces its media partnership with the 14th National Exhibition, Asia Labex 2024 in Gandhinagar.
Semnur Pharma to go public via $2B merger with SPAC, focusing on non-opioid pain treatment SP-102 for sciatica.
Samsung Biologics inks $1.06B deal with unnamed U.S. pharma, boosting manufacturing amid BIOSECURE Act concerns.
Eli Lilly partners with Radionetics Oncology for $140M, with a $1B acquisition option to advance radiopharmaceuticals.
Codexis sells investigational compounds for Fabry and Pompe diseases to Crosswalk Therapeutics, securing milestone payments.
Legal battle over Covid-19 vaccine patents: Moderna wins partial victory against Pfizer and BioNTech in UK court.
GSK leads on new mRNA flu and COVID vaccines with CureVac, gaining full control; CureVac receives €400M upfront plus milestones.
Pharma Now partners with the Digital Transformation in Life Science R&D Conference. Don't miss this pivotal event!
Radionetics Oncology partners with Eli Lilly to develop GPCR-targeted radiopharmaceuticals for treating solid tumors.
Mankind Pharma aims to acquire Bharat Vaccines and Serums for $1.7-$2B, enhancing its market presence in critical healthcare.
Sun Pharma acquires 85.1% of JSC Biosintez for $24M to boost its Russian market presence with local manufacturing.
"SIRTURO® achieves FDA and EC full approvals for MDR-TB, marking a pivotal advancement in TB treatment."
Aurigene partners with Edity Therapeutics to provide discovery services for cell therapy, boosting clinical development in oncology, gene therapy, and more.
Herantis Pharma tests HER-096 for safety in Parkinson’s, aiming to protect and restore dopamine-producing brain cells.
Philogen and Sun Pharma's Nidlegy™ MAA validated by EMA, aims to treat locally advanced, resectable melanoma.
Viatris sold its OTC business to Cooper Consumer Health, finalizing a $3.37B divestiture plan to refocus and reinvest.
AstraZeneca to invest Rs 250 crore in Chennai, creating 1,300 jobs and expanding its Global Innovation and Technology Centre.
Torque Pharma wins "Best Healthcare Brand of 2024" by ET Edge, launches 'Better Together' rebranding for global expansion.
Aluflexpack launches 4∞ Form, a fully recyclable aluminium blister pack for the pharmaceutical industry, reducing waste.
Direct Pharma Logistics expands into Bulgaria with Medex, plans Moldova entry, aiming for 50M euros turnover, says Forbes.ro.
AstraZeneca's Tagrisso, approved by the EU, combines with chemotherapy for first-line NSCLC treatment in adults with EGFR mutations, improving survival rates.
Federal judge dismisses Boehringer Ingelheim's challenge to Medicare drug price negotiation, dealing a blow to pharma's legal stance.
Emcure Pharmaceutical's IPO raises Rs 1,952 crore, subscribed 67.87 times. Backed by Bain Capital, priced Rs 960-1,008 per share for Rs 19,060 crore valuation.
Pulsus Group, led by CEO Dr. Srinubabu Gedela, announces a Rs 300 crore AI-driven pharma healthcare IT hub in Ameenpur, Telangana.
GSK plc and Medicines for Malaria Venture introduce a groundbreaking single-dose medication, tafenoquine, to prevent Plasmodium vivax malaria recurrence.
Recce Pharmaceuticals' R327 shows promising results, achieving over 99.99999% reduction in superbug Acinetobacter baumannii, outperforming ciprofloxacin.
Yuhan Corp. and ProGen announce R&D collaboration to develop innovative drugs for obesity and diabetes using bispecific antibody platform.
Ascentage Pharma's olverembatinib approved in Macau for treating resistant CML, expanding regional reach and collaborations.
Valeant ups Salix bid to $10.96B, outbidding Endo in major cash deal, marking its largest acquisition with financial and strategic implications.
Myricx Bio, a UK-based biotech firm, secured £90M to expand its NMT inhibitor ADC platform, backed by Novo Holdings, Abingworth, and other key investors.
Novartis, Pfizer, Otsuka, and Novo Nordisk reprimanded by PMCPA for ABPI code breaches. Novo Nordisk faces public reprimand over £7.8M.
Lotte Biologics breaks ground on its first plant in Incheon, marking a 4.6 trillion won investment and a significant step in Korea's biotech industry.
Aptamer Group plc collaborates with AstraZeneca to enhance siRNA delivery using Optimer binders, targeting fibrotic liver cells for innovative gene therapies.
Biostar Pharma's Utidelone Injection gets FDA approval for a Phase 2 study targeting HER2- breast cancer brain metastasis.
Körber partners with Anrate Biopharmaceutical to enhance operations with advanced manufacturing solutions for a smart factory in China's biopharma sector.
MedPharm merges with Tergus Pharma to form a CDMO, enhancing drug development and manufacturing services globally. Majority owned by Ampersand Capital Partners.
IASO Bio acquires global rights to FUCASO® from Innovent Biologics, expanding its cell therapy portfolio for treating multiple myeloma and autoimmune diseases.
Roche announces the re-release of Susvimo® for intravitreal use in the US, offering a new ocular implant for neovascular AMD treatment, following FDA approval.
ORLADEYO® approved by DIGEMID in Peru for preventing hereditary angioedema attacks in adults and children aged 12+, a milestone in treatment options.
Emergent BioSolutions to receive $50M from Johnson & Johnson to settle COVID-19 vaccine production dispute, ending a problematic collaboration.
Discover YARAL Pharma, supplying exclusive gel-cap levothyroxine sodium for hypothyroidism treatment in the U.S., made for absorption & allergen-free benefits.
Discover Shilpa Pharma Lifesciences, Raichur, Karnataka. Awarded ANVISA GMP Certification for oncology and non-oncology APIs, ensuring global quality standards.
Alembic Pharmaceuticals secures USFDA approval for its generic Bromfenac Ophthalmic Solution, boosting its ANDA approvals to 207 with a market size of $168M.
Reviva Pharmaceuticals secures European Patent for brilaroxazine to treat pulmonary hypertension, expanding their CNS and cardiometabolic treatment portfolio.
XyloCor Therapeutics teams with SmartWise to advance gene therapy for refractory angina using the innovative Extroducer® Catheter System®.
OKYO Pharma pioneers therapies for dry eye disease and neuropathic corneal pain, unveiling Phase 2 trial insights on key symptom endpoints.
Elevar Therapeutics announces intention to resubmit NDA for rivoceranib and camrelizumab, advancing treatment for Unresectable Hepatocellular Carcinoma.
Thermo Fisher Scientific finalizes $3.1B acquisition of Olink Holding AB, enhancing its proteomics solutions and expanding capabilities in life sciences.
Evotec SE and Pfizer announce a multi-year research collaboration targeting metabolic and infectious diseases.
Novo Nordisk and Bio Farma partner to enhance insulin packaging in Indonesia, combining Novo's diabetes care expertise with Bio Farma's local infrastructure.
Pfizer selects preferred once-daily formulation for danuglipron, advancing in obesity treatment. Study shows promising pharmacokinetics and safety profile.
MedPharm, Ltd. and Tergus Pharma merge to form a leading CDMO specializing in topical and transepithelial products, led by CEO Michael Kane.
Novo Nordisk receives FDA Complete Response Letter for once-weekly basal insulin icodec, addressing manufacturing and type 1 diabetes indication concerns.
Sichuan Biokin Pharmaceutical Co. aims to raise $500M through a Hong Kong IPO, with Goldman Sachs, JPMorgan, and Citic as joint sponsors
Algernon Pharmaceuticals announces a non-brokered private placement to raise $250,000 via units priced at $0.12 each, closing July 20, 2024.
Merz Therapeutics boosts its neurology portfolio by acquiring INBRIJA® and AMPYRA®, enhancing treatments for Parkinson's disease and entering the MS market.
FDA raids in Vasai reveal illegal drug manufacturing by Gaharwar Pharma, seizing items worth Rs. 1.41 crore; investigation ongoing.
AbbVie submits applications to FDA and EMA for upadacitinib approval to treat adult patients with giant cell arteritis.
Merck acquires EyeBio, enhancing its pipeline with Restoret™ for retinal diseases, entering pivotal trials in 2024.
Alembic receives USFDA tentative approval for Selexipag Injection, 1,800 mcg/vial, treating PAH to delay disease progression.
Federal court dismisses Boehringer Ingelheim's challenge to Medicare Drug Price Negotiation, upholding Biden administration's policy.
Senate passes Affordable Prescriptions for Patients Act to limit patent barriers, boosting biosimilars and generics.
USFDA inspection clears Piramal Pharma's Ahmedabad site, boosting FDA-approved clinical and commercial batch services.
Curi RMB and Oasis challenge Taisho Pharma buyout in court, arguing the tender offer undervalues the shares.
Moderna and Mitsubishi Tanabe partner to co-promote mRNA respiratory vaccines, including Spikevax, in Japan till 2029.
Daewoong Pharmaceutical's Nabota, now approved in Argentina as Clodew, is the first Korean BTX product to enter the market, set for Q4 launch.
Recce Pharmaceuticals Ltd received a $2M grant from the U.S. Dept. of Defense to develop RECCE 327 Gel for treating military burn wound infections.
Medicus Pharma updates FDA with non-invasive basal cell carcinoma treatment using doxorubicin micro-needle arrays in Phase 2 protocol submission.
MIRA Pharmaceuticals, Inc. reports preclinical results for MIRA-55, an innovative oral marijuana analog, showing potential to treat anxiety & cognitive decline.
GC Cell and Checkpoint Therapeutics unite to synergize cosibelimab and Immuncell-LC in groundbreaking cancer therapies.
Heron Therapeutics celebrates CMS's 2025 Non-Opioid Policy inclusion of ZYNRELEF® for post-surgery pain relief, aiming to reduce opioid use.
Lupin sells US women's health business to Evofem Biosciences, focusing on respiratory and neurological diseases.
India tightens Schedule G drug ad rules to curb misleading promotions. Public feedback invited on draft changes to the Drugs and Cosmetics Rules, 1945.
Silo Pharma acquires exclusive global license for SPC-14, targeting Alzheimer's, leveraging FDA's 505(b)(2) pathway.
Legend Biotech, known for its CAR-T therapy, evaluates takeover bid; J&J speculated as potential acquirer.
Emmaus Life Sciences achieves FDA compliance success, ensuring drug safety and quality with top inspection results.
Supreme Court supports NPPA's recovery of Rs 4.65 crore from Sun Pharma for violating DPCO pricing on Roscilox.
Sumitomo Pharma's DSP-5336, targeting AML with KMT2A rearrangement or NPM1 mutation, earns FDA Fast Track with strong clinical results.
FDA rejection of Hengrui's camrelizumab cites facility issues; resubmission planned, reinspection needed for approval.
SPI Pharma and Inimmune team up to create and commercialize innovative adjuvant systems, enhancing vaccine efficacy.
OMERS acquires Aclaris's future royalty payments from Lilly's OLUMIANT sales for alopecia areata, paying $26.5M.
Johnson & Johnson to pay $505M to settle disputes with talc suppliers, resolving ongoing conflicts amid talc cancer lawsuits.
Genomics plc and Vertex Pharmaceuticals renew collaboration for three more years, leveraging human genetics and AI to advance precise healthcare solutions.
Kindeva Drug Delivery's Woodbury, MN facility achieves FDA VAI status, ensuring top-tier analytical services for pharmaceuticals and medical devices.
Sionna Therapeutics acquires global rights from AbbVie to develop cystic fibrosis treatments galicaftor, navocaftor, and ABBV-2851, advancing CF care.
Upperton Pharma Solutions secures MHRA approval for a new 50,000 sq ft GMP facility in Nottingham, enhancing oral, nasal, and pulmonary drug production.
The FDA warns Cadila Pharmaceuticals Ltd for CGMP lapses at its Ankleshwar plant, risking US export license. Urgent corrective measures required within 15 days.
ICER warns Verona Pharma's $2,950/month COPD drug Ohtuvayre may face access barriers due to high cost.
Corden Pharma invests €900M to enhance peptide production capacity, addressing diabetic drug shortages.
Glenmark gains FDA approval for Topiramate Capsules, enhancing its US portfolio with Janssen's Topamax® equivalents.
Seers' mobiCARE, a 19g device, offers 9-day ECG monitoring, improving early heart disease detection using AI.
Zensar Technologies acquires BridgeView Lifesciences for $25M, boosting healthcare and life sciences offerings.
Sanofi plans €400M investment in Hyderabad, India, increasing its global capacity centre workforce to 2,600.
GC Biopharma sells Hong Kong subsidiary to CR Pharmaceutical for 350B won, boosting financial stability and exports.
Kintor pivots to cosmetic market with KX-826 hair loss treatment after clinical trial failures to boost revenue.
Endo USA recalls clonazepam tablets due to labeling error. Cartons incorrectly state 0.125mg instead of 0.25mg, though blister packs are correct.
Acurx Pharmaceuticals secures a new patent for ibezapolstat, targeting C. difficile infection, enhancing gut health, with Phase 3 trials upcoming.
Dermata Therapeutics reaches halfway in Phase 3 trial for DMT310, a once-weekly acne treatment. Topline data expected Q1 2025.
Scorpius Holdings Inc. completes initial cGMP microbial batches at San Antonio, marking a pivotal step in clinical manufacturing with strong client interest.
Phathom’s VOQUEZNA gains FDA approval for Non-Erosive GERD, offering novel 24-hour heartburn relief.
Med journal publishes LILAC studies showing DAYBUE improves Rett syndrome symptoms with a consistent safety profile.
Silo Pharma and Resyca BV partner on nasal spray tech for SPC-15, enhancing brain delivery for PTSD treatment.
Zuellig Pharma & Institut AllergoSan Forge Decade-Long Partnership to Boost Probiotic Brand OMNi-BiOTiC® in Asia's Growing Market.
Teva’s Phase 3 SPACE study shows AJOVY (fremanezumab) effectively prevents migraines in kids and teens, with a safe profile and no new concerns.
GSK's Blenrep MAA for relapsed/refractory multiple myeloma, combined with BorDex or PomDex, is accepted by EMA. CHMP review underway for potential approval.
Jonjo O'Neill Racing has secured a sponsorship deal with Wasdell Group, Europe's largest independent contract packer and a rising star in pharma manufacturing.
Daewoong Bio banned from China's VBP due to manufacturing errors; cefodizime sodium supply affected.
60 Degrees Pharmaceuticals Begins Clinical Trials for Tafenoquine to Treat Babesiosis in Partnership with Top Medical Centers.
Capra Biosciences wins $7.5M project to scale U.S. biomanufacturing of APIs, enhancing domestic production and addressing supply chain issues.
SemaPhore™ nanoparticles deliver SOD2 mRNA to treat AAA, lowering aortic dilation, rupture risk, and boosting survival.
Shuttle Pharma's HDAC inhibitor SP-1-303 shows potential in inhibiting estrogen receptor positive breast cancer growth.
EMA validates Opdivo + Yervoy as first-line treatment for advanced HCC, with significant OS improvement in CheckMate -9DW trial.
Athenahealth completes UDS+ synthetic testing, enhancing FQHC support with streamlined data submission and improved patient outcomes via advanced technology.
LEO Pharma’s delgocitinib cream trial results featured in The Lancet, marking a milestone for new treatments in chronic hand eczema.
Boehringer Ingelheim launches a Humira biosimilar at 92% off, priced at $550 via GoodRx, aiming to boost access and market share.
EMA accepts Ono Pharma's MAA for vimseltinib to treat TGCT, following $2.4B Deciphera acquisition, eyeing $1B sales.
Medicamen Organics partners with Depot Pharmacy Yego, investing $75K to launch operations in Rwanda, leveraging Kigali's strategic location and tax benefits.
Ayesha T. Haq calls for policy reforms to address regulatory and economic barriers for pharma MNCs in Pakistan.
Lupin's U.S. partner, ForDoz Pharma, secures FDA approval for generic Doxorubicin Hydrochloride Liposome Injection, targeting ovarian cancer and more.
TME Pharma Unveils Strategy to Outsource and Capitalize on NOX-E36 for Ophthalmic Diseases, Citing Strong Clinical Potential and Market Opportunity.
Addex Therapeutics confirms Janssen halts ADX71149 epilepsy development after Phase 2 results but will continue data analysis and collaboration efforts.
Meitheal Pharmaceuticals acquires North American rights to CONTEPO for drug-resistant UTIs, with FDA decision expected in 2024.
Traws Pharma appoints KPMG LLP as its new independent accounting firm, effective December 2024, after no disputes with previous auditor Ernst & Young.
STADA and Alvotech launch Uzpruvo® in Europe, the first Stelara® biosimilar, enhancing access for Crohn's disease and psoriasis patients.
Tobinco’s Lufart wins Best Pharmaceutical Product at Ghana International Products Event, showcasing local innovation in healthcare.
RADIAN to fund HIV initiatives in EECA, extending aid to Ukrainian refugees, improving access to vital services.
Chugai transfers MONILAC Syrup rights to Maruishi, including manufacturing and marketing permissions, to optimize the product's value.
MIRA's Ketamir-2, a novel oral ketamine analogue, shows potential for treating neurological conditions with enhanced absorption.
Aligos and Amoytop partner on a Phase 1b trial to evaluate ALG-000184 and PEGBING® for chronic hepatitis B treatment.
SynaptixBio extends collaboration with Evotec to develop new ASO drug candidates for TUBB4A leukodystrophy treatment.
Agilent Technologies to acquire BIOVECTRA for $925M, expanding capabilities in biologics and accelerating drug development. Deal expected to close before 2025.
Kobayashi Pharmaceutical’s chairman and president resign amid scrutiny over red yeast rice supplement linked to health issues and disclosure delays.
Hikma expands acetaminophen injection recall to include consumers due to possible dexmedetomidine mix-up, posing serious health risks.
aTyr Pharma completes Phase 3 EFZO-FIT™ trial enrollment for efzofitimod in pulmonary sarcoidosis. Results expected in Q3 2025, marking a key milestone.
Cytoki Pharma's CK-0045 demonstrates positive Phase 1 results in reducing obesity and type 2 diabetes markers.
MidEuropa will acquire a majority stake in Famar, a pharmaceutical CDMO, to support its growth and expansion, with the deal expected to close in late 2024.
Mayne Pharma sues Sun Pharma over patent infringement on menopause treatment IMVEXXY, triggering a 30-month FDA stay.
Autobahn Labs and Charles River collaborate to advance early-stage therapeutics, with Charles River joining as an investor.
Scorpius to launch its first cGMP mammalian manufacturing campaign at San Antonio facility in Q3 2024, expanding biopharma.
Alcami expands Garner facility, enhancing storage for vaccines and biopharmaceuticals, and creating new jobs.
Tonix receives $34M from DoD for developing a broad-spectrum antiviral targeting CD45 protein over five years.
FDA expands BioMarin's BRINEURA approval to treat all ages with CLN2 disease, based on new clinical trial data.
FDA doubts AstraZeneca's Imfinzi efficacy and safety for lung cancer, with pivotal trial results and overtreatment risks.
Carbogen Amcis triumphs in FDA inspections, with spotless reports for Neuland and Aarau facilities, reinforcing excellence.
Novo Nordisk is building a $4.1B aseptic production plant in Clayton, NC, adding 1,000 jobs and boosting output by 2029.
Mankind Pharma is in advanced talks to acquire Bharat Serums for $1.5B; deal could be finalized soon.
SPI Pharma's ValensTM brand launches, uniting products for vaccines, biologics, and parenteral dosage forms.
Gland Pharma's Hyderabad site gets 2 procedural observations in surprise US FDA inspection, plans remedies.
Sun Pharma's LEQSELVI gets FDA nod for treating severe alopecia areata in adults, offering new hope.
Cue Biopharma refocuses on autoimmune programs, cutting costs and staff to extend cash runway to mid-2025.
Catalyst partners with Kye Pharmaceuticals to bring AGAMREE, a novel DMD treatment, to the Canadian market.
Summit Therapeutics and MD Anderson join forces for a five-year partnership to develop ivonescimab for cancer.
Windtree updates on istaroxime's clinical progress, with Phase 2 results expected soon and new studies planned.
Biopharma Q2 2024 earnings strong; drug price negotiations under the Inflation Reduction Act progressing with limited impact.
EU rejects Eisai and Biogen's Alzheimer's drug Leqembi due to serious brain swelling risks and limited trial benefits.
Biopharma company delists from OTCQB due to low volume, continues trading on London Stock Exchange's AIM Market.
SFV drum pump provides efficient fluid transmission for various needs, with material choices, connections, and motor options.
FDA authorizes LIVMARLI label expansion for cholestatic pruritus in PFIC patients aged 12 months and older.
JSR Life Sciences' KBI Biopharma extends a $250M manufacturing deal with a global pharma partner, committing to produce two therapeutic products through 2029.
Checkpoint Therapeutics' cosibelimab BLA for cSCC accepted by FDA for review, with a PDUFA goal date of Dec 28, 2024, after resubmission resolves prior concerns
QuVa Pharma acquires LogicStream, integrating predictive analytics to tackle drug shortages and improve pharmacy operations.
Kobayashi Pharmaceutical didn't report certain items to the health ministry; instructed to submit a report by Wednesday.
FDA grants Orphan Drug and Rare Pediatric Disease status to Cellectis' UCART22 for treating Acute Lymphoblastic Leukemia.
Abbott ordered to pay $495M after jury finds specialized formula caused NEC in preterm infants, leading to lawsuit.
A dengue prevention initiative by Takeda and USAID, educating communities in Maharashtra, Odisha, and Uttar Pradesh on disease prevention.
New $20M pharmaceutical plant opens in Kabul, adhering to WHO standards, promoting local manufacturing and reducing imports.
Daewoong's Versiporosin safe in Phase 2 IPF trials; IDMC final review in 2025 for unique collagen inhibitor.
Schrödinger launches a new initiative to enhance its platform for assessing toxicology risks in early drug discovery, backed by a $10M Gates Foundation grant.
Pharmaceutical Society of Kenya opposes a bill to exclude miraa's psychoactive elements from regulation, warning of health risks & international law violations.
Mauritius' antitrust office investigates potential price-fixing by pharmaceutical importers and wholesalers, affecting drug prices.
Novalead Pharma launches Esmolol-based DFU gel post-Indian approval, aims for global market with further trials.
Paratek's Nuzyra, Phase III study for CABP shows safety, efficacy, and non-inferiority to moxifloxacin, paving the way for broader applications.
Fiocruz partners with the University of Coimbra to develop radiopharmaceuticals and enhance healthcare systems in Brazil and Portugal.
HLS Therapeutics and Alberta Health finalize PLA for Vascepa reimbursement in cardiovascular disease treatment.
Cyclo Therapeutics receives European patent for Alzheimer's treatment method, effective August 21, 2024, enhancing their patent estate.
Boehringer Ingelheim acquires Nerio Therapeutics up to $1.3B, enhancing its immuno-oncology portfolio with innovative PTPN1/2 inhibitors for cancer treatment.
Eli Lilly launches a powerful Olympic campaign with Team USA, urging everyone to fight for their health and embrace the uniqueness of their bodies.
Calliditas Therapeutics Secures Full EU Marketing Authorization for Kinpeygo, Expanding Treatment Access for IgAN Patients.
Roche acquires LumiraDx's point-of-care tech, enhancing decentralized diagnostics, global healthcare access, and molecular testing.
GSK partners with Flagship Pioneering to develop transformative drugs and vaccines in immunology and respiratory treatments.
Amneal Pharmaceuticals gains FDA approval for potassium phosphates IV bags, simplifying hypophosphatemia treatment ready-to-use, preservative-free injections.
Celldex Therapeutics announces positive topline results from its Phase 2 trial of barzolvolimab, a promising treatment for chronic inducible urticaria.
GSK and Ronald Kimbrow settle lawsuit with GSK denying guilt. Scientific studies find no cancer risk from ranitidine.
Cytiva's Supor Prime filters enhance high-concentration biologic production, lowering blockages and minimizing product loss.
Icure signs with UITC to export Ketoprofen Plaster for joint pain relief. Expands global reach with contracts in Latin America, the U.K., and the UAE.
Waters Corp. launches TA Instruments RS-DSC, a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations.
Genzyme sues Sarepta for infringing viral vector patents, seeks damages and a jury trial over Elevidys production.
Vertex's suzetrigine NDA accepted by FDA, potentially the first new acute pain treatment in 20 years. Priority review, PDUFA date set for Jan 30, 2025.
CinFina Pharma launches Phase 1 MAD trial for CIN-110, a promising PYY3-36 analog, to assess its safety, tolerability, and effectiveness in treating obesity.
Eli Lilly pledges $5,000 per Team USA record/medal to health equality groups, could donate over $1M during Olympics.
CNS Pharmaceuticals announces an exclusive licensing deal for TPI 287 to advance treatments for brain cancer. Join the webcast on July 30 for insights.
NeuroBo Pharmaceuticals has signed an exclusive license with MThera Pharma for NB-01, aimed at treating painful diabetic neuropathy in clinical trials.
Jacobs secures a contract to upgrade Onondaga County's sewer system using innovative management and Digital OneWater solutions.
Botanix's SofdraTM approved by FDA for axillary hyperhidrosis; $70M secured, launch starts Q3 2024 with digital release in Q4.
Telix's TLX250-CDx BLA faces FDA sterility issue; resubmission in 90 days, no change to 2024 forecast.
Celltrion Inc. gains Health Canada approval for its biosimilar Steqeyma, targeting autoimmune diseases, marking its entry into the North American market.
Chugai secures exclusive rights for inavolisib, a PI3K alpha inhibitor for advanced HR-positive, HER2-negative breast cancer, in a deal with Roche.
Adial Pharmaceuticals files a new patent for AD04, aiming to protect its lead treatment for AUD until 2044.
The FDA grants RPDD to Theriva Biologics' VCN-01 for retinoblastoma, enhancing treatment development for this rare cancer.
Tonix Pharmaceuticals highlights NASEM's Long COVID definition linking fibromyalgia to SARS-CoV-2, expanding the market potential for its drug Tonmya.
Contineum Therapeutics' PIPE-307, an M1 receptor antagonist for RRMS, shows positive preclinical data and enters Phase 2 trials.
AbCellera and Lilly expand partnership to develop therapeutic antibodies for immunology, neurology, and cardiovascular diseases.
Sound Pharmaceuticals completes Phase 3 trial for SPI-1005, a groundbreaking treatment for Meniere’s Disease, improving hearing loss and tinnitus.
Johnson & Johnson's DARZALEX FASPRO® gains FDA approval for a new quadruplet therapy, expanding treatment options for newly diagnosed multiple myeloma patients.
CHMP Recommends Approval for Amivantamab with Chemotherapy for Advanced NSCLC, Reduces Disease Progression by 52%.
Medicilon and Hengrui Pharma partner to advance preclinical drug assessments, boosting innovation in China's pharmaceutical sector.
MedPharm and Tergus Pharma merge to enhance CDMO capabilities in topical pharmaceuticals, boosting scientific expertise and production efficiency.
Otsuka Pharmaceutical plans to acquire Jnana Therapeutics for over $1 billion, aiming to enhance its drug pipeline and research capabilities in Boston.
CereMark Pharma and Hall of Fame Health partner for Phase 3 study of Alzheimer's and CTE diagnostic agent.
Jagat Pharma introduces Isotine Eye Gummies to support eye health and combat digital strain for all ages.
Halia Therapeutics and Biolexis use AI to identify a promising treatment targeting NLRP3-driven neuroinflammation for Parkinson’s and neurodegenerative diseases
First patient dosed in Phase 3 trial comparing ifinatamab deruxtecan to standard chemotherapy for relapsed SCLC.
Chugai's Alecensa gets Taiwan TFDA approval for adjuvant treatment in ALK-positive NSCLC post-tumor removal.
Vectura Fertin Pharma and Aurora partner to launch new CBD lozenge on Aurora's Canadian medical cannabis platform for patient feedback.
MilliporeSigma acquires Mirus Bio for $600M, bolstering its viral vector production solutions for gene therapies.
BioIVT partners with Germfree to launch a state-of-the-art cleanroom facility in Winchester, VA, enhancing support for cell and gene therapy.
SMS Pharmaceuticals and Sri Avantika Contractors plan a $200M investment in a pharmaceutical park in Vietnam, aiming for $4-5B in additional investments.
Regeneron’s Eylea sales surged to $304M in Q2, revitalizing its franchise despite competition and FDA delays for linvoseltamab.
Merck explores combining Keytruda with RNA-based vaccines alongside Moderna to enhance melanoma treatment options before the drug's patent expiration in 2030.
Sanofi and Vir sign exclusive deal for masked T-cell engagers to target cancer and infectious diseases.
Calls grow for Gilead to reduce lenacapavir price for HIV prevention, highlighting disparity in global drug access.
Alembic Pharma gets US FDA nod for Nelarabine Injection, used for T-cell leukemia/lymphoma, marking its 211th ANDA approval. Market size: $23M.
AMX0035, designated as an orphan drug, improves glycaemic control and vision in Wolfram syndrome patients.
JAMP Pharma recalls digoxin pills for potential misdosing. Patients should consult their pharmacist immediately.
CDSCO and SDCs enforce drug quality laws, inspecting 400 facilities and taking over 300 actions against violations.
FDA grants fast-tracked approval to Tecelra for treating synovial sarcoma, marking a key milestone for Adaptimmune.
Zevra Therapeutics gets FDA GeMDAC's backing (11-5) on arimoclomol for Niemann-Pick disease type C. FDA decision due by September 21, 2024.
SCHOTT Pharma unveils a 160-syringe nest for prefillable syringes, boosting efficiency by 67%, cutting costs, and reducing carbon footprint by 17%.
Freudenberg Medical Expands Biopharma Line with Custom Single-Use Assemblies for Protein Production and Bioprocessing.
Sanofi plans to invest €1.3bn in a new insulin facility in Frankfurt by 2029, supported by German government initiatives to strengthen pharma production.
PA Governor invests $3M in Adare Pharma's $16.8M expansion, creating 115 jobs, relocating HQ to Philly, and boosting the state's life sciences hub.
Vietnam's $7B pharmaceutical market faces infrastructure and financial challenges, yet shows 7.3% annual growth, aiming to be a regional hub by 2030.
Dr. Jaideep Gogtay of Cipla highlights the urgent need for enhanced surveillance and drug discovery to combat Antimicrobial Resistance (AMR) in India.
Court dismisses drug manufacturers' IRA price-setting challenges; Novo Nordisk plans appeal, others continue objections.
UP Manila develops E-Tox POCT kits for detecting poisoning drugs and NPS, filling a critical emergency need.
CordenPharma invests €900M ($981M) to boost GLP-1 peptide manufacturing in Europe and the US, aiming for €1B sales by 2028. Largest investment in 18 years.
Attendees experienced a heartfelt documentary that honoured Dr. KH Sancheti's journey, highlighting his commitment to affordable healthcare and patient care.
Ono Pharmaceutical partners with Monash University to develop new anti-GPCR antibodies, aiming to create treatments for autoimmune and inflammatory diseases.
Eli Lilly and Novo Nordisk race to meet high demand for GLP-1 weight-loss drugs, aiming to supply a market projected to reach $150 billion by the early 2030s.
DKSH partners with Kyowa Kirin to enhance healthcare access across Asia-Pacific, promoting established medicines and driving sustainable growth in the region.
FDA accepts LK's JLK-CTP application. Korean AI firm aggressively pursuing U.S. market for stroke diagnostic solutions.
Formosa Pharma partners with Apotex to market APP13007 in Canada for post-op eye inflammation relief.
Kakao Healthcare's research alliance with top hospitals aims to revolutionize global healthcare through AI and big data.
Destiny Pharma to present data at IPS 2024 showing XF-73 reduces MRSA in burn wounds by 99.99% and prevents sepsis, a breakthrough in infection control.
Biotech startup Ribon Therapeutics ceased operations in 2024, auctioning its assets, including PARP inhibitors.
Rznomics and SK pharmteco sign a multi-year MOU to develop and market RNA-based gene therapy products.
Agenus regains AGEN1777 after Bristol Myers cancels a $1B cancer immunotherapy deal amid strategic realignment.
BioMarin refocuses ROCTAVIAN® on the U.S., Germany, and Italy, cutting costs to $60M by 2025 for severe hemophilia A.
Asymchem opens a new European facility in Kent, U.K., to boost R&D and manufacturing with advanced, sustainable technologies.
The FDA rejects Telix Pharmaceuticals' TLX250-CDx PET imaging agent for kidney cancer due to sterility concerns, though approval is still anticipated.
WCG acquires Array to enhance clinical research training, improving efficiency, safety, and outcomes through innovative engagement and data insights.
Lantern Pharma's AI-driven HARMONIC™ phase 2 trial of LP-300 with chemotherapy shows promising safety and efficacy in NSCLC patients post-TKI treatment.
Yaskawa and Astellas partner to enhance cell therapy production, bridging research to commercialization efficiently.
Quoin Pharmaceuticals starts a New Zealand trial for QRX003, aiming to treat Peeling Skin Syndrome in children.
Lupin's Phase 3 trial of LUBT010, a biosimilar to Lucentis, shows therapeutic equivalency in treating wet AMD.
Celltrion's Zymfentra, a subcutaneous infliximab, joins major US PBM insurance lists after March launch.
CereMark Pharma's Phase III trial will investigate F-18 flornaptitril, targeting proteins in Alzheimer's and CTE.
Henrietta Lacks' family sues Novartis and Viatris for profiting from HeLa cells taken without consent in 1951, seeking justice and restitution.
Cloudbreak Pharma partners with Santen Pharmaceutical to develop CBT-001 in Southeast Asia, while preparing for a Hong Kong listing amid rising losses.
Sangamo and Genentech collaborate on gene therapies for neurological diseases, aiming to tackle conditions like Alzheimer's.
Reviva Pharmaceuticals secures USPTO patent for brilaroxazine, enhancing IP for treating lung diseases including IPF and COPD.
Daiichi Sankyo and Merck expand global partnership to develop MK-6070, a DLL3-targeting therapy for neuroendocrine tumors and SCLC.
Nestlé Health Science acquires Seres' VOWST, funding Seres' pipeline and improving outcomes for fragile patient groups.
NeuroBo Pharmaceuticals, partnering with Dong-A ST and ImmunoForge, is developing a long-acting, once-monthly version of DA-1726, targeting obesity treatment.
Tonix Pharmaceuticals announces a new publication on COVID-19 convalescent sera screening in "Microorganisms," highlighting their advanced imaging technology.
Compass Therapeutics enrolls 150 patients in the COMPANION-002 trial to assess CTX-009 for BTC. New IST approved at MD Anderson for first-line treatment.
Cadrenal Therapeutics is in talks with Abbott for a tecarfarin study in LVAD patients, aiming to enhance anticoagulation and prevent strokes.
Roche, Chugai sign agreement for RG6631, an anti-TL1A antibody for Crohn's and ulcerative colitis treatment in Japan.
WHO alert, Counterfeit Oxymorphone Hydrochloride 40mg tablets found in Finland. Contains dangerous metonitazene, report adverse effects to authorities.
Shanton Pharma has completed enrollment for its Phase 2b trial of SAP-001, targeting refractory gout patients, with topline data expected in Q1 2025.
Aurobindo Pharma Receives USFDA Approval for Estradiol Inserts, Reaches 521 ANDA Approvals, Reports 79.5% Profit Increase in Q4 FY24.
Vertex, NHS England provide gene therapy for beta thalassaemia; CASGEVY approved by UK MHRA and NICE.
FDA approves Purdue Pharma's Zurnai auto-injector for opioid overdose, treating adults and children 12+.
Formosa and Eyenovia team up to develop Clobetasol Propionate for dry eye, leveraging advanced nanoparticle technology.
Pharmacosmos acquires G1 Therapeutics for $405M, enhancing COSELA's reach for lung cancer patients, benefiting stakeholders.
Abbott and Medtronic team up to create an integrated CGM system, enhancing diabetes management with automated insulin delivery.
Adial Pharmaceuticals completes dosing for AD04 study targeting Alcohol Use Disorder, with top-line results expected in Q4 2024.
Agenus Inc. unveils a study on botensilimab, a novel anti-CTLA-4 antibody, showing efficacy in resistant cancers, transforming the tumor microenvironment.
Silo Pharma partners with WuXi AppTec to study SPU-16 peptide for MS treatment, leveraging CNS targeting for enhanced drug delivery and reduced toxicity.
Lonza boosts Bend, Oregon facility for clinical bottling, enhancing early-phase trial efficiency and product delivery.
Mallinckrodt launches the Acthar Gel SelfJect™ Injector, a user-friendly option for patients with chronic inflammatory and autoimmune conditions.
Samsung Biologics becomes the first Korean CDMO to join the PSCI, committing to sustainable practices and enhancing its ESG efforts in global healthcare.
CVC Capital Partners agrees to acquire Mallinckrodt's Therakos division for $925 million, aiming to enhance its global reach in immune-related therapies.
FDA approves CREXONT, a new CD/LD formulation for Parkinson's, offering longer "Good On" time with fewer doses.
Conduit Pharmaceuticals and AstraZeneca partner to advance AZD5904, AZD1656, and AZD5658 for autoimmune diseases and infertility in Phase II trials.
Iris Acquisition Corp is progressing with its merger plans with Liminatus Pharma, filing an amended Form S-4 and securing a Nasdaq listing extension.
Merck terminates Phase 3 KeyVibe-008 trial for small cell lung cancer due to failure to meet survival endpoints and increased adverse events.
Apellis Pharmaceuticals and Sobi reveal promising Phase 3 VALIANT study results, showing pegcetacoplan's potential for C3G and IC-MPGN.
USSF invests $15M to expand its Lehigh Valley biopharma facility, boosting clean room capacity and creating 100+ jobs, enhancing its pharmaceutical services.
Merck acquires CN201 for $700M with up to $600M in milestones, targeting B-cell disorders; closing in Q3 2024.
FDA approves Neffy, the first needle-free epinephrine for severe allergies, improving patient care and outcomes.
Vivint Pharma invests $48M in Hyderabad facility, creating 1,000 jobs to produce injectables for critical care and cancer.
Angiex begins Phase 1 trial dosing for AGX101, an innovative TM4SF1-directed ADC targeting solid tumors.
Novartis' Fabhalta gets FDA approval for IgAN, targeting complement system to reduce proteinuria in kidney disease.
Meiji Seika Pharma Co., Ltd. opens a new Boston office, its venture into life sciences investments to develop innovative therapies for global health needs.
Oncimmune wins $1.5M contract with major pharma, expects FY24 revenue of £3.0M and profitability by FY25.
Granules India secures FDA approval for trazodone tablets, enters $128M U.S. market with expected strong growth.
India's pharma industry highlights HVAC's vital role in ensuring product quality, worker safety, and regulatory compliance.
LTS and GRAMME team up to provide pharma firms with turnkey solutions for biologic drug delivery and market access.
FDA charges BMS with fabricating data on Krazati's effectiveness for KRAS cancer, challenging trial findings.
Recursion buys Exscientia for $688M, expanding AI-based drug development pipeline and forming new pharma alliances.
Merck's Aarogya program, launched in Patalganga, Raigad, offers health screenings, diagnostics, and awareness, impacting 800+ lives with comprehensive care.
Chifu and CTC BIO sign exclusive deal to distribute One-two Tab in Taiwan, with plans for global expansion.
GC MS signs a $2.9M export deal with Hong Kong's Firstlink Healthcare for Gcare Lipid devices, expanding its global reach in diagnostic technology.
Tobinco Pharmaceuticals cleared by Accra High Court, FDA allegations of counterfeit drug importation dismissed. Legal victory announced August 2024.
FDA issues CRL for Lykos Therapeutics' PTSD drug, citing safety concerns; requests more Phase III trials.
Atul Bioscience receives FDA EIR for Ambernath plant, with zero findings after successful May 2024 inspection.
GC Biopharma's GC1130A for Sanfilippo syndrome gets Japan PMDA approval for phase 1 trial, following U.S. and Korea approvals.
Marker Therapeutics receives $2M NIH grant to study MT-601 for relapsed non-Hodgkin's lymphoma post CAR-T therapy.
LENZ Therapeutics files NDA with FDA for LNZ100, showing promise in Phase 3 for presbyopia treatment.
Wave Life Sciences' WVE-N531, targeting Duchenne muscular dystrophy, receives FDA Rare Pediatric Disease designation.
Breas Medical recalls 8,186 Vivo 45 LS ventilators due to potential formaldehyde exposure, impacting units distributed between Feb 2021 and July 2024.
Pneuma Systems' PneumaFlow Controller joins the FDA's Safer Technologies Program, enhancing infusion safety and streamlining patient care.
60 Degrees Pharma grants the University of Kentucky FDA reference rights for ARAKODA®, advancing a Phase IIb study on malaria treatment with SJ733.
Ascendis Pharma's YORVIPATH gains FDA approval for hypoparathyroidism, offering a once-daily treatment option for patients.
Syros Pharmaceuticals halts patient enrollment in SELECT-AML-1 Phase 2 trial after interim results show no superiority of triplet therapy for AML treatment.
Astria Therapeutics Partners with Ypsomed to Develop Autoinjector for STAR-0215, Offering Patients Flexible, Low-Burden Administration Options.
Daiichi Sankyo's ENHERTU® gains conditional approval in China for advanced HER2+ gastric/GEJ adenocarcinoma.
Blue Earth Therapeutics expands its partnership with Seibersdorf Labor to produce 225Ac-based radioligand therapy for clinical trials in the UK, EU, and U.S.
Taiwan Bio Therapeutics and TRACT Therapeutics advance TregCel technology transfer, setting the stage for a global Phase 2 trial in kidney transplant patients.
Celltrion's Yuflyma biosimilar is now available at Costco, offering uninsured members significant discounts on this crucial medication for chronic conditions.
CMS assigns Abeona's pz-cel gene therapy a specific procedure code, enhancing hospital billing and reimbursement for RDEB.
Florida's Grant Cancer Centre first in U.S. to use Accuray Radixact® System with VitalHoldTM, boosting cancer treatment precision.
NeuroBo completes enrollment for Phase 1 trial of DA-1726, a dual agonist for obesity with superior pre-clinical results.
Boudicca Dx and Adial partner to develop a companion diagnostic for AD04, a precision treatment for alcohol use disorder.
Kiromic's KB-GDT-01 (Deltacel) therapy shows promising PFS results in NSCLC patients in the Deltacel-01 trial, with no dose-limiting toxicities observed.
Galderma's Nemluvio receives FDA clearance for prurigo nodularis, aiming to ease severe itching and skin nodules. Blockbuster potential in dermatology.
Baxter shifts strategy by planning to sell Vantive to Carlyle, aiming to enhance shareholder value and focus on growth, marking a pivotal transformation.
Medtronic's brain modulation division reports low double-digit growth, boosted by Percept RC demand and new asleep DBS approval, enhancing its competitive edge.
Rivus' HU6 shows promise in Phase 2a trial for obesity-related heart failure, achieving key weight loss goals.
Kerato partners with the University of Montreal to develop an innovative corneal treatment, aiming to simplify procedures and improve patient outcomes.
Medison Pharma expands its collaboration with Alnylam Pharmaceuticals to enhance access to RNAi therapies across Central and Eastern Europe, Israel, and more.
Alera Pharma, Lobe Sciences’ US subsidiary, focuses on neurology, merging with the Australian branch soon.
AstraZeneca's sBLA for Imfinzi in LS-SCLC has been accepted by the FDA with Priority Review, backed by the ADRIATIC trial's positive survival results.
Nanoform and Takeda partner to develop plasma-derived therapies for rare diseases. Non-GMP nanomaterials will help advance formulations to market by 2025.
Hoth Therapeutics teams with Aronnax to advance HT-KIT, an FDA Orphan Drug for mast cell cancers, refining dosing and trial protocols.
Gilead's Livdelzi (seladelpar) wins FDA accelerated approval for primary biliary cholangitis, showing notable reductions in ALP levels and pruritus.
FDA recalls B. Braun and Baxter sodium chloride batches due to endotoxins, particle leaks, and contamination risks.
Medtronic partners with Abbott to integrate CGM tech into insulin pumps, aiming to revive diabetes care segment.
Cuban-China joint venture prepares China trials for Itolizumab, tech transfer for cancer drugs, and R&D projects.
Abbott's AVEIR DR system enables Canada's first dual chamber leadless pacemaker implants for better heart rhythm care.
Uzbekistan and AstraZeneca explore partnership opportunities for expanding pharmaceutical production and investment.
FDA issues a warning to Aurobindo Pharma's unit after inspection; shares dip amid compliance concerns.
NMPA approves marketing change for Baiyunshan’s Pseudoephedrine and Paracetamol products, boosting its portfolio.
Eli Lilly acquires Morphic Holding to enhance its IBD treatment options with innovative oral integrin therapies.
Bavarian Nordic's Imvanex mpox vaccine seeks EMA approval for teen use, backed by successful Phase II trials.
Sanyou Biopharmaceuticals launches AI-powered oneClick+ platform to accelerate antibody development with advanced design tools and automated analysis.
Novo Nordisk invests 1.5 billion DKK in a Køge facility to boost GLP-1 drug production, marking a key step in their global expansion strategy.
IMBiologics transfers autoimmune tech to Huadong Pharmaceutical in a deal worth up to $375M. Huadong gains rights to develop in Asia, excluding key markets.
NorthStar and Convergent are advancing prostate cancer treatment with CONV01-α, using Ac-225 and a monoclonal antibody.
Nuntius and Taiho partner to boost mRNA cancer therapy with advanced nanocarrier tech. Financials undisclosed.
Hikma Pharmaceuticals extends KLOXXADO® nasal spray’s shelf life to 36 months, doubling naloxone dose per spray.
Inspira Technologies secures AMAR approval for its INSPIRA ART100, advancing extracorporeal membrane oxygenation and cardiopulmonary bypass solutions globally.
SciSparc secures exclusive rights to develop SCI-160 pain therapy, with potential $6M+ in earnings and milestone fees.
Huawei’s Watch D2, now medically certified in China, features advanced blood pressure monitoring. Release and price details are still pending.
Avantor divests clinical services to Audax for $650M to focus on lab and production growth, per CEO Michael Stubblefield.
Dr Reddy’s close to buying Nicotinell from Haleon in a deal worth hundreds of millions, aiming for EU market growth.
Discover advanced cleanroom solutions at CPHI & PMEC India 2024. Explore innovations in modular cleanrooms, HVAC systems, and contamination control.
Control Bionics' NeuroNode gets CMS approval with HCPCS code E2513, securing $4,300 reimbursement and aiding users with severe movement impairments.
Alembic Pharmaceuticals gains USFDA approval for Dabigatran Etexilate Capsules, 110 mg, boosting its ANDA total to 211.
Opaganib reduces HFD-induced weight gain and glucose intolerance, targeting a new pathway for obesity treatment.
EMA review of Breyanzi for relapsed/refractory FL could extend CAR T therapy benefits to high-risk lymphoma patients.
Daewoong's NUCEIVA® Botulinum Toxin Launches in Australia at Aesthetics 2024, Marking Global Expansion and New Opportunities in Aesthetic Treatments.
Tanvex BioPharma USA, Inc. secures FDA approval for NYPOZI™ and BLA acceptance for TX-05, advancing biosimilar innovation for cancer treatment.
FDA lifts partial hold on MediLink's BNT326/YL202 Phase I trial, resuming recruitment with new safety measures and updated protocols.
Visiox Pharmaceuticals merges with Ocuvex Therapeutics to enhance eye care leadership, expanding their product range and market impact.
Oncimmune lands a $1.5M contract to profile IgE autoantibodies, expanding its global pharma partnership. Revenue expected in FY 2025.
Germany faces drug shortages as states halt China inspections due to new espionage laws, risking supply chain disruptions in Europe.
Hyundai Pharm launches Slinda in South Korea through an exclusive deal with ASKA Pharmaceutical, offering a new progestin-only contraceptive option.
Nightingale Health secures additional HSA approval in Singapore for expanded blood tests including fatty acids analysis.
ZOLL® wins bid for Vyaire Medical’s ventilator business, pending court approval, enhancing its respiratory care portfolio.
Regeneron receives CRL for linvoseltamab in R/R MM, awaiting FDA re-inspection after manufacturing concerns.
Marksans Pharma's Goa plant receives EIR from USFDA, inspection classified as Voluntary Action Indicated (VAI).
Granules Pharma’s ANDA for Glycopyrrolate Oral Solution 1mg/5mL, bioequivalent to Cuvposa, accepted by FDA.
Fujifilm Diosynth Biotechnologies expands its facility, tripling production capacity to support specialized treatment for wet age-related macular degeneration.
VGXI Inc. joins the BioMap Consortium, enhancing U.S. biopharmaceutical production with its extensive expertise and leading plasmid DNA capacity.
eXmoor Pharma gains MHRA licence for GMP-grade cell and gene therapies at its new Bristol facility, marking a key milestone in its global expansion
Delhi High Court rules that trademark laws apply to corporate names, overturning Mankind Pharma's case dismissal against Mercykind Pharmaceuticals.
IGC Pharma’s AI suggests IGC-1A may be a GLP-1 agonist, offering growth potential in Alzheimer’s and weight loss markets.
BerGenBio teams with Tempus to advance bemcentinib for NSCLC, leveraging AI for data-driven insights and synthetic controls.
Sigachi Industries launches PureCoat and UltraMod, revolutionary pharmaceutical coatings designed to enhance drug stability, delivery, and bioavailability.
Benuvia to source DEA-approved cannabis and psychedelics from Bright Green for cGMP pharmaceutical APIs.
Touchlight and Nottingham University collaborate on scalable DNA vaccine for Zika, backed by UK Vaccine Network.
Vantedge Medical, backed by Aterian, acquires precision device maker Hobson & Motzer to expand in surgical staplers and enhance manufacturing for top OEMs.
SI-Bone’s TNT Implant earns FDA clearance, offering enhanced fixation and reduced screw backout for pelvic fractures. Designed for sacropelvic anatomy.
Amplitude Vascular Systems partners with Jacobs Institute to test Pulse IVL system for improved coronary and carotid artery treatments and stroke care.
TNF Pharmaceuticals to begin mid-stage trials for MYMD-1, targeting sarcopenia and expanding into autoimmune conditions.
RedHill Biopharma launches Talicia in the UAE to treat H. pylori infections, marking the region’s first low-dose rifabutin therapy.
Tris Pharma initiates Phase 3 trials for cebranopadol, designed to provide opioid-level pain relief with less addiction risk.
ST Pharm signs deal with Gilead, driven by US biosecurity measures, to supply APIs for blockbuster HIV drug Biktarvy.
Troy M. Wagner named VP of Quality Assurance at Tempest Therapeutics, focusing on late-stage oncology candidate amezalpat.
Leo Pharma’s TMB-001 for congenital ichthyosis fails Phase III trial, missing key goals, halting FDA submission plans.
Innocan Pharma’s subsidiary achieves MoCRA compliance, advancing plans for premium cosmetics in the US market.
eXmoor Pharma earns MHRA approval, enabling GMP manufacturing of cell and gene therapies for clinical trials in the UK.
Novartis and Versant launch Borealis Biosciences, advancing kidney disease research with xRNA-based innovations in Canada.
Bridge Biotherapeutics partners with HitGen to fast-track the discovery of novel anticancer drugs, leveraging HitGen's DNA-encoded library technology.
Samjin Pharmaceuticals donates Geworin to underserved communities and disaster zones, boosting global healthcare efforts.
UK approves Leqembi for early-stage Alzheimer’s, but NHS access denied due to high costs and uncertainty over long-term effectiveness.
The FDA is launching a new surveillance system to better track risks of defective medical devices, aiming to prevent injuries and deaths. Launch by Dec 2024.
Alkem MedTech partners with Exactech to manufacture and market joint implants in India, boosting local production and expanding orthopedic access.
PharmaTech Expo 2024 returns in Gujarat, emphasizing pharmaceutical advancements and industry collaboration.
DuPont strengthens medical device capabilities with acquisitions of Donatelle and Spectrum Plastics, enhancing growth.
VION acquires Echelon Biosciences, boosting lipid-based excipients for mRNA therapies and expanding product offerings.
OKYO Pharma’s OK-101 shows promise in Phase 2 trials for dry eye and corneal pain, addressing unmet medical needs.
Altamira expands Bentrio® distribution to Sweden and Denmark via Pharma Nordic, following success in Norway’s market.
Eli Lilly extends partnership with Oblique Therapeutics to discover a second antibody using AbiProt’s epitope technology.
Ingenza and Cellugy team up to advance bacterial cellulose production for bio-based alternatives to petrochemicals.
India’s BioE3 Policy aims to drive biotech growth, innovation, and biomanufacturing jobs through green economy models.
BioIVT acquires ZenBio to enhance biospecimen offerings, expand cell services, and boost support for pharma and cosmetics R&D.
LBT Innovations upgrades APAS® Independence to support 55mm plates, boosting pharmaceutical environmental monitoring capabilities.
Alembic Pharma gets USFDA approval for Betamethasone Valerate Foam, 0.12% for scalp dermatoses. Total 213 ANDAs approved.
Innocan Pharma’s BI Sky Global achieves FDA MoCRA registration, meeting high standards for U.S. cosmetic products.
PPPI aims to partner with PhilHealth to secure medicine supplies for Konsulta and GAMOT programs, with new Botika ng Bayan for distribution.
Orchid Pharma and Cipla launch Cefepime-Enmetazobactam for cUTI, HAP, and VAP, boosting AMR efforts and nationwide distribution in India.
Siemens Healthineers buys Novartis’ AAA diagnostics unit for €200M, enhancing PET scan imaging and market reach.
SurGenTec’s FDA-approved B-MAN Kit enhances bone marrow aspiration with CELLect tech for optimal, contaminant-free results.
The Union Cabinet approves BioE3 policy, boosting India's biomanufacturing with a focus on innovation, sustainability, and net zero emissions by 2070.
Tonix Pharmaceuticals and Bilthoven Biologicals team up to advance TNX-801, a promising mpox vaccine candidate, showing strong preclinical results.
Sana Biotechnology names Dr. Dhaval Patel as EVP & CSO, advancing clinical programs and Type 1 diabetes trials, with a stock target increase.
Regeneron's Ordspono gets EU nod for relapsed or refractory follicular lymphoma and DLBCL, marking its first bispecific.
A new initiative by IFC and The Netherlands aims to strengthen Jordan's pharmaceutical sector, enhancing exports and attracting foreign investments.
FDA approves Moderna and Pfizer mRNA Covid-19 vaccines targeting Omicron KP.2, offering enhanced protection for ages 6 months and up.
Avery Dennison introduces AD Minidose U9XM, a high-memory UHF RFID tag for precise tracking and authentication of small pharmaceutical items.
EyePoint Pharmaceuticals faces new FDA scrutiny over Yutiq manufacturing at its Watertown facility, following a Form 483 and recent warning letter.
OKYO Pharma secures U.S. Patent No. 12,053,501 for OK-101, enhancing dry eye disease treatment and strengthening its IP portfolio.
Sanofi halts flu vaccine distribution in China due to reduced effectiveness concerns. The pause affects Vaxigrip and VaxigripTetra for the 2024-25 season.
Bharat Biotech Launches HILLCHOL Oral Cholera Vaccine to Bridge Global Supply Gap with 200M Dose Production Capacity.
Chinese medical device companies are expanding globally to tackle domestic competition and regulatory hurdles, driving growth.
AIIMS Delhi partners with Osaka University to set up a center in Jhajjar for medical device development under "Make in India.
Pharma Now partners with Indian Vaccine Leaders Conclave 2024, spotlighting vaccine advancements, collaboration, and top achievers.
Explore Cardinal Health's new 8,000-sq-ft Advanced Therapy Innovation Center, offering cutting-edge logistics for cell & gene therapies in Tennessee.
Pharma giants Alkem and Entod seek Delhi HC relief to deplete banned FDC drug stocks, challenging a new government ban on 156 such combinations.
New Mpox variant Clade 1b spreads rapidly from Africa to Europe and Asia, prompting a global health emergency and a $135M funding call by WHO.
GAO audit exposes FDA's challenges in tracking medical device safety, highlighting risks to patient health and well-being
UCSB secures $22M NSF grant to create ExFAB, the first U.S. biofoundry focused on harnessing extreme microbes for innovative biotech solutions.
NSF invests $75M in 5 biofoundries to advance biology, AI, and health, democratizing research access and supporting innovation across diverse fields.
Novartis' Leqvio (inclisiran) shows promise in a Phase III trial, significantly lowering LDL-C levels in ASCVD patients, paving the way for regulatory approval.
Natco Pharma files with the FDA for a generic version of Novartis' Tabrecta, seeking 180 days of exclusivity. Shares drop as Sensex rises.
New PFAS-free method from Amsterdam scientists adds trifluoromethyl groups to drugs, enhancing safety and sustainability.
FDA cites Global Calcium for major production and documentation issues following Tamil Nadu plant inspection.
Pfizer launches PfizerForAll, a direct-to-consumer platform for easier access to treatments like vaccines and migraine therapies.
Irrimax Corporation introduces new kits to extend the use of its IRRISEPT solution, focusing on infection reduction and improved care.
OxiWear's FDA-approved ear-worn pulse oximeter revolutionizes real-time SpO₂ monitoring, enhancing patient care.
AMRA Profiler 4 secures EU MDR certification, paving the way for advanced body composition analysis in Europe.
India's BioE3 policy aims to drive innovation and bio-manufacturing, targeting Rs 25 lakh crore growth by 2030 while promoting a cleaner, greener economy.
FDA clears Cosmo IMD’s GI Genius hardware with ColonPRO AI, enhancing polyp detection and improving colorectal cancer screenings during endoscopy.
Lilly is ramping up GLP-1 production with advanced tech and sustainable practices to meet rising demand and minimize environmental impact.
Torrent Pharma's Indrad facility receives USFDA EIR with VAI classification, ensuring operations and reinforcing its position in regulated markets.
Zydus Lifesciences receives FDA approval for Scopolamine Transdermal System. Production to begin at Matoda facility; product targets nausea and motion sickness.
Sanyou Biopharmaceuticals introduces a new monkeypox product line with 65 items, including antigens, antibodies, and cell lines for diagnostics and research.
WHO urges manufacturers to submit mpox diagnostic tests for emergency use listing as cases rise in Africa, especially in the DRC.
WHO Regional Committee for Africa sets a goal for 55% local production of medicines and vaccines by 2035 to tackle health crises.
Kiyatec’s 3D Predict Glioma test improves survival rates for high-grade glioma patients by predicting chemotherapy response.
DePuy Synthes debuts MatrixSternum chest fixation system, claiming superior strength and reduced procedure time in surgeries.
Tanvex BioPharma secures U.S. FDA approval for Nypozi, a Neupogen biosimilar, and advances its TX-05 BLA for HER2-positive cancer treatment.
Swiss pharma firms, like Novartis, use patent battles to block generics and keep drug prices high, affecting global access and costs.
NXP800 earns FDA Orphan Drug status for ARID1a-deficient ovarian cancers, boosting development and exclusivity.
Servier Korea launches Tibsovo, targeting IDH1 mutation in cholangiocarcinoma and AML, offering new hope for patients with rare cancers.
GSK Boostrix vaccine sales halted due to a packaging defect, affecting two batches with future expiration dates.
Zealand Pharma's DREAM trial reveals dapiglutide reduces weight by up to 4.3% in 12 weeks with good safety and tolerability.
Bayer AG’s Kerendia demonstrates a 16% risk reduction in heart failure complications, boosting growth prospects amid challenges in its pharma division.
FDA warns Eugia Pharma for manufacturing lapses and data issues at its Telangana plant. Corrective actions required.
Biocon Pharma receives USFDA approval for its generic Sacubitril/Valsartan Tablets to treat chronic heart failure.
Cosmo IMD's GI Genius™ boosts polyp detection by 8.3% over standard colonoscopy, as revealed in a new Lancet study, advancing colorectal cancer screening.
GT201, Grit Biotechnology's advanced TIL therapy, secures U.S. FDA IND approval. A breakthrough in solid tumor treatment, powered by proprietary platforms.
Dr. Krishna Ella of Bharat Biotech challenges multinational priorities and media coverage, urging balanced innovation.
Aspivix’s Carevix device receives MHRA approval, advancing gynecology with enhanced patient comfort and care standards in the UK.
FDA authorizes Novavax’s updated COVID-19 vaccine; CDC recommends for individuals 12+ with nationwide distribution soon.
BioPhorum expands with Brookwood Global acquisition, boosting training services in clinical research and life sciences.
Emcure gains court relief from FDC ban, sparking industry debate on the regulation and approval of drug combinations.
Abbott and Medtronic partner to create a diabetes management system, combining FreeStyle Libre CGM with advanced insulin delivery for optimal glucose control.
Johnson & Johnson's nipocalimab aims for FDA approval as a new treatment for generalized myasthenia gravis, showing promising Phase 3 results.
GSK's hepatitis B drug bepirovirsen earns FDA Fast Track status amid a series of promising treatment updates.
Aurobindo Pharma accelerates its specialty portfolio with 14 biosimilars, boosting supply chain efficiency and investing heavily in R&D and biologics.
Explore cutting-edge PNH treatments, including crovalimab and PiaSky, revolutionizing care with new therapies and improving patient outcomes.
The ARC Centre of Excellence in Quantum Biotechnology aims to revolutionize biotechnology and biosciences in Australia.
Entod Pharmaceuticals secures DCGI approval to market PresVu, India's first eye drops for presbyopia treatment
Sareum Holdings obtains US patent for SDC-1801, protecting its innovative autoimmune disease therapy.
Innocan Pharma secures FDA support for expedited approval of its LPT-CBD drug, advancing chronic pain treatment innovation.
Athira Pharma's LIFT-AD study showed fosgonimeton didn't meet primary endpoints but showed promising biomarker and subgroup results.
Zydus Lifesciences receives FDA warning for its Jarod plant after Form 483 citations; plans to address the issues promptly and ensure compliance.
Acepodia teams up with Pfizer Ignite to advance its Nobel-winning cell therapies for cancer and autoimmune diseases, without financial transactions.
Lilly and EVA Pharma partner to locally produce baricitinib, aiming to improve healthcare access in 49 African countries.
Essential Pharma acquires Renaissance Pharma, adding Hu14.18 to its portfolio to address pediatric oncology needs.
Roche's fenebrutinib reveals potential in MS treatment, with positive Phase II extension results presented at ECTRIMS.
Recipharm’s ReciPredict platform applies Quality by Design to accelerate drug development, cut API use by up to 70%, and ensure efficient tech transfers.
Olon plans to acquire HuvePharma Italia Srl and its Garessio facility, boosting production capacity. This expands Olon's presence in Italy and API expertise.
AdvaMed earns ANSI accreditation to set new standards for medical imaging, cybersecurity, and AI, driving innovation in medtech.
MHRA approves Moderna's updated Covid-19 vaccine targeting the JN.1 variant, available via NHS and private purchase for high-risk individuals.
Novartis invests $200M in U.S. radiotherapy with new facilities in California and upgrades in Indiana to boost production and tackle isotope shortages.
EMA's pilot program offers free expert guidance to advance orphan medical devices for rare and pediatric conditions.
The FDA has published a paper on health equity in medical devices, requesting public feedback on key considerations.
Abbott teams up with Beta Bionics to integrate FreeStyle Libre with iLet Bionic Pancreas, streamlining diabetes care.
Paragonix partners with NORA to create a new organ transport service using commercial flights to improve distribution equity.
Astellas opens a new life sciences hub in Massachusetts, featuring a cutting-edge SakuLab to foster biotech innovation and collaboration with 400 employees.
CHECK and RWEAL studies reveal high prevalence of chronic hand eczema in Europe and Canada, stressing the need for better treatments.
Purdue Pharma wins an 18-day extension to continue settlement talks over the Sacklers' role in the opioid crisis, amid criticism and legal scrutiny.
Emcure launches Arth, a range of products focused on easing menopause symptoms and empowering women's health.
Evotec partners with X-Chem to accelerate early drug discovery using DEL technology and advanced data mining tools.
WHO launches guidance to curb antimicrobial resistance by addressing antibiotic pollution from manufacturing waste.
Takeda partners with Sun Pharma and Cipla to commercialize Vonoprazan in India, targeting GERD treatment needs.
Lotus Pharmaceutical acquires Alpha Choay rights from Sanofi in Vietnam & Cambodia, enhancing its anti-inflammatory drug market presence in Southeast Asia.
BlueRock’s OpCT-001 gets FDA IND approval for treating primary photoreceptor diseases. Phase 1/2a trial launching soon.
Novartis CEO Vas Narasimhan announces a $1 billion deal to sell U.S. dermatology and generics divisions to India's Aurobindo Pharma, driving strategic refocus.
NImmune teams up with BioTherapeutics to enhance immunology therapeutics with preclinical and regulatory expertise.
Qiagen and Eli Lilly team up to create an in vitro diagnostic for Alzheimer's detection using APOE genotyping.
Ivonescimab shows significant promise in treating NSCLC, reducing disease progression by 49% over Keytruda.
Firebrick Pharma's Nasodine nasal spray is under review in Europe, with approval anticipated by December 2024.
Sun Pharma and Moebius Medical receive USFDA fast track designation for MM-II, a non-opioid knee osteoarthritis therapy.
Nano4Imaging teams with Arrotek to enhance U.S. production and development of MRI-compatible medical devices.
Suven Pharmaceuticals' share price jumped 3.67% to Rs 1,245 after its Hyderabad facility received a VAI status from the US FDA.
AstraZeneca's new inhalers with a 99.9% eco-friendly propellant mark a major step in cutting greenhouse gas emissions.
Cizzle Biotech partners with Moffitt Cancer Center to test its CIZ1B biomarker for early lung cancer detection.
ProKidney announces strategic updates for rilparencel Phase III trials, targeting faster FDA approval process.
Agilent Technologies launches its Biopharma CDx Services Lab, offering cutting-edge diagnostics and precision medicine solutions for biopharma clinical trials.
Scantox Group acquires UK-based Gentronix, a leader in genetic toxicology, expanding services and global reach in predictive toxicology for drug development.
Newcells Biotech's CiliaBeat software and Lung Ciliary Beat Frequency Assay revolutionize drug testing with precise, predictive insights on ciliary function.
Aptar Pharma partners with PULMOTREE to advance the Kolibri™ Non-Propellant Inhaler, enhancing drug delivery with comprehensive support.
Formosa Pharmaceuticals has shipped its new clobetasol ophthalmic suspension to the US, marking a major step towards its September 2024 launch.
India to locally manufacture Clavulanic Acid and Penicillin G under the PLI scheme, boosting antibiotic production.
GST Council reduces tax on cancer drugs to 5%, enhancing affordability and accessibility for patients across India.
FDA clears Femasys' FemCheck, a diagnostic tool for fallopian tube occlusion, supporting non-surgical birth control.
Abbott rolls out Aveir DR leadless pacemaker in the UK, a dual-chamber system that improves heart rhythm treatment.
Keen Vision Acquisition Corp. and Medera to merge, creating a $622.6M entity focused on gene therapies and Nasdaq listing.
CPHI Milan announces 2024 Pharma Awards finalists, featuring new "Woman of the Year" and "Future Leader" categories celebrating industry innovation.
Roche opens its state-of-the-art pRED Center in Basel, enhancing global R&D collaboration to accelerate innovation and improve patient outcomes.
Novartis is expanding with a new California facility and an Indianapolis upgrade to boost radiopharmaceutical production and meet growing demand.
iCardio.ai partners with SARC MedIQ to integrate AI into ultrasound imaging, improving diagnosis speed and accuracy.
Vasa Therapeutics' lead drug, VS-041, enters clinical trials, aiming to treat heart failure with preserved ejection fraction.
Pharma Now announces media partnership with Pharma Packaging and Labeling Forum 2024, covering innovations and trends.
Nxera Pharma Co. recognizes Centessa's promising Phase 1 results for ORX750, a potential narcolepsy treatment, demonstrating strong safety and efficacy.
Ascendis Pharma's YORVIPATH secures FDA Orphan Drug exclusivity for treating adult hypoparathyroidism, granting seven years of U.S. market exclusivity.
Chicago Rockford International Airport (RFD) launches a GDP-certified pharma trade lane from India, boosting efficiency and cutting CO2 emissions.
BIOCAPTIVA’s new US patent for liquid biopsy tech boosts cfDNA extraction, enhancing disease detection and personalized medicine.
Sanofi and Regeneron's Dupixent shows strong potential in treating bullous pemphigoid, chronic urticaria, and COPD, possibly changing treatment standards.
GSK’s HSV vaccine candidate fails phase II, halting progress. The company continues safety and follow-up analysis.
Novo Nordisk's weight loss pill shows promising early results, with up to 13% body weight loss in 12 weeks.
BGS Beta-Gamma-Service opens its first U.S. sterilization facility, addressing growing demand for E-Beam technology.
Turbine’s AI platform helps Ono identify cancer targets, accelerating drug discovery with in vitro validation.
Tesla BioHealing and Cell Biotechnology partner to revolutionize stem cell therapies with advanced biophoton technology.
Sino Biological and BioGeometry team up to revolutionize protein design and optimization with advanced AI technology.
Pharma M&As drive innovation, expand reach, enhance healthcare solutions, and strengthen market positions worldwide.
DeCODe consortium launches to support paediatric and orphan device development for children with rare diseases in Europe.
C2 PHARMA introduces Naphazoline HCL, a versatile API for red eyes and nasal relief. Awaiting CEP approval, with US-DMF and Brazil filings set for 2024.
Zeto teams up with Firefly Neuroscience to integrate AI with EEG headsets, improving brain health diagnostics.
Nona Biosciences and Umoja Biopharma partner to develop novel CAR-T cell therapies using proprietary antibody platforms.
NS Pharma's NS-050/NCNP-03 for Duchenne receives FDA Rare Pediatric Disease status, bringing new hope with its exon-skipping approach.
Arrowhead Pharmaceuticals’ RNAi treatment, plozasiran, gains FDA breakthrough status, speeding up development for rare genetic condition FCS.
Moderna’s mRNA-4359 vaccine shows promise in early trials for advanced cancer, boosting immune response with minimal side effects.
AdjuTec Pharma begins Phase I trials for APC148, targeting antibiotic resistance, with safety studies starting on Sept 18 in Uppsala, Sweden.
FDA authorises first over-the-counter hearing aid software for AirPods Pro, making hearing support more accessible.
Biocomposites introduces its NanoBone product range in the UK, providing surgeons with cutting-edge bone graft solutions.
Merck's KEYTRUDA improves 5-year overall survival by 34% in high-risk early-stage TNBC, showing a significant benefit.
MOB-015 Phase 3 trial shows fewer clinical cures than expected; Cypher holds Canadian commercialization rights.
Prelude's PRT3789 shows early efficacy in Phase 1 trial, reducing tumors in SMARCA4-mutated cancers with mild to severe effects.
Ascendis Pharma's TransCon IL-2 β/γ shows 29% clinical response in pretreated, platinum-resistant ovarian cancer patients.
Richter Biologics unveils its new P2 production facility, expanding capacity for pDNA, vaccines, nanobodies, and recombinant proteins, with a €95M investment.
Aarti Drugs and IPCA Laboratories face ransomware attacks; sensitive financial and employee data exposed online.
Eli Lilly's eczema drug, Ebglyss, gets FDA approval for adults and children over 12, offering monthly doses for atopic dermatitis. Available soon in the US.
FDA approves Strides Pharma's generic fluoxetine, boosting dosage options and expanding the market for depression treatment.
Piramal Pharma's GHG reduction goals get SBTi approval, aiming for a 42% cut in scope 1 and 2 emissions by FY2030.
J&J MedTech’s Shockwave Medical introduces the E⁸ IVL catheter, tackling complex peripheral artery disease
FDA approves Roche’s Ocrevus Zunovo, the first subcutaneous injection for relapsing and primary progressive MS.
Myeloid Therapeutics debuts Aurora Biosynthetics in Sydney to drive GMP production of RNA therapeutics in Asia-Pacific.
APIIC secures $16.4M to produce crucial APIs for asthma, diabetes, and anxiety, boosting U.S. pharmaceutical manufacturing and supply chain resilience.
Argon Medical launches a Thrombectomy system CLEANER Vac™, that aids blood clot removal, eases technically compound procedures for physicians.
Tonix Pharma's TNX-801 mpox vaccine meets WHO criteria, promising single-dose effectiveness and ambient temperature stability.
Utah will resume its lawsuit against Richard Sackler and Purdue Pharma, seeking justice for deceptive OxyContin marketing after a 60-day pause.
Smith’s Medical Recall Airway tubes, linked to several injuries & one death, received warning letters and frequent quality problems.
Epitomee Medical gains U.S. FDA clearance for its drug-free Epitomee® Capsule, helping adults with BMI 25-40 manage weight through diet and exercise.
Sanofi ships BEYFORTUS, the first RSV prevention antibody for infants, to healthcare providers ahead of RSV season.
Zentalis announces FDA has lifted the hold on azenosertib studies. The company will reveal new data and updates at a corporate event later this year.
nfigratinib by BridgeBio earns FDA Breakthrough Therapy Designation, advancing treatment options for achondroplasia.
Boston Scientific’s INGEVITY™+ Pacing Leads now FDA-approved for expanded use in conduction system pacing and left bundle branch area monitoring.
Liquidia secures a win as United Therapeutics is found liable for $137M in losses over delayed Treprostinil launch.
Capricor Therapeutics and Nippon Shinyaku bind a term sheet for augmentation of sales and development of Deramiocel.
LEO Pharma launches a single-dose auto-injector for Adbry (Tralokinumab) in the U.S., enhancing treatment for moderate-to-severe atopic dermatitis.
Novo Nordisk GBS launches Eco Med Safe to revolutionize medication disposal and safeguard the environment.
GSK partners with Brooke Shields for THRIVE@50+, empowering those over 50 to prioritize health, raise shingles awareness, and embrace aging confidently.
The MHRA launches a strategy to transform safety communications, providing clear, targeted safety updates for the UK.
MIRA Pharmaceuticals aims to demonstrate clinical efficacy of its oral ketamine analog in 2025 with Phase I/II trials.
AstraZeneca’s Fasenra approved by FDA for EGPA, a rare vasculitis. It helps patients reduce dependence on steroids.
Aligos Therapeutics to announce Phase 2a results for MASH treatment ALG-055009 and host webcast on September 19, 2024.
Rocket Pharmaceuticals completes enrollment for pivotal Phase 2 trial of RP-A501, a gene therapy for Danon disease.
Merck’s KEYTRUDA gains FDA approval for first-line use in advanced mesothelioma, improving survival when combined with chemotherapy.
Plus Therapeutics will present its innovative radiotherapeutics for GBM and CNS cancers at the 2024 CNS Annual Meeting in Houston, TX.
BioMarin's ISDS 2024 data shows VOXZOGO® boosts height and quality of life in children with achondroplasia and other genetic disorders.
Pharma Now partners with Evolution Summit 2024 to spotlight clinical trial innovations and insights.
Zydus Lifesciences recently announced its acquisition of Sterling Biotech’s API for cash compensation of Rs 84 crore.
Charles River and CEBINA announce collaboration for novel neuroscience research, fulfilling medical needs globally.
Patients with EGFR-mutated NSCLC who had previously received EGFR-TKI treatment were treated with Patritumab Deruxtecan and achieved vital endpoints.
Genentech's Xofluza reduces influenza transmission in a Phase III trial, showing promise for pandemic preparedness.
Newron Pharmaceuticals reports strong clinical progress with evenamide for schizophrenia, plus H1 2024 financial updates.
Hyphens Pharma launches Ceradan® Advanced Hand Balm with patented pH control, offering targeted relief and protection for hand eczema.
Pharma Now to cover key trends and innovations at the Global Pharma Supply Chain & Logistics Forum, Munich 2024.
GSK's Blenrep, in combination therapies, is under review by Japan's MHLW for relapsed/refractory multiple myeloma.
Astellas Pharma’s DIGITIVA™ earns FDA listing as a Class I SaMD, debuting in the U.S. digital health market with at-home heart failure monitoring.
Takeda to disclose new data on TAK-861 for Narcolepsy at Sleep Europe 2024, September 24-27 in Seville, Spain”
Tonix Pharmaceuticals gets U.S. Patent No. 12,090,139 for Tosymra®'s intranasal migraine treatment, enhancing its market position and IP protection.
Hovione and iBET launch ViSync® in Portugal to enhance drug delivery and stabilization in cell and gene therapy, combining expertise in pharma and biotech.
Abbott India signs an agreement with Takeda to commercialize Vonoprazan, offering better GERD treatment options.
Novartis reports significant Kesimpta outcomes in reducing MS progression, showing promise for first-line treatment.
FUJIFILM Irvine Scientific's Oceo Rover, automated hydration system changing media prep and bioprocessing efficiency.
Achilles Therapeutics halts its TIL-based trials, shifts focus to new cancer treatments, and explores strategic options with BofA Securities.
Glenmark Pharmaceuticals' Aurangabad plant successfully passes U.S. FDA inspection with zero observations.
FDA approves Sarclisa with VRd for newly diagnosed multiple myeloma patients, improving progression-free survival by 40%.
Lupin receives FDA approval for generic Bumetanide Injection, used to treat edema linked to heart, liver, and kidney diseases.
AbbVie’s ELAHERE® receives EMA recommendation for treating platinum-resistant ovarian cancer after prior therapies.
EMA recommends Pfizer-BioNTech's Omicron KP.2-adapted COVID-19 vaccine for individuals 6 months and older in the EU.
Teva's SOLARIS trial shows TEV-749, a monthly injectable, reduces schizophrenia symptoms with no PDSS and a strong safety profile.
Dupixent receives a positive opinion from European regulators for treating eosinophilic esophagitis in young children.
Zeposia shows sustained brain volume loss reduction and maintains safety in long-term study for multiple sclerosis.
Teva presents new data on transitioning schizophrenia patients from Perseris® to UZEDY® at ECNP Congress.
Imexpharm focuses on talent recruitment, R&D, and global expansion to secure a leading position in Vietnam’s pharmaceutical market.
AdjuTec Pharma launches phase 1 trial for APC148, aiming to combat antibiotic resistance and improve public health.
Longboard’s lead candidate, bexicaserin, gains FDA Rare Pediatric Disease and Orphan Drug designations for Dravet syndrome.
HudsonAlpha team employs long-read sequencing to re-analyze genomes, improving diagnostic rates for rare genetic disorders.
Huawei establishes an AI driven system that aids accuracy, diagnosis and intelligent quality control.
Pharma Giant Novo Nordisk to reveal the massive demand for its weight loss drugs, Ozempic and Wegovy.
Capricor Therapeutics will discuss the latest FDA regulatory updates for its Duchenne program during a webcast.
Tonix Pharmaceuticals reveals Phase 3 success for TNX-102 SL in fibromyalgia, aims for 2025 FDA approval.
AstraZeneca’s Fasenra recommended in EU for relapsing eosinophilic granulomatosis with polyangiitis, based on Phase III data.
Innate Pharma receives FDA clearance to begin Phase 1 trial of IPH4502, a Nectin-4-targeting ADC for solid tumors.
LEO Pharma gains EC approval for Anzupgo® cream, offering a new treatment for moderate to severe chronic hand eczema.
Datopotamab deruxtecan shows progression-free survival benefits but fails to meet overall survival in key breast cancer trial.
BioAtla and Context Therapeutics sign a deal for BA3362, a TCE antibody for solid tumours, with Context leading development and commercialization efforts.
Chugai wins approval for Evrysdi to treat pre-symptomatic SMA, enabling early intervention for infants through genetic screening.
Japan approves Veltassa® for hyperkalemia treatment in adults, offering effective potassium control for CKD and HF patients.
India's largest-ever analytica Anacon India, India Lab Expo, and Pharma Pro&Pack Expo to bring global insights to Hyderabad.
atalyst Pharmaceuticals' partner, DyDo Pharma, gets approval to commercialize FIRDAPSE® in Japan for LEMS.
Allergan Aesthetics launches 2024 BOTOX® Cosmetic grants, empowering women entrepreneurs through mentorship, grants, and crowdfunding support.
Acurx Pharmaceuticals unveils exciting ibezapolstat research, spotlighting its potential against C. difficile infections.
Takeda gains approval in Japan to market FRUZAQLA for advanced colorectal cancer, providing new hope for patients.
Dr. R.N. Gupta appointed as National President of IPA for 2024-2026. With 50 years in pharma, he has made significant contributions to the industry.
Preclinical data for the treatment of KRAS mutated cancers to be presented at the 6th Annual RAS-Targeted Drug Development Summit.
Alvotech begins a trial for AVT16, a biosimilar to Entyvio®, to test its effectiveness and safety for Ulcerative Colitis.
Merck's KEYTRUDA (pembrolizumab) has gained expanded approval in Japan for non-small cell lung cancer and urothelial carcinoma, offering new treatment options.
Sanner's acquisition of Gilero enhances its global CDMO services and capabilities in drug delivery and medtech.
AbbVie’s analysis shows upadacitinib improves moderate-to-severe atopic dermatitis in the head and neck over 16 weeks.
Pfizer voluntarily recalls all OXBRYTA® lots from global markets, addressing concerns for sickle cell disease treatment.
Analytica Anacon, India Lab Expo & Pharma Pro & Pack Expo 2024, Hyderabad, attracts over 25,000 participants exploring innovations in pharma and packaging.
Acurx’s ibezapolstat enhances microbiome health, reduces CDI recurrence, and shows activity against anthrax in trials.
Enanta Pharmaceuticals reports promising Phase 2a results for EDP-323, showing significant RSV viral load reduction and strong safety.
NI Pharmaceuticals unveils FDA-approved Ketoconazole Shampoo, 2%, a generic to Nizoral®, in a $69.2M market.
Merck unveils new long-term data on tulisokibart for UC and CD at UEG Week 2024, showcasing sustained efficacy and safety from Phase 2 studies.
Vertex reveals Phase 3 data on vanza triple CF therapy at NACFC, showing long-term benefits of TRIKAFTA in children.
Acadia’s Board grants equity awards to new CEO Catherine Owen Adams as part of the 2024 Inducement Plan.
Tonix Pharmaceuticals secures a U.S. patent for Zembrace® SymTouch® autoinjector, promoting non-oral treatments for faster migraine relief.
New preclinical data on Ketamir-2 will be presented at the 18th Annual Pain Therapeutics Summit in Boston.
Lupin's unit received a Form 483 with three observations, Alembic got an EIR, while Piramal received no observations and an EIR from USFDA.
Jeil Pharmaceutical launches Jaqbo, a P-CAB for peptic ulcers, marking its first in-house drug in 65 years and entering Korea's $1 billion market.
Bayer submits sNDA for NUBEQA to the FDA, aiming to expand its use in metastatic prostate cancer with ADT.
Eris Lifesciences secures CDSCO approval to manufacture an FDC for type 2 diabetes, with Phase IV trials required post-launch.
AbbVie applies for FDA accelerated approval of telisotuzumab vedotin for previously treated non-small cell lung cancer.
Dupixent, by Sanofi and Regeneron, is now FDA-approved for COPD, marking its sixth indication for this blockbuster drug.
Innate Pharma and the Icahn School of Medicine will co-host a hybrid symposium, "Next Generation Immunotherapy Discoveries," on October 3, 2024.
Daewoong Pet enters the CRO sector to develop specialized veterinary medicines, addressing the growing demand for pet pharmaceuticals and clinical trials.
The FDA granted Priority Review for Enhertu, targeting HER2-low breast cancer patients based on positive DESTINY-Breast06 trial results.
Ascendis Pharma submits sBLA to the FDA for TransCon hGH to treat adults with growth hormone deficiency.
Seres Therapeutics sells VOWST™ rights to Nestlé, refocusing on biotherapeutics for high-risk infections in vulnerable patients.
Scorpius Holdings partners with a clinical-stage immuno-oncology firm, offering bioanalytical services and expanding GMP manufacturing capabilities.
Aligos Therapeutics names David Perry as VP of Business Development to drive partnerships and advance its drug pipeline.
BioAtla to showcase Evalstotug (BA3071), a CAB anti-CTLA-4 antibody, at the 2024 Society for Melanoma Research Congress.
Plus Therapeutics presents encouraging safety and efficacy data from Phase 1/2 trial for recurrent glioblastoma therapy.
Surmodics gains FDA approval for the Pounce XL Thrombectomy System, broadening its platform for treating peripheral arteries.
Addition of CN201’s bispecific antibody, enhances Merck's pipeline, targeting B-cell malignancies and autoimmune diseases.
Amneal and Metsera have partnered to develop and supply new global weight loss medicines for obesity and metabolic diseases.
SAWC Fall offers a platform to educate clinicians on the AC5 Advanced Wound System, showcase case studies, and hold strategic meetings with wound care firms.
Recipharm and Exela Pharma Sciences have partnered to enhance sterile manufacturing in the US, focusing on injectable pharmaceutical production.
Pliant Therapeutics appoints Dr. Gary Palmer as Senior VP of Medical Affairs, bringing 25+ years of medical leadership
Brazil honored by WHO for eliminating lymphatic filariasis, a major public health issue. Through strong measures, it joins 19 countries free from the disease.
Scorpius selected for MCDC membership, advancing medical countermeasures to protect against CBRN threats and safeguard national security.
Processa Pharmaceuticals dosed its first patient in a Phase 2 trial for NGC-Cap, aiming to improve breast cancer chemotherapy.
Recursion announced FDA clearance for its IND application to begin a Phase 1/2 trial of REC-1245, targeting biomarker-enriched solid tumors and lymphoma.
Charles River and Lundbeck have partnered to use AI-powered Logica® to enhance the discovery of novel drugs targeting central nervous system disorders.
In 2024, Globus set forth several new system extensions, including the TENSOR™ Suture Button System, & received FDA clearance for orthopaedic products.
Alembic Pharmaceuticals has secured US FDA final approval for its Lamotrigine Extended-Release Tablets in 200 mg, 250 mg, and 300 mg dosages.
Gilead signs licensing deals with six manufacturers to produce generic lenacapavir for HIV prevention in 120 nations.
Afton Scientific Expands Virginia Facility with $200M Investment, creating 200+ Jobs and Boosting Local Biopharma Innovation and Economic Growth.
Lonza acquires Roche's Vacaville biologics site for $1.2 billion, enhancing U.S. manufacturing capacity for next-gen therapies.
Norgine appoints Janneke van der Kamp as CEO, effective January 1, 2025, to drive growth and innovation.
Lilly invests $4.5B in a new Medicine Foundry to boost drug innovation, optimize production, and create 400 jobs in Indiana's LEAP District.
Nicomac Mangini unveils ANIMA AI at CPHI Milan 2024, optimizing pharmaceutical production with real-time monitoring and digital twin simulation.
Kane Biotech gets $75k in NRC IRAP support for DispersinB® Wound Gel R&D, plus $200k for revyve™ tech advancement.
Legend Biotech announces a new R&D facility in Philadelphia, set to boost its next-gen cell therapies by Q3 2025.
David Meline adds deep financial and industry expertise to Lonza’s Board, while Olivier Verscheure has chosen not to stand for re-election at the 2025 AGM.
analytica Anacon India 2024 highlighted 7,000+ products, attracting 25,000 visitors and fostering global innovation.
Charles River Laboratories will showcase 18 scientific posters at Neuroscience 2024, held from October 5-9 in Chicago, collaborating with clients and experts.
Amira Modi joins Sygnature Discovery as COO and Board Member, bringing extensive life sciences experience to drive growth and innovation.
Discover Cellevate's innovative nanofiber microcarriers at CPHI Milan, enhancing viral vector production with 60x more cell growth area.
Sterling Pharma Solutions partners with Soligenix to manufacture GMP-quality synthetic hypericin for clinical development of HyBryte™ targeting rare diseases
WHO established the Global Strategic Plan to tackle diseases like dengue and Aedes -borne arboviruses.
Theriva Biologics presents positive DSMC review for Phase 1b/2a trial of SYN-004 in allogeneic hematopoietic cell transplant recipients, advancing to Cohort 3.
WHO lists first mpox diagnostic under Emergency Use, expanding testing capacity in countries facing outbreaks.
WHO clears single-dose HPV vaccine Cecolin®, expanding vaccine access and helping prevent cervical cancer in girls worldwide
Recordati strengthens its rare diseases portfolio by acquiring Enjaymo®, the only treatment for cold agglutinin disease.
Halozyme collaborates with argenx, adding four new targets for ENHANZE® technology to enhance subcutaneous drug delivery.
Telix’s Illuccix® gains Health Canada approval for selecting mCRPC patients for PSMA-targeted radionuclide therapy.
With 12 fatalities from Marburg, Rwanda initiates a vaccine trial to combat the outbreak and safeguard citizens' health.
AstraZeneca has licensed CSPC's Lp(a) disruptor, YS2302018, aiming to enhance treatments for dyslipidaemia.
DKSH Korea acquires Kyowa Kirin Korea’s specialty pharma unit, enhancing its hematology and nephrology portfolio with key products like Grasin.
Aspire Pharma expands its dermatology and allergy lines by acquiring Canute Pharma, enhancing its portfolio with innovative patient care products.
OnKure merges with Reneo to form OnKure Therapeutics, trading as ‘OKUR,’ advancing cancer treatment innovation.
Discover the 800% surge in mRNA licensing agreements since 2019, highlighting growing confidence in innovative therapies and vaccines.
Afton Scientific expansion in Albemarle County with a $200M investment, adding 200+ jobs and advancing biotech capabilities.
Airsupra significantly reduces the risk of severe asthma attacks, showing positive results in the BATURA Phase IIIb trial.
MTPA shares insights on RADICAVA ORS® treatment for ALS patients at the 2024 NASP Annual Meeting & Expo.
At CPHI Milan 2024, Thermo Fisher will highlight innovations in drug development and sustainability initiatives in healthcare.
Nobel Prize in Medicine honors two Americans for discovering microRNAs, essential in controlling gene expression.
Vincerx Pharma's Phase 1 trial of VIP943 demonstrates positive results in AML, HR-MDS, and B-ALL with complete responses, no dose-limiting toxicities.
Orchard Therapeutics teams up with Er-Kim to distribute Libmeldy, a gene therapy for early-onset MLD in Turkey & Eurasia.
Celly Nutrition partners with FUSION to expand the reach of unbuzzd™, an alcohol metabolism supplement.
Inozyme Pharma adds Erik Harris to its board, leveraging his expertise to advance rare disease therapy INZ-701.
Nipro Launches D2F™ Vials with Stevanato Group's EZ-fill® Technology for Pharma Industry's RTU Needs.
Boehringer Ingelheim's survodutide receives FDA Breakthrough Therapy status for metabolic dysfunction-associated steatohepatitis, accelerating clinical trials.
Synexa Life Sciences boosts its bioanalysis capabilities with the acquisition of Alderley Analytical, enhancing biomarker services for drug development.
Virios Therapeutics and Wex Pharmaceuticals team up to launch Dogwood Therapeutics, advancing treatments for neuropathic pain, fibromyalgia, and Long-COVID.
Discover innovations in battery production, energy storage, and electric mobility at AMPTECH India Expo 2024, Gujarat.
KEYNOTE-689 trial shows KEYTRUDA’s success in improving event-free survival and pathological response in LA-HNSCC.
Positive results from the Phase 3 ASPEN study highlight brensocatib’s potential in treating bronchiectasis effectively.
India has been commended by WHO for eliminating trachoma as a public health problem through effective sanitation efforts.
RTI Surgical has agreed to acquire Collagen Solutions, aiming to boost its capabilities in collagen-based medical devices.
Intas Pharmaceuticals welcomes Sridharan S as Executive VP of API Operations, bringing 28 years of expertise to the role.
Colorcon partners with LOTTE to expand pharma solutions, offering exclusive access to advanced drug formulation and delivery polymers.
Eppendorf launches the CellXpert CS220, a CO2 incubator shaker with 180˚C sterilisation for superior contamination protection and increased flask capacity.
Kindeva Drug Delivery's Bridgeton facility marks a milestone with its first registration batch, boosting injectable fill-finish services and capacity.
BD and ten23 Health Partner to Innovate Aseptic Manufacturing with RFID Technology for Enhanced Prefillable Syringe Traceability.
Tonix Pharmaceuticals partners with X-Chem to harness AI in developing broad-spectrum antiviral drugs, aiming to boost virus-fighting capabilities worldwide.
Novo Nordisk's new global initiative aims to prevent childhood obesity through tailored interventions in six cities.
Cipher Pharmaceuticals names Dr. Hamed Ghanei as CBO, bringing 15+ years of experience in pharmaceuticals and M&A deals.
Catalyst Pharmaceuticals contributes $100,000 to the American Red Cross to aid families destroyed by Hurricane Helene.
Attend the 6th Annual Pharma Manufacturing and Automation Convention in Hyderabad on October 17-18 for industry insights.
Capricor initiates FDA rolling submission for deramiocel to treat DMD cardiomyopathy and seeks full approval by 2024.
Viatris announces successful Phase 3 trial in Japan, showing EFFEXOR®'s efficacy and safety for treating GAD.
Entrada Therapeutics shares positive clinical and preclinical data on DMD treatments at the World Muscle Congress 2024.
Merck will showcase critical findings from its vaccine and infectious disease portfolio at IDWeek 2024, including RSV and HIV research.
Pharma Now celebrates CPHI Milan's 14 awardees for innovation in pharma, from AI-enabled APIs to sustainability, showcasing industry excellence.
Insitro teams up with Eli Lilly to develop AI-driven therapies targeting metabolic diseases, including MASLD.
Mestag collaborates with MSD to discover novel drug targets for inflammatory diseases using its RAFT platform.
Pharma Now recaps CPHI Milan's first two days, highlighting industry innovations, networking, and culinary delights.
Panthera Biopartners becomes the first UK clinical trial site to join Parexel’s global Site Alliance Vaccine Network.
Foghorn's selective SMARCA2 oncology program is part of a U.S. co-development and commercialisation collaboration with Lilly.
Tempest Therapeutics collaborates with Roche to evaluate amezalpat in a Phase 3 trial for unresectable liver cancer.
Cytovale has secured $100 million in funding to accelerate the commercial expansion of IntelliSep for sepsis detection.
Genentech's Itovebi gains FDA approval for PIK3CA-mutated breast cancer, significantly improving treatment outcomes
Nicomac Mangini showcases AI innovations and seismic-certified cleanrooms for optimal pharma production at CPHI 2024.
Pharma Now partners with PharmaPack 2024, covering innovations in pharmaceutical packaging on October 17-18 in California.
Burning Rock and Dizal receive NMPA approval for their co-developed EGFR exon20ins CDx, a first for lung cancer in China.
Arbele collaborates with BioAI and Chime Biologics to accelerate AI-powered cancer therapies and companion diagnostics.
Lipocine's qEEG study confirms CNS engagement of oral brexanolone, supporting its use in psychiatric and neurological conditions.
At IDWeek 2024, GSK and ViiV Healthcare will showcase data on vaccines and treatments for infectious diseases.
Pharma Now celebrates CPHI 2024's success in Milan, featuring groundbreaking pharma innovations, new award categories, and key startups shaping the future.
PW Skills launches School of Healthcare to address India's shortage of trained medical professionals, offering practical and hands-on vocational training.
The second phase of Gaza's polio vaccination campaign starts, aiming to protect 591,700 children with a second dose.
Explore innovations, trends, and regulatory updates in the pharma and chemical industries at Baddi Expo 2024 from Oct 21-23.
The FDA reconsiders the decision, allowing compounders to keep selling cheaper alternatives to Lilly's weight loss and diabetes drugs.
Evonik reorganizes the Coating & Adhesive Resins and Health Care divisions, focusing on core growth areas and divesting non-core businesses for growth.
Enhertu gets conditional approval in China for treating HER2-mutant NSCLC, pending confirmation of clinical benefits.
New data shows Evrysdi helps children with SMA achieve key mobility milestones, underscoring the benefits of early treatment for improved outcomes.
Jonathan Dickinson joins Innate Pharma as CEO and Chairman, bringing extensive biotech expertise to advance innovative immuno-oncology therapies.
LTR Pharma's SPONTAN® shows 470% faster absorption for ED treatment, promising enhanced spontaneity and safety in pivotal study results.
FDA guides Clarity Pharmaceuticals' Phase III trial for 64Cu-SAR-bisPSMA, enhancing prostate cancer diagnostics.
RedHill Biopharma's opaganib selected by BARDA for Ebola treatment, advancing through FDA's Animal Rule with promising results in survival studies.
Samsung Biologics introduces S-HiConTM, a platform enhancing stability and efficacy in high-ose biopharmaceuticals
Ardena secures Catalent's New Jersey facility to boost oral drug manufacturing and broaden its US services.
Exelixis and Merck collaborate to study zanzalintinib with KEYTRUDA and WELIREG in cancer clinical trials.
Lundbeck announces the acquisition of Longboard Pharmaceuticals, which is advancing neurological therapies.
Noul partners with PT Kirana Jaya Lestari to distribute its AI blood testing solution, miLab BCM, in Indonesia, enhancing healthcare efficiency.
Eli Lilly reports promising one-year histologic outcomes for mirikizumab in Crohn's disease, showing significant improvements over ustekinumab.
Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals, offering an 80% premium amid ongoing refusal to engage.
Suven Pharma names Declan Ryan as Chief Commercial Officer. He has 25 years of experience with companies like WuXi, Johnson & Johnson, and Novartis.
Bayer seeks EMA approval for elinzanetant to treat moderate to severe menopause-related hot flashes.
Indaptus progresses Decoy20 Phase 1 trial, with unrestricted patient enrollment at the lower dose approved.
Jazz Pharma Reports Significant Overall Survival and Progression-free Survival for Zezelca and Atezolizumab in First-Line ES-SCLC Maintenance Therapy
Omega Therapeutics announces that it will share preclinical data on epigenomic mRNA medicines at three key conferences.
Pfizer appoints ex-Vanguard CEO Tim Buckley to its Board, joining the Governance, Sustainability, and Audit Committees.
LGM Pharma expands its testing services with endotoxin and rapid sterility testing, offering faster, cost-effective solutions for drug developers.
Pharma India Expo 2024 showcases the latest in pharma machinery, drug development, and networking with industry leaders.
Commit Biologics appoints Dr. Mikkel Pedersen as CSO to lead R&D and develop its BiCE™ technology for cancer and autoimmune therapies.
Berry Global's ClariPPil™ bottles provide sustainable, recyclable packaging with enhanced product protection and reduced CO₂ emissions.
FDA accepts UroGen's NDA for UGN-102, a potential breakthrough for non-muscle invasive bladder cancer, with a PDUFA date of June 2025.
Lantern Pharma's LP-184 secures FDA Fast Track Status, advancing treatment options for Glioblastoma and offering hope for patients.
Circle Pharma's CID-078 enters Phase 1 trials, offering innovative oral treatment options for advanced solid tumors.
LEO Pharma launches Anzupgo® cream in Germany, offering a new treatment for moderate to severe Chronic Hand Eczema.
Astria's navenibart granted OMPD in Europe for HAE, showing 90-96% attack reduction in early trials.
Theriva's VCN-01 receives EU orphan status for retinoblastoma, marking progress in pediatric cancer therapy.
Perspective Therapeutics ships its first patient doses from a new NJ facility, marking a milestone in producing radiopharmaceuticals for cancer treatment.
Keros Therapeutics announces Dr. Yung H. Chyung as Chief Medical Officer, effective November 1, 2024.
Apellis Pharmaceuticals reveals an oral presentation on pegcetacoplan at ASN Kidney Week and two additional posters.
Medical Affairs Summit 2024 in Boston will spotlight strategic innovations, best practices, and regulatory insights in healthcare.
Univercells debuts scale-X™ nexo bioreactor for efficient, scalable cell culture, reducing costs by up to 60%.
Olivier Falut joins EUROAPI as CFO on October 17, 2024, bringing 30 years of financial expertise to the role.
Uhlmann Pac-Systeme inaugurates its new Pune office, showcasing cultural performances and a commitment to innovation.
Tonix Pharmaceuticals submits NDA for TNX-102 SL, which shows efficacy in fibromyalgia in Phase 3 trials and is now under FDA review.
Health Canada approves Acadia’s DAYBUE™ as Canada’s first treatment for Rett syndrome, offering new hope for patients and families.
Matica Bio partners with Mongoose Bio to advance lentivirus production for TCR-T cell therapy, boosting innovation in Texas's biocluster.
Cellular Origins & Fresenius Kabi partner to scale CGT automation, integrating Cue® with Constellation™ for efficient cell therapy production.
AbbVie's VYALEV receives FDA approval as the first 24-hour levodopa-based subcutaneous infusion for advanced Parkinson's.
Kane Biotech signs a 5-year deal to distribute XSONX's Wound Hygiene System across Canada, Australia, and GCC.
Swissmedic grants marketing approval of FILSPARI® for IgAN treatment based on significant phase-III PROTECT trial results from CSL Vifor and Travere.
Charles River introduces the Retrogenix® Non-Human Protein Library to improve off-target assessments.
Orano inaugurates its first 4.0 plant in Cherbourg, producing the TN Eagle cask for safer, efficient nuclear fuel storage.
Virica and eXmoor collaborate, funded by Canada-UK program, to enhance AAV production and reduce gene therapy costs.
Amylyx's AMX0035 shows promising Phase 2 results, improving pancreatic function in Wolfram syndrome patients.
Poseida selects a new CAR-T candidate with Roche, targeting hematologic cancers to enhance treatment options.
Sanofi and Orano Med partner to advance next-gen targeted alpha therapies for rare cancers, combining biopharma and nuclear expertise for precision treatment.
Merck's Clesrovimab cuts RSV risk in infants by 60% in trials, showing promise in preventing severe cases during their first RSV season.
Novo Nordisk's Alhemo® may soon offer the first once-daily subcutaneous treatment for haemophilia A or B with inhibitors.
World Drug Safety Congress 2024 in Boston highlights AI integration, regulatory updates, and innovations in drug safety.
Eylea 8 mg offers extended dosing intervals up to 20 weeks, reducing treatment burden and enhancing patient outcomes.
Korea BNC partners with Dongkook Pharmaceutical to distribute Bienox, a botulinum toxin that reduces frown lines.
FibroBiologics collaborates with Charles River to manufacture fibroblast-based CYWC628 for diabetic foot ulcer trials.
BOTOX® Cosmetic has gained FDA approval for treating platysma bands, becoming the first product in four aesthetic areas.
Dharmesh Kharwar appointed Independent Director at ENTOD Pharmaceuticals, bringing vast industry expertise.
Gland Pharma names Shyamakant Giri as CEO, effective January 2025, bringing over 25 years of global pharma experience.
Omnipaque is approved in Korea for contrast-enhanced mammography, boosting breast cancer detection and patient outcomes.
FDA approves Astellas' gastric cancer treatment, Vyloy, enhancing survival rates alongside chemotherapy.
Egypt is certified malaria-free by WHO, becoming the third country in its region to achieve this milestone.
Eleven monkeys died from melioidosis infection at Hong Kong Zoo, likely due to contaminated soil brought into enclosures.
VYLOY is the first CLDN18.2-targeted therapy that has gained FDA approval for treating advanced gastric and GEJ cancer.
The investigational once-weekly islatravir and lenacapavir combination shows 94.2% viral suppression in HIV patients after 48 weeks.
Angelini Pharma partners with Cureverse to advance CV-01, a breakthrough brain health treatment, securing global development rights.
CHMP recommends WAINZUA (eplontersen) for EU approval to treat hereditary polyneuropathy, offering a potential self-administered option.
Paris backs a €15 billion sale of Sanofi's paracetamol unit to US fund CD&R, ensuring job security and no impact on essential medicines.
MIRA's KETAMIR-2 shows superior efficacy and safety over current therapies in preclinical pain management studies.
Novo Nordisk’s concizumab receives FDA fast-track status, accelerating development for hemophilia A and B treatment.
Amneal's NDA for Pyridostigmine Bromide Extended-Release tablets gets FDA approval for nerve agent poisoning treatment in military use.
Inventiva to present Phase 2 LEGEND study on lanifibranor & empagliflozin in MASH & T2D at AASLD Liver Meeting 2024, Nov 18, 8 AM-5 PM PST, San Diego.
Acurx announces evaluation of the new Phase 2B trial of Ibezapolstat, presented at the IDWeek meeting.
Recursion partners with Google Cloud to leverage AI and tech for faster, cost-effective drug discovery.
Nucleus expands R&D and manufacturing capacity to address radiopharmaceutical supply chain constraints with two new sites.
Pharma Tech Industries names Darrin Schellin as CEO to drive innovation and growth in contract manufacturing.
ABIONYX Pharma advances CER-001 for LCAT deficiency with EMA support, completing a key step in its EU conditional approval process.
B.Grimm Pharma partners with Inter Mohosot to expand access to essential medicines in Cambodia, improving healthcare for key conditions.
WHO and SNOMED International discuss linking ICD-11 and SNOMED CT to improve global health data interoperability.
Recursion's Phase 2 trial begins with the first patient dosed, testing REC-994 for cerebral cavernous malformation (CCM).
Scorpius Holdings forms a strategic partnership with U.S. biotech, transferring RCB for future biomanufacturing.
Alvotech and Teva's SELARSDI receives FDA approval for a new formulation, launching in the U.S. by early 2025.
Aligos receives FDA approval for Phase 1 study of ALG-000184, targeting Chronic Hepatitis B with potential superior efficacy.
Peli BioThermal introduces the Credo Vault, ensuring safe transport of temperature-sensitive pharmaceuticals globally.
Lonza opens a new facility in Geleen, Netherlands, to boost production of plasmid DNA for gene therapies.
Indaptus and BeiGene will start a 2025 trial combining Decoy20 with PD-1 inhibitor tislelizumab for innovative cancer treatment.
Samsung Biologics inks a $1.24B deal with an Asia pharma giant, expanding global manufacturing through 2037.
Parexel appoints Keri Mattox as Chief Business Officer to drive growth and innovation in a pivotal leadership shift.
Bormioli Pharma and Chiesi launch Carbon Capture PET bottles, reducing CO2 emissions by 21.9% in pharma packaging.
NorthStar Medical Opens A New Facility In Beloit, boosting radiopharmaceutical production for cancer therapies & medical imaging.
Avantor strengthens its partnership with NIBRT, enhancing biopharma manufacturing and training critical industry talent.
Cold Chain Technologies strengthens its product portfolio and global presence by acquiring Tower Cold Chain’s reusable packaging.
Kane Biotech donates revyve™ Antimicrobial Wound Gel to Ukraine, aiding the treatment of war-related injuries.
Agios finishes Phase 3 trial enrolment for Mitapivat, aiming to improve treatment of sickle cell disease.
Alphina Therapeutics names Nick Galli as CEO to lead the development of its promising NAMPT inhibitor for solid tumors.
Schreiner MediPharm and WuXi XDC create an innovative Light-Protect-Label for ADCs, ensuring drug safety in trials.
SwRI's new 21,000-square-foot facility will enhance its R&D for small-batch therapeutics, vaccines, and stem cell therapies.
United Therapeutics and Lung Bioengineering celebrate 500 EVLP lung transplants, advancing transplant access with innovative organ evaluation technologies.
NImmune Biopharma gains exclusive rights to develop and commercialize omilancor for I&I conditions in Asia, advancing Phase 3 trials for ulcerative colitis.
Evotec and Bristol Myers Squibb expand their partnership with a $50M investment to advance drug discovery using molecular glue technologies.
Merck acquires Modifi Biosciences for $30M, aiming to boost cancer therapies targeting DNA repair-deficient tumors, with up to $1.3B in milestones.
Merck’s CAPVAXIVE™ earns CDC ACIP recommendation for pneumococcal vaccination in adults 50+, enhancing protection against pneumonia.
Merck's Keytruda secures its 30th European approval, expanding into treatments for gynecologic cancers.
Rigel Pharmaceuticals issues safety advisory for GAVRETO to providers, stressing vigilance in cancer patient care.
Rhythm Pharmaceuticals partners with Axovia Therapeutics for research to better understand Bardet-Biedl syndrome.
AbbVie partners with Richter to discover and develop neuropsychiatric treatments, building on years of CNS research.
ImmunityBio begins trial in South Africa testing CD19 CAR-NK cell therapy for relapsed non-Hodgkin’s lymphoma.
Matica Biotechnology and KaliVir Immunotherapeutics team up to advance scalable viral vector production for cancer therapies.
Walgreens and Veeva Unite to transform pharma collaboration and enhance patient outcomes through integrated data solutions.
Coronado Research appoints Professor Jennifer Visser-Rogers as Chief Scientific Officer to advance clinical research.
Inozyme Pharma shares promising Phase 1 trial results for INZ-701 in ESKD patients at ASN Kidney Week 2024.
Rentschler Biopharma announces a record investment for a new buffer media station in Laupheim, enhancing production efficiency.
Fabhalta by Novartis demonstrates significant one-year benefits for C3G, showing sustained proteinuria reduction and improved kidney function.
Phathom Pharmaceuticals will present VOQUEZNA findings at the ACG meeting, exploring the efficacy of as-needed treatment for GERD relief.
Astellas pulls EMA application for ACP but remains committed to advancing GA treatment options across Europe.
AstraZeneca's Fasenra (benralizumab) receives EU approval for eosinophilic granulomatosis with polyangiitis, providing new hope for patients.
Recce Pharmaceuticals advances its Phase II ABSSSI trial for R327G, showing promising results for diabetic foot infections.
Lilly’s mirikizumab demonstrates sustained remission in UC and Crohn’s patients, with strong safety and symptom control.
Shuttle Pharma launches Phase 2 trial of Ropidoxuridine, aiming to enhance radiation treatment for glioblastoma patients.
Merck and Moderna launched Phase 3 of the V940 trial with KEYTRUDA, targeting non-small cell lung cancer patients post-surgery.
MIRA’s Ketamir-2 significantly outperforms gabapentin in preclinical chemotherapy-related neuropathic pain relief trials.
Monte Rosa licenses MRT-6160 and VAV1-targeting MGDs to Novartis for global development in immune-mediated diseases.
Chime Biologics partners with MedPacto to enhance biomanufacturing capabilities and advanced cancer therapeutics in South Korea.
Sai Life Sciences achieves FDA approval for Indian sites, reinforcing quality and compliance in global CRDMO operations.
Evoke Pharma, in partnership with EVERSANA, reveals GIMOTI's effectiveness in reducing healthcare visits for DGP patients.
AbbVie will acquire Aliada Therapeutics for $1.4 billion, focusing on innovative therapies for CNS diseases like Alzheimer’s.
CluePoints names Richard Young as Chief Strategy Officer to boost innovation in Risk-Based Quality Management.
First volunteers receive a long-acting injectable in a pivotal trial aimed at enhancing malaria prevention and combating this deadly disease.
Ryvu and nCage unite to create ADCs using TRAP cage tech, enhancing targeted cancer therapy safety and efficacy.
Naobios and Sumagen achieve a key production milestone for the SAV001 HIV-1 vaccine, moving closer to clinical trials.
Ardena announces a new bioanalytical lab in Oss and expands Assen's capabilities to support diverse drug development needs.
Merck invests €70M in St. Louis facility to triple ADC capacity, advancing targeted cancer and bioconjugate treatments.
In October 2024, WHO's Global Health Emergency Corps activates to aid 18 African nations in fighting mpox outbreaks.
Genascence appoints Dr. Jeymi Tambiah as the CMO, who brings extensive experience in gene therapy and clinical development leadership.
Shuttle Pharma's Phase 2 trial doses initial glioblastoma patients with Ropidoxuridine to boost radiation therapy outcomes.
Antheia achieves milestone with first commercial thebaine delivery, advancing resilient biomanufacturing for essential medicine production.
Resolian announces leadership changes, with Rob Stachlewitz as CEO, aiming to enhance global growth and innovation.
PharmaLogic opens a new radiopharmaceutical facility in Los Angeles, enhancing production and research to improve patient care and diagnostics.
Kiora Pharmaceuticals prepares Phase 2 trial of KIO-301 to explore vision restoration in patients with retinitis pigmentosa.
Celltrion debuts Steqeyma, its Stelara biosimilar, in Germany, planning broader EU expansion to boost market presence.
Volpara Health signs a $7.3M DHA contract to supply breast cancer screening software across U.S. military facilities.
CinFina Pharma’s CIN-109 and CIN-110 demonstrate strong Phase 1 results for weight reduction and appetite control.
Lokon Pharma and BeiGene team up in a Phase 2 trial to target pancreatic cancer with a new gene therapy combo.
Cytoki Pharma has begun Phase 2 trials for CK-0045, targeting obesity and type 2 diabetes, with results anticipated in 2026.
Tonix Pharmaceuticals teams with KEMRI to develop TNX-801 vaccine for mpox and smallpox, aiming for effective global response.
Alvotech & Advanz Pharma seek EMA approval for AVT05, a Simponi® biosimilar, promising cost-effective inflammatory care.
NeuroBo finalizes Phase 2a trial of DA-1241 for MASH, assessing efficacy, ALT reduction, cholesterol, and safety data
Scorpius partners with Celltheon to provide advanced cell line development, biomanufacturing services and scaling to GMP.
Alan Bash is appointed as the President of CARVYKTI® at Legend Biotech, leading commercial, technical, & quality operations.
Ascendis collaborates with Novo Nordisk and grants exclusive rights to TransCon tech for metabolic and cardiovascular drugs.
Conduit Pharmaceuticals secures patents for CDT1656, combining AZD1656 with a novel compound to target autoimmune disorders.
Syndax Pharmaceuticals has partnered with Royalty Pharma in a $350M synthetic royalty agreement for Niktimvo sales.
Catalyx and INEL unite to enhance pharmaceutical packaging with innovative automation, improving efficiency, compliance, and inspection processes globally.
CureVac N.V. appoints Axel Sven Malkomes as CFO, bringing 30 years of biotech finance experience to drive growth in mRNA therapies.
Synaffix collaborates with BigHat to advance ADC development, leveraging AI for antibody design and effective targeting.
Olon's Rodano facility for ultra-potent compounds will be operational by January 2025, ensuring safer API handling.
FUJIFILM Diosynth and TG Therapeutics partner for multi-year BRIUMVI® manufacturing, beginning operations in 2025.
Evotec SE divests Halle site to Monacum Partners, supporting core focus and growth strategy through "Priority Reset."
Acadia Pharmaceuticals sells Rare Pediatric Disease PRV for $150M, with proceeds supporting CNS and rare disease R&D. Neuren to receive one-third share.
Tarsus names Dr. Elizabeth Yeu as Chief Medical Officer, strengthening its commitment to advancing eye care innovation and patient outcomes.
FUJIFILM Diosynth starts global expansion, increasing production and creating 2,200 jobs to meet healthcare demands.
Legend Biotech's CARTITUDE-4 data at ASH 2024 shows CARVYKTI®'s superior MRD negativity in multiple myeloma patients.
iotaSciences launches advanced XT platform for automated single-cell cloning, aiding cell line development and gene editing.
WHO identifies 17 critical pathogens for new vaccine development, targeting major health burdens and antimicrobial threats.
Hanmi’s HM17321 obesity treatment targets fat reduction while preserving muscle, presenting a novel approach to metabolic health.
Pharos iBio’s PHI-101 demonstrates 50% complete response in AML phase 1 trial, targeting FLT3 mutation for potential early commercialization.
Dupixent® (dupilumab) is now approved in the EU for treating eosinophilic esophagitis (EoE) in children as young as one, offering a new treatment option.
The Access and Allocation Mechanism distributes 900,000 mpox vaccines to African countries, prioritizing highest-need regions.
Plus Therapeutics partners with SpectronRx to produce Rhenium (186Re) Obisbemeda for CNS cancer treatment.
Redwire, in collaboration with Eli Lilly, returns ISS-grown insulin crystals with potential to accelerate drug discovery.
I-Mab appoints Dr. Sean Fu as permanent CEO, bringing decades of life sciences and biotech expertise.
Acumen Pharmaceuticals appoints Dr. Amy Schacterle as Chief Regulatory Officer to lead regulatory and quality efforts for Alzheimer's treatment development.
Cumberland's Ifetroban receives Orphan Drug and Rare Pediatric Disease designations for DMD-related cardiomyopathy treatment.
Kwality Pharma gains EU entry as Greece approves Leuprorelin, expecting $3M yearly sales from strategic CDMO deal.
Biosynth names Matt Gunnison CEO and Kieran Murphy Chairman to drive growth and innovation in life sciences.
Sonrai Analytics partners with MGH’s Termeer Center to integrate AI tech for faster, more efficient analysis of complex cancer research data.
Xilio’s vilastobart shows encouraging early data in treating MSS colorectal cancer, potentially targeting resistant tumors.
Mustang Bio’s MB-108, an HSV-1 oncolytic virus for malignant glioma, receives FDA Orphan Drug status, enhancing GBM treatment.
Kincell Bio appoints Stewart McNaull as CCO, enhancing its commitment to cell therapy innovation and client solutions.
CalciMedica appoints Stephen Bardin as CFO, bringing deep capital and finance expertise to advance company growth.
Aptar Pharma partners with CHI to launch Quattrii DPI, a platform aiming for efficient, high-dose respiratory drug delivery.
Geron raises $375M to advance RYTELO for blood cancers, supporting U.S. and EU launch, trials, and supply chain.
RNAi technology advances beyond liver treatments, with startups targeting CNS and genetic diseases using new delivery methods.
GC Cell partners with Artiva and Merck to advance two CAR-NK cancer therapies, assuming global R&D leadership rights.
Aurinia adds Craig Johnson to the Board of Directors, enhancing financial expertise as the company grows.
Collegium appoints Vikram Karnani as CEO. He brings leadership in rare disease pharmaceuticals and global expansion.
FDA reviews oral phenylephrine efficacy, proposing removal from OTC nasal decongestants. Public feedback is invited before a final decision. Learn more.
Grünenthal and Averitas Pharma complete enrollment for Phase III trial of QUTENZA® in post-surgical neuropathic pain, with results expected in 2025.
Biocon’s Bengaluru site receives FDA VAI status post-inspection, with minor issues not requiring regulatory action.
India’s ₹500 crore scheme aims to enhance local medical device manufacturing, reduce imports, and promote innovation.
Corvus presents promising data on ciforadenant's role in reducing immunotherapy resistance in metastatic prostate cancer.
GI Innovation's GI-101A and GI-108 show potential to enhance CAR-T therapy durability and counter tumour immunity challenges.
Merck strengthens its presence in Korea by investing in life sciences and semiconductors and forming a collaborative partnership with KAIST.
Swissport’s Madrid and Barcelona cargo centres receive GDP certification, boosting the global pharma logistics network.
Clarity teams with Nucleus RadioPharma to boost 67Cu-SAR-bisPSMA manufacturing and prepare for U.S. commercialization.
Recce Pharmaceuticals receives ethics approval to start a Phase 3 trial in Indonesia for R327G gel, targeting diabetic foot infections.
Boost immunity with Thymotas by Intas, featuring Thymoquinone. Clinically tested, it supports recovery, fights infections, and enhances overall immune health.
Indaptus’s Decoy20 platform combines innate and adaptive immune activation, showing promise for durable cancer therapy responses.
ARS Pharma licenses ALK exclusive rights to commercialise neffy, a needle-free epinephrine spray, in Europe, Canada, and geographies.
Pharma Two B and Hepion secure SEC approval for the merger, aiming to close in late 2024 pending shareholder vote.
RAPT Therapeutics halts the zelnecirnon program for asthma and dermatitis after the FDA holds the trials due to a severe liver injury case.
AbbVie’s Phase 2 EMPOWER trials for emraclidine in schizophrenia did not meet the efficacy target, while the safety profile was acceptable.
GenScript opens a logistics center in Sydney, improving delivery efficiency and supporting Australia’s biotech growth.
Longeveron appoints Devin Blass as CTO and Senior VP of CMC to lead technological and manufacturing strategies.
Citius Pharmaceuticals and Citius Oncology reveal promising Phase I trial results combining pembrolizumab with LYMPHIR™ for recurrent solid tumors.
Koneksa appoints Eric Luthi as Chief Business Officer, bringing 25+ years of life sciences expertise to lead business development and strategic partnerships.
Altimmune appoints Greg Weaver as CFO, bringing more than 25 years of experience in biotech finance and capital market expertise.
Syndax’s Phase 2 trial of revumenib for relapsed AML shows 23% remission and 47% response rate, with manageable side effects.
Spyre's SPY001, an α4β7-targeting antibody, shows promise for IBD with a 90+ day half-life, Phase 2 in 2025
Tempest Therapeutics advances to Phase 3 trial with FDA approval to test liver cancer drugs in combination therapy.
AstraZeneca and Daiichi Sankyo submit new BLA for EGFR-mutated lung cancer drug adjust trials based on FDA feedback.
Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO, succeeding Steven Ratoff, who remains on the board.
The KOMET trial demonstrates Koselugo's effectiveness for adult patients with inoperable plexiform neurofibromas in NF1.
Recursion's OpenPhenom-S/16 enhances microscopy data analysis in Vertex AI, aiding life sciences and drug discovery
Syros’ Phase 3 trial of tamibarotene with azacitidine fails to meet the primary endpoint for CR in HR-MDS patients, causing loan default.
Kane Biotech’s acquisition of FB Dermatology boosts wound care and skin treatment products in Europe, Australia, and the U.S.
AstraZeneca announces a $3.5B U.S. investment to expand R&D, manufacturing, and create 1,000+ jobs by 2026.
Longboard Pharmaceuticals launches Phase 3 trial of bexicaserin for seizures in Developmental and Epileptic Encephalopathies.
Rhythm’s setmelanotide trial shows BMI and hunger reduction in young children with genetic obesity syndromes, FDA review pending.
Tarsus Pharmaceuticals welcomes Dr. Kate Goodrich to its Board, bringing expertise in clinical leadership and health equity.
A new study shows diabetes cases have multiplied by four since 1990, with 800 million adults affected and treatment gaps in LMICs.
X4's study finds a daily mavorixafor safely raising ANC in chronic neutropenia, reducing G-CSF doses for many patients.
Zentalis Pharmaceuticals names Julie Eastland CEO and Scott Myers Board Chair as it advances azenosertib registrational studies.
Eli Lilly’s three-year study shows tirzepatide reduces type 2 diabetes risk, supports weight loss, and improves health markers.
Continuity Biosciences focuses on advanced cell reprogramming, immune modulation, and drug delivery to treat chronic diseases.
Pulmatrix and Cullgen merge to advance targeted therapies for cancer and more, with Cullgen to lead the combined company. Expected closure by March 2025.
TRexBio raises $84M in Series B to advance immune therapies, pushing innovative autoimmune treatments closer to clinical trials.
Affinia and Forge Biologics partner to manufacture gene therapies under cGMP, targeting heart and neuro diseases.
FDA grants approval for Kebilidi, a pioneering gene therapy to treat AADC deficiency, improving motor skills in young patients.
Corvus’s ITK inhibitor, soquelitinib, reduces fibrosis and lung damage in systemic sclerosis models, showing strong preclinical results.
Health Canada approves Kane Biotech's revyve™ Antimicrobial Wound Gel, granting immediate market access in Canada.
Merck enters an exclusive deal with LaNova for LM-299, with a $588M upfront payment and up to $2.7B in milestones.
Relmada Therapeutics initiates Phase 1 SAD trial to evaluate REL-P11 as a potential treatment for metabolic disease.
Omega Therapeutics updates include new leadership, strategic partnerships, and progress in clinical trials for innovative therapies.
Cellectar secures Ac-225 supply from NorthStar, driving CLR 121225 radiotherapy development for hard-to-treat cancers.
Cue Biopharma appoints Dr. Daniel Baker as interim CDO while Dr. Anish Suri transitions to a research advisor role.
FDA to review Dupixent® for chronic spontaneous urticaria, offering new hope for patients unresponsive to antihistamines.
Avantor's Bridgewater Innovation Center boosts biomanufacturing and accelerates life sciences therapies.
Amgen loses $12B in market value after hidden MariTide trial data reveals potential bone density concerns, rebounds later.
Boehringer Ingelheim adopts Veeva Vault CRM, enhancing agility and innovation across commercial operations.
Revuforj® gains FDA approval as the first menin inhibitor for leukemia with KMT2A translocation, launching November.
CHMP recommends KEYTRUDA for EU approval in MPM; KEYNOTE-483 shows improved survival with chemotherapy combination.
Dr Raymond Zheng joins Harbour BioMed as CBO, focusing on global partnerships and strategic product development.
PreveCeutical sells IP assets to BioGene in a USD $1.35M deal, including cash & shares, with plans to distribute shares to shareholders soon.
Neurophet names CTO Kim Dong-hyeon as Co-CEO, aiming to enhance R&D and global operations ahead of its planned IPO
Sanofi invests €40M in its Lyon site to boost antibody production, supporting transplant and type 1 diabetes treatments while advancing immunology.
Eyenovia’s CHAPERONE study misses the primary endpoint; the company considers mergers, asset sales, or other strategies.
Barinthus' HBV003 trial highlights VTP-300 and nivolumab's potential to deliver functional hepatitis B cures.
Arbutus' Phase 2a trial shows a 50% functional cure rate in HBV patients with low HBsAg, using imdusiran and Interferon.
China’s NMPA accepts Ascentage Pharma’s NDA for lisaftoclax, a novel Bcl-2 inhibitor for relapsed CLL/SLL treatment.
G20 leaders back WHO’s cervical cancer elimination campaign, highlighting global progress in vaccines, testing, and care equity.
Carisma unveils preclinical data on engineered macrophages, showing promise in tackling liver fibrosis and advanced MASH at AASLD 2024.
Tagrisso gains EU approval recommendation for EGFR-mutated NSCLC, with Phase III trials showing 84% reduced progression risk.
Alnylam's nucresiran achieves >90% TTR reduction with a single dose in Phase 1, showing promise for biannual/annual dosing in ATTR amyloidosis.
EC approves AbbVie's ELAHERE®, the first ADC targeting FRα, offering new hope for platinum-resistant ovarian cancer patients across Europe.
Island Pharmaceuticals' ISLA-101 trial hits a key milestone, exploring its potential as a treatment and preventative for dengue fever.
NeuroBo rebrands as MetaVia, advancing cardiometabolic drug pipeline with key trials in MASH and obesity set for 2024-2025.
Medicus Pharma appoints Dr. Faisal Mehmud as CMO. With 20+ years in clinical development, he’ll boost the company’s drug pipeline and strategic initiatives.
CPHI PMEC India 2024, Nov 26–28, Greater Noida, showcases global pharma trends, machinery, and tech innovations.
Medexus completes pCPA negotiations for Trecondyv®, aiming to secure public drug plan availability for Canadian patients.
Eli Lilly’s muvalaplin reduces Lp(a) by 85.8% in Phase 2, offering a promising oral option for heart disease.
AbbVie’s ELAHERE® approved in the EU for FRα-positive platinum-resistant ovarian cancer, showing survival benefits.
Ratio Therapeutics collaborates with Novartis on SSTR2-targeting radiopharmaceutical for cancer, worth $745M.
Dogwood reveals IMC-2 reduces Long-COVID fatigue at low doses; high doses cause GI side effects, limiting efficacy.
Preclinical results for Silo Pharma's SPC-15 reveal enhanced efficacy for depression via dual-receptor targeting therapy.
HCW Biologics partners with WY Biotech in a global agreement to develop and commercialize a novel immunotherapy.
Min Park named Chief Commercial Officer at Matica Bio, leveraging 25+ years of experience in global life sciences.
IDEAYA Biosciences names Stu Dorman as Chief Commercial Officer, bringing 20+ years of oncology expertise to lead its commercial efforts.
Sapio Sciences partners with Waters Corporation to boost lab efficiency and data accuracy through LC-MS and LIMS integration.
Sakura and MEDIPATH partner to improve cancer diagnostics in France using automated Tissue-Tek AutoTEC® a120 systems.
Scorpius Ventures supports biotech firms with cGMP services and equity stakes, boosting U.S. biologics production.
ImmunityBio's ANKTIVA-BCG therapy achieves a 71% complete response rate in bladder cancer, with durable responses reaching 54 months.
Abzena launches GMP cell-based potency assays in UK and US, boosting bioassay services for biopharmaceutical development.
Mirai Bio appoints Jens Vogel, Ph.D., as President and COO to accelerate genetic medicine development and in vivo delivery systems.
Steritas and argenx collaborate to use STOX® Suite in trials, addressing steroid toxicity in autoimmune disease treatments.
Merck's subcutaneous pembrolizumab shows noninferiority to intravenous KEYTRUDA in efficacy and safety for metastatic NSCLC.
Simon Fry joins Conduit Pharmaceuticals' Board, bringing over 30 years of experience in investment banking.
Circio partners with Certest Biotec to formulate circVec-LNPs for tissue-specific gene therapy targeting genetic diseases.
Asimov partners with RevOpsis to advance RO-104, a tri-specific biologic targeting retinal vascular diseases.
The Recursion-Exscientia merger combines AI expertise to advance drug discovery, expanding clinical and preclinical pipelines.
Capricor's deramiocel receives Orphan drug and ATMP designations, boosting the development of Duchenne muscular dystrophy therapy.
Voyager selects VY1706 for Alzheimer’s, with promising tau reduction results in preclinical NHP studies.
Pfizer names Dr. Chris Boshoff as Chief Scientific Officer and R&D President, effective January 2025, succeeding Dolsten.
Ziihera gains FDA acceptance for HER2-positive BTC; Phase 2b data show a 52% response rate and confirmatory trials are in process.
Samsung Biologics announces USD 668M in contracts, expands ADC services, and plans a new Bio Campus II.
BIMZELX (bimekizumab) receives FDA approval for moderate-to-severe hidradenitis suppurativa treatment in adults.
WHO announces ethical principles for managing genomic data, emphasising informed consent, equity, and transparency.
Alloy Therapeutics and Takeda partner to advance iCAR-T and iCAR-NK cell therapies for cancer treatment using iPSC technology.
Pfizer's HYMPAVZI™ wins EU nod as the first anti-TFPI therapy for severe hemophilia A & B, enabling once-weekly dosing with an auto-injector.
Syntegon achieves SBTi validation for climate goals, aiming for 48.3% Scope 1 & 2 emissions reductions by 2030 and greener operations.
Amneal progresses with FDA resubmission for migraine autoinjector and approval of exenatide for type 2 diabetes.
Protagonist advances PN-881, an oral IL-17 antagonist, into preclinical studies for immune-driven skin conditions.
Conduit Pharmaceuticals earns Japan patent for AZD1656, advancing its portfolio of autoimmune disorder treatments
CNSide CSF Assay detects biomarker changes in LM patients, the data to be presented at SNO 2024 in Houston.
Novartis acquires Kate Therapeutics for $1.1B to enhance gene therapies targeting neuromuscular diseases.
Genpact renewed its partnership with Ferring to streamline finance, accounting, and procurement, including AI.
Vetter appoints three senior leaders to its management team to drive sustainable growth and meet global customer needs, starting January 1, 2025.
Transposon Therapeutics acquires nucleoside analogs from PrimeFour, boosting its oncology pipeline with potential for targeted cancer treatments.
Dr. Reddy's names Vaibhav Rane as Head of Project Management at R&D Centre to optimize product strategies.
Merck welcomes Emerson’s CEO, Surendralal Karsanbhai, to its board, further strengthening its leadership team in 2025.
CNSide’s FORESEE trial shows superior accuracy and treatment impact for breast and lung cancer patients with LM.
Globus Medical’s ExcelsiusHub™ revolutionises spine surgery with real-time navigation, imaging flexibility, and safety features.
Merck’s WELIREG gains approval in China for VHL disease, demonstrating significant tumour response in critical trials.
Japan expands approval for GSK’s Arexvy, allowing use in adults 50-59 at high risk of severe RSV disease.
Gattefossé opens a state-of-the-art Mumbai Technical Center, advancing pharmaceutical and personal care R&D in India.
Kim Kyung-jin joins Samyang as biopharma president, driving CDMO expansion and advancing mRNA delivery technologies.
Firebrick partners with Guardian to make Nasodine available in 121 pharmacies, including Changi Airport outlets.
Truqap (capivasertib) with abiraterone and ADT boosts survival in PTEN-deficient prostate cancer, showing promising results in a Phase III trial.
Ascentage Pharma appoints Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors to enhance governance and support growth.
Hanmi's BH3120 immunotherapy, targeting PD-L1 and 4-1BB, shows promise in Phase 1 trials for solid tumors.
Pharma Now proudly announces its media partnership with Evolution Summit 2024, spotlighting pharma industry innovation.
Qosina names Lee Pochter as CEO, with Scott Herskovitz continuing as Chair and Medical Division President.
Lee Patterson named CEO of Metrion Biosciences, focusing on growth and global presence as Dr. Andrew S. steps down.
Delegates unite at WHO’s first oral health summit to address global challenges and ensure balanced care access.
Eton Pharmaceuticals secures U.S. rights to Amglidia for neonatal diabetes, aiming for FDA approval by 2026.
iiCON leads a £3.2M trial for PnuBioVax, tackling resistant pneumococcal strains like SPN3 to combat global health and antimicrobial resistance.
Citius Pharma advances Mino-Lok program post-FDA Type C meeting, aiming for NDA submission after pivotal Phase 3 success.
Merck reports vital Phase 3 ZENITH trial results for WINREVAIR in pulmonary arterial hypertension (PAH).
Arlington Capital Partners acquires TEAM Technologies, enhancing healthcare manufacturing and strategic supply solutions.
Dr. Deyaa Adib joins AffyImmune as CMO, bringing decades of oncology expertise to advance (CAR) T therapies.
IGC Pharma reports Phase 2 interim data showing IGC-AD1 reduces agitation and enhances cognition in Alzheimer's trials.
Biohaven’s taldefgrobep shows motor function and fat mass benefits in SMA, with potential for obesity treatment progress.
Freudenberg strengthens its commitment to India with innovative product launches at CPhI & PMEC 2024, driving industry growth.
Island Pharmaceuticals’ ISLA-101 shows safety and antiviral activity in Phase 2a dengue trial, with Phase 2b set to start in January 2025.
Dr. Reddy's, in collaboration with Senores Pharmaceuticals, introduces Ivermectin 3 mg tablets in the U.S. market.
Shuttle Pharma launches Phase 2 trial of ropidoxuridine, targeting improved radiation therapy outcomes for glioblastoma.
Afatinib, combined with DFP-14323, receives a seal of approval in Japan's 2024 guidelines for NSCLC therapy.
Tillotts Pharma and Pioneer Pharma team up to distribute Asacol® 800mg in China, addressing the rising prevalence of ulcerative colitis.
Roche announces SKYSCRAPER-01 trial results, with tiragolumab plus Tecentriq missing the overall survival endpoint in PD-L1-high NSCLC.
Acadia signs a global licensing deal with Saniona to develop SAN711 for essential tremor, aiming for Phase 2 trials in 2026.
Nexus Pharmaceuticals secures FDA approval for Methylene Blue Injection to treat methemoglobinemia, enhancing access to life-saving medication.
KalVista Pharmaceuticals appoints Laurence Reid, Ph.D., to its Board, bringing expertise in biotech growth, innovation, and strategic leadership.
Exelixis announces FDA review of CABOMETYX for advanced pNET and epNET, based on phase 3 CABINET trial data, at ODAC in March 2025.
Roche acquires Poseida Therapeutics to boost development of next-gen off-the-shelf CAR-T therapies, targeting oncology, immunology, and neurology.
Outlook Therapeutics reveals NORSE EIGHT trial results, showing vision improvement and safety, with a BLA resubmission planned for Q1 2025.
Glenmark introduces Travoprost Ophthalmic Solution, bioequivalent to Travatan Z®, enhancing its U.S. product portfolio.
Prelude Therapeutics will participate in the JMP Hematology and Oncology Summit, featuring a webcast fireside chat.
Syndax CEO Michael Metzger to discuss novel oncology mechanisms during the Citi 2024 Global Healthcare Conference panel.
BioStem signs a Letter of Intent to acquire revyve™ Wound Gel and technologies from ProgenaCare and Kane Biotech.
Carisma Therapeutics' CEO Steven Kelly to join a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 5th.
Amylyx Pharmaceuticals announces participation in the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024.
ADVANZ PHARMA reacts to the European Commission revoking OCALIVA® approval for PBC treatment in Europe.
Perspective Therapeutics to present at Piper and Evercore HealthCONx conferences, highlighting cancer treatment innovations and growth strategies.
Novartis gains EC approval for Kisqali® in HR+/HER2-early breast cancer, offering a new option to reduce recurrence risk in high-risk patients.
Nemolizumab shows significant improvements in itch, skin lesions, and sleep in prurigo nodularis, earning FDA approval as Nemluvio®.
Dev4All collaborates with Pharmaseed to integrate expertise to provide comprehensive preclinical drug development solutions.
Telix & Grand Pharma dose first patient in the Phase III ZIRCON-CP trial of TLX250-CDx PET imaging for kidney cancer at Beijing Cancer Hospital.
Dr. Reddy’s launches Toripalimab in India, advancing RM-NPC treatment with immuno-oncology innovation.
Innovent adds SINTBILO® and olverembatinib to China's NRDL, expanding cholesterol and CML care options.
The WHO confirms mpox as a public health emergency, emphasising coordinated international efforts and resources.
Lupin receives FDA approval for Sitagliptin and Metformin tablets, a generic Janumet®, enhancing diabetes care options.
Huons Biopharma partners with VERNI Aesthetics to commercialize MRC101, a fat decomposition injection, boosting its aesthetics portfolio and R&D efforts.
Bayer opens Co.Lab Berlin, a life science incubator, with MyoPax as its first resident, boosting biotech innovation and muscle regeneration research.
Silo Pharma collaborates with Kymanox to develop a ketamine implant and insertion device aimed at treating chronic pain and fibromyalgia.
WHO highlights critical gaps in preventing healthcare-associated infections, urging stronger IPC measures to protect patients and healthcare workers.
Evotec announces COO Dr Craig Johnstone's step down by December 2024; operations will be restructured internally.
ABIONYX adopts vital resolutions, including new director appointments and bylaw changes, at its 2024 General Meeting.
Nanolek and GC Biopharma seek approval for trials of a new chickenpox vaccine, aiming for registration by 2027.
Afreximbank and Med Aditus partner to build a $40M pharma plant in Kisumu, boosting medicine production in Kenya.
Nirmala Sitharaman calls for India to establish pharma standards, scale global innovations, and embrace an Indian identity.
NEXT BIOMEDICAL secures U.S. FDA approval for Nexpowder's use in treating lower GI bleeding, expanding its scope.
Brainomix earns LSX and OBN honors for its AI imaging platform, driving advances in stroke care and lung fibrosis treatment worldwide.
CBC Group and Mubadala acquire UCB's neurology and allergy assets in China, launching NeuroGen Pharma for growth.
Experience 12x faster MRI scans with GE HealthCare’s Sonic DL for 3D, enhancing imaging for neurology, orthopedics, and body exams.
Everest Medicine’s VELSIPITY® NDA accepted in Hong Kong for treating moderately to severely active ulcerative colitis.
FDA approves Biocon Biologics' YESINTEK™, a Stelara® biosimilar for Crohn's, Ulcerative Colitis, psoriasis, and arthritis.
Bayer highlights AI advancements, low-dose contrast agents, and smart imaging systems at RSNA 2024, enhancing radiology workflows and patient care.
GE HealthCare introduces AI-powered technologies at RSNA 2024, aimed at improving radiology workflows, boosting efficiency, and enhancing patient care.
Merus will present updated data on petosemtamab for r/m HNSCC at ESMO Asia Congress 2024, Singapore.
Novocure’s Phase 3 PANOVA-3 trial shows TTFields therapy improves survival in pancreatic cancer, with 2-month advantage over standard chemo.
Medicus Pharma teams up with Swanielle Inc. to expand its Phase 2 BCC clinical trial into Asia-Pacific, accelerating global skin cancer treatment.
Mapi Pharma presents innovative Depot technologies at Evercore HealthCONx 2024, offering partnership opportunities for long-acting injectable treatments.
Orexo AB and GAIA AG end their Deprexis® partnership for the U.S., impacting Q4 2024 income but maintaining cash position and future profitability.
Eckert & Ziegler launches Ac-225 production, addressing shortages and paving the way for clinical radiopharmaceutical use.
IntegriChain presents at Trade & Channel Strategies, exploring pharma trends and AI-powered distribution insights.
PTC and Novartis partner on Huntington’s therapy, with $1B upfront, milestone payments, and U.S. profit-sharing.
Rigel’s R289 secures FDA Fast Track for transfusion-dependent lower-risk MDS, aiming to address unmet needs with its dual IRAK1/IRAK4 inhibitor.
TORL BioTherapeutics names Dr. Aran Maree as CMO and launches a Phase 2 trial for TORL-1-23 in CLDN6+ platinum-resistant ovarian cancer.
Medexus revises milestone payments for treosulfan, anticipates FDA approval by Jan 2025, and strengthens financial flexibility for U.S. launch.
AC Health collaborates with USAID to improve HIV care in the Philippines, expanding telehealth, testing, and access to essential medications nationwide.
Spyre initiates Phase 1 studies of anti-TL1A antibodies, with safety and pharmacokinetics data expected in 2025.
Eckhard Niemeler joins Nouscom as Chief Business Officer, bringing 20+ years of expertise in life sciences leadership.
Novo Nordisk presents groundbreaking data on sickle cell disease and hemophilia treatments at ASH 2024, focusing on unmet needs in rare blood disorders.
Jazz Pharmaceuticals showcases oncology and hematology data at SABCS and ASH 2024, focusing on HER2-positive cancers and blood disorders.
Keros licenses elritercept to Takeda for global development, focusing on anaemia and rare blood disorders.
Plus Therapeutics and IsoTherapeutics extend the partnership, ensuring scalable production of cGMP Re-186 for key treatments.
Recursion launches a trial for REC-1245, an AI-discovered therapy targeting biomarker-enriched tumours and lymphoma.
Lawrence Kenyon becomes Interim CEO of Outlook Therapeutics after Russell Trenary steps down from the role.
Martin Pharmaceuticals partners with Mitsubishi Tanabe for exclusive access to docarpamine data for GI conditions outside Japan.
Romaco Holding GmbH appoints Ann-Xiaoyan Li as Group CFO & Managing Director, overseeing finance, HR, IT, and operations to drive growth and efficiency.
Coeptis Therapeutics to acquire NexGenAI's AI marketing platform, boosting efficiency in biotech and pharma.
Ipsen and Biomunex collaborate on BMX-502, a bispecific antibody using MAIT cells to target cancer, offering safer, innovative immunotherapy solutions.
AstraZeneca appoints Iskra Reic as EVP for International, overseeing strategy and growth across key markets, including Asia, China, and Latin America.
Jazz will discuss Ziihera® approval, clinical trial data, and commercialisation plans in the upcoming webcast.
Corvus highlights soquelitinib’s mechanism to boost tumour immunity, with Phase 3 and Phase 1 trials underway for various uses.
X4 Pharmaceuticals will present Mavorixafor trial-in-progress data poster and preclinical data at the 2024 ASH Meeting, December 7-10.
Franklin Biolabs appoints Dr. Vatsala Naageshwaran as CEO, bringing over 20 years of experience in advancing gene therapy and biopharmaceutical operations.
Circio unveils circVec 3.0, a circular mRNA lasting 75x longer than linear mRNA, transforming nucleic acid medicine durability and safety.
Nxera Pharma announces Phase 3 trial of daridorexant for insomnia treatment in South Korea, with results expected by 2026.
Vincerx Pharma cuts costs to advance VIP943 Phase 1 study, focusing on innovative cancer treatment with its ADC therapy.
Atea Pharmaceuticals announces successful Phase 2 trial results for HCV treatment, paving the way for Phase 3 trials in early 2025.
Amylyx Pharmaceuticals initiates a Phase 3 trial for avexitide to treat post-bariatric hypoglycemia, building on promising Phase 2 study results.
Bayer and Liveo Research unveil innovative blister packaging with a reduced environmental footprint, setting new industry standards.
Plus Therapeutics will present Phase 1 ReSPECT-LM data at the 2024 San Antonio Breast Cancer Symposium, focusing on Rhenium Obisbemeda for LM treatment.
Merck starts Phase 3 clinical trial for LAGEVRIO, evaluating its effectiveness in high-risk COVID-19 patients to prevent severe disease.
Monte Rosa shares interim data from the MRT-2359 trial in MYC-driven cancers, highlighting safety, dosing, and pharmacodynamics.
Charles River announces its Incubator Program to support early-stage biotech companies in advancing therapies and innovation.
Theriva gains FDA input on Phase 3 study design for VCN-01 in combination with chemo for pancreatic cancer.
PDF Radiopharma announces Techne® Pyrophosphate Injection’s listing on Japan’s NHI, with a launch scheduled for February 2025.
Novartis announces positive results from Phase III3B APPULSE-PNH study of Fabhalta® in PNH patients switched from anti-C5.
FDA grants Imfinzi approval for LS-SCLC, offering improved survival rates and marking a major advance in treating this aggressive cancer.
MaaT Pharma treats its first U.S. aGvHD patient with MaaT013 under compassionate use, marking progress in life-saving microbiome therapies.
ProBio names Allen Guo as CEO, Whitney Winters as SVP, and Michael Vreeland as U.S. Site Head to drive innovation in advanced therapies.
Teva is selling its stake in the Teva-Takeda venture in Japan to JKI as part of its Pivot to Growth strategy, with completion expected by April 2025.
NorthStar and PDRadiopharma collaborate to advance innovative radiopharmaceuticals for clinical trials and cancer care.
FDA accepts Priority Review for Imfinzi in MIBC, with Phase III data showing reduced progression and improved survival.
Lupin secures FDA approval for its pediatric HIV treatment, a generic version of Triumeq PD®, made in Nagpur.
Torii submits NDA for TO-208 in Japan, marking progress toward the first approved molluscum contagiosum treatment.
Novo's Catalent acquisition gets EU approval; final steps and regulatory clearances are expected by year-end 2024.
WHO selects experts worldwide to update guidelines on advanced HIV care, focusing on CD4 testing and treatment strategies.
Enanta Pharmaceuticals announces December 9 webcast to share topline Phase 2 RSV study results in pediatric patients.
Jazz Pharmaceuticals presented new data at AES 2024, showing Epidiolex® improves seizure control and behavior in TSC and epilepsy patients.
Dr. Reddy's appoints Chiranjoy Chowdhuri as Head of Data and AI CoE to drive digital transformation and AI initiatives, enhancing business impact and growth.
Five-year POLARIX data highlights Polivy + R-CHP efficacy in DLBCL, reducing death risk and enhancing remission durability.
Calquence with venetoclax achieves better survival and safety outcomes than chemoimmunotherapy in CLL patients.
Leukogene appoints Dr. Gupta as CEO, leveraging his oncology expertise to drive its MT2™ platform for "cold" tumors.
Merck’s zilovertamab vedotin, in combination with R-CHP, hits 100% complete response rate in a Phase 2 trial for untreated DLBCL treatment.
AbbVie highlights emotional and cultural challenges among diverse CLL patients, emphasising gaps in support and communication.
Recce secures approval in Indonesia for a Phase 3 trial of RECCE® 327 Gel, advancing treatment for diabetic foot infections.
Tonix's TNX-102 SL, a sublingual cyclobenzaprine, shows promise in improving pain, sleep, and symptoms for fibromyalgia.
Hikma debuts FDA-approved Furosemide Injection in 50mL and 100mL forms, enhancing its U.S. injectable offerings.
Seres' FDA-designated SER-155 reduces bloodstream infections in allo-HSCT patients, showing transformative potential.
GSK's Nucala shows promise as an add-on therapy for COPD with eosinophilic phenotype, based on MATINEE study.
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease.
Enanta reports Phase 2 success for zelicapavir, showing strong antiviral effects and safety in RSV pediatric study.
Acurx advances ibezapolstat into Phase 3 trials for C. difficile, focusing on efficacy, safety, and recurrence prevention.
Syndax shares positive trial results for Revuforj in AML, including its use in combination therapies for new patients.
Recursion's Phase 1 data highlights REC-617's potential as a best-in-class CDK7 inhibitor for advanced solid tumors.
CARVYKTI® achieves 89% MRD negativity in relapsed multiple myeloma, showcasing transformative potential in the CARTITUDE-4 study.
Carisma shifts focus to its macrophage engineering platform, halting CT-0525 development and reducing the workforce.
Acadia names Thomas Garner as CCO to drive growth and promotes Holly Valdiviez to lead the NUPLAZID franchise.
Cellipont adopts Xiogenix's Ares™ X20, enhancing automation, scalability, and precision in cell therapy production.
Emmes names Bryan Patterson as Senior Vice President to drive growth and innovation in U.S. government clinical research efforts.
Cipher evaluates MOB-015 trial findings while prioritizing Natroba™ integration and future growth initiatives in key markets.
FDA clears Astria Therapeutics’ STAR-0310 IND for clinical trials targeting atopic dermatitis and other conditions.
Sound Pharmaceuticals' SPI-1005 Phase 3 trial achieves hearing and speech improvements for Meniere's disease patients.
CPHI & PMEC India 2024 attracts 50,000+ attendees and 2,000 exhibitors, showcasing pharma innovation globally.
Arvinas and Pfizer present promising Phase 1b data on vepdegestrant and abemaciclib for breast cancer at San Antonio Breast Cancer Symposium 2024.
aTyr Pharma's Phase 3 EFZO-FIT™ study on efzofitimod for pulmonary sarcoidosis progresses unchanged by DSMB.
Zealand Pharma enrolls first participant in ZUPREME-1 trial, testing petrelintide for obesity and weight-related conditions.
Ketamir-2 by MIRA achieves preclinical safety milestone, paving the way for trials targeting neuropathic pain in 2025.
Baxter's 2024 launches include injectables for infections, cancer, GERD, seizures, enhancing efficiency and safety.
Pharma Now’s Nov-Dec edition explores pharma machinery breakthroughs, leadership insights, and coverage from key industry events.
AbbVie completes the acquisition of Aliada, focusing on ALIA-1758, an Alzheimer's drug with CNS-targeting technology.
Astria’s STAR-0215 shows 90-95% attack reduction in HAE trial, entering Phase 3 in 2025 with strong safety results.
Phathom seeks FDA approval to extend VOQUEZNA tablets' market exclusivity to 2032, citing NCE provisions under GAIN.
OlympiA trial confirms Lynparza improves survival and reduces recurrence in high-risk breast cancer patients.
Acadia’s PRV sale of $150M focuses on investing in operations, primarily in R&D, commercial operations, and future growth opportunities.
Hepion Pharmaceuticals cancels merger with Pharma Two B Ltd. and withdraws December 12 stockholder meeting.
Monte Rosa teams up with Novartis to advance VAV1-targeted molecular glue degraders, including MRT-6160, for immune diseases.
Prelude's PRT2527 shows preliminary activity and acceptable safety in relapsed/refractory lymphoid malignancies.
Conduit partners with SARBORG to integrate AI and cybernetics, boosting efficiency in drug discovery and trials.
FLOW trial shows Ozempic® cuts CKD progression, cardiovascular risks, and mortality, earning EMA's CHMP approval.
Zentalis Pharmaceuticals appoints Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer to drive innovation in cancer therapies.
Amar Urhekar takes over as CEO of Avalere Health, aiming to drive innovation in healthcare solutions
Keros holds high-dose TROPOS trial arms due to safety review; 1.5 mg/kg dosing continues, data in Q2 2025.
Medicus Pharma receives FDA MUMS status for D-MNA to treat horse cancer, granting 7-year exclusivity.
IBRANCE® boosts progression-free survival by 15+ months in HR+/HER2+ metastatic breast cancer, per Phase 3 PATINA trial at SABCS 2024.
Ascendis Pharma's sBLA for TransCon hGH in adult GHD was accepted by the FDA, with a decision due July 2025.
ARS Pharma's neffy nasal spray sees approval filings in China, Japan, and Australia after U.S. and EU success.
Takeda highlights its late-stage pipeline, featuring breakthrough therapies and key Phase 3 data expected in 2025.
Novo Nordisk finalises plans to acquire three Catalent sites, prioritising strategic investments over buybacks in 2025.
Glenmark debuts Lacosamide Oral Solution, generic for Vimpat®, growing its U.S. portfolio with 201 approved products.
CHMP recommends advancing affordable healthcare access, including Celltrion’s biosimilars, Eydenzelt, Stoboclo, Osenvelt, and Avtozma.
SK plasma partners with Janssen Korea to distribute Velcade, bolstering its portfolio of cancer treatment options.
Novo Nordisk invests DKK 8.5B in a sustainable Odense facility, creating 400 jobs and advancing rare disease treatments by 2027.
GSK’s Jemperli gets FDA Breakthrough Designation for rectal cancer, showing 100% clinical response in 42 patients.
Thermal Energy inks $2.8M deal with pharma leader, enhancing efficiency and cutting emissions by 728 tons annually.
Reviva’s brilaroxazine shows sustained efficacy, strong safety, and tolerability in 1-year Phase 3 schizophrenia trial.
Merck’s KEYTRUDA is approved in China for stage II-IIIB NSCLC, combining chemo pre-surgery and monotherapy post-surgery.
Foghorn Therapeutics stops independent development of FHD-286 in AML; prioritises pipeline and Lilly collaboration programs.
Xilio Therapeutics names Caroline Hensley as Chief Legal Officer, bringing extensive legal and compliance expertise to the team.
Jazz CEO Bruce Cozadd announces retirement by 2025; Board starts search for a successor as Cozadd remains Board Chair.
GSK'227, a B7-H3-targeted ADC, receives EMA PRIME Designation for treating relapsed extensive-stage SCLC.
Innovent and Lilly expand partnership to distribute and promote Jaypirca® for mantle cell lymphoma in Mainland China.
Single Use Support names Darren Verlenden as CEO to drive global growth and innovation in biopharma solutions.
Acumen Pharmaceuticals appoints Dr. Amy Schacterle as Chief Regulatory Officer to lead regulatory and quality efforts for Alzheimer's treatment development.
United Therapeutics achieves first living human UKidney transplant, advancing organ supply through genetic engineering.
Tonix's TNX-102 SL receives FDA acceptance for fibromyalgia treatment, backed by positive Phase 3 trial results.
Merck's clesrovimab aims to protect infants from RSV; FDA decision expected by June 2025 after positive trial data.
Evergen, formerly RTI Surgical, advances as a CDMO pioneer, offering allograft and xenograft biomaterials at scale.
Portage Biotech signs a letter of intent with Immunova for potential acquisition of iOx Therapeutics, advancing PORT-2 development.
Regeneron’s EYLEA HD shows non-inferior results in RVO treatment; FDA submission is planned for early 2025.
EVA Pharma's insulin glargine gets Egyptian Drug Authority approval, advancing diabetes treatment in underserved regions.
Corvus Pharmaceuticals will announce Phase 1 results for soquelitinib in atopic dermatitis on December 18, 2024.
Marker Therapeutics receives a $9.5M CPRIT grant to advance MT-601 for metastatic pancreatic cancer, and clinical trials are set for 2025.
Dr. Marc Damelin joins Alphina as CSO, bringing expertise to advance its NAMPT inhibitor targeting solid tumors.
Russia’s mRNA cancer vaccine, set for 2025, shows early success in tumor suppression and metastasis reduction.
Borosil Renewables plans ₹675-crore Indian expansion, ₹700-crore fundraising, and adjusts German operations amid challenges.
Merck partners with Hansoh Pharma, securing global rights to HS-10535 for cardiometabolic advancements and therapies.
Silo Pharma initiates a study on SP-26, a ketamine-based injectable implant targeting chronic pain and fibromyalgia treatment.
Agios' mitapivat receives orphan designation in the EU for sickle cell disease, promising innovative treatment options.
Corvus shares interim data showing soquelitinib's safety and efficacy in treating moderate atopic dermatitis.
MetaVia's DA-1241 significantly reduces ALT, HbA1c, and CAP levels in the Phase 2a trial for MASH, showing strong potential.
Nxera Pharma and Shionogi launch QUVIVIQ™ in Japan, offering a new treatment for insomnia relief in adults.
Prasinezumab shows potential in slowing Parkinson's progression, with further analysis and trials ongoing.
Adicet Bio appoints Dr. Julie Maltzman as Chief Medical Officer, advancing its pipeline in oncology and autoimmune diseases.
CPHI & PMEC India 2024 concluded with record-breaking attendance, highlighting cutting-edge pharma innovations.
Macron and WHO launch the WHO Academy in Lyon to train health leaders and address the global healthcare workforce gap.
Shuttle Pharma partners with UCSF to develop PSMA-B, a theranostic agent redefining prostate cancer care and treatment.
MT-601 by Marker Therapeutics achieves 78% response in Phase 1 lymphoma trial, offering hope for relapsed patients.
Hikma secures rights to 17 Takeda brands in MENA, ensuring supply stability and enhancing profitability.
PTC submits vatiquinone NDA to the FDA for treating Friedreich ataxia in children and adults with strong efficacy and safety data.
Vertex reports Phase 2 success for suzetrigine, demonstrating meaningful pain reduction and a strong safety profile in LSR.
Merck’s Phase 3 results confirm DOR/ISL’s efficacy and safety for HIV-1, with plans to present findings and file data.
Lifecore Biomedical partners with Nirsum Labs advance NRS-033, a promising treatment for opioid and alcohol addiction, leveraging sterile injectable expertise.
Neffy, the first FDA-approved epinephrine nasal spray, ensures broad access via Express Scripts’ formularies.
Ascendis Pharma’s YORVIPATH delivers 24-hour PTH exposure for adults with hypoparathyroidism, transforming care.
AIOCD delegation visits AXA & Heilsa plants, applauding commitment to high-quality, affordable medicines in India.
Regeneron’s Phase 2 trials show promising results for Factor XI antibodies with strong safety profiles in anticoagulant treatment.
Xilio shares plans to present Phase 2 vilastobart data in MSS CRC at ASCO GI 2025, highlighting treatment progress
Merck secures global rights for LM-299 with LaNova Medicines, investing $588M upfront and $2.7B in milestones.
GSK’s phase III trial finds that the Zejula and Jemperli combo boosts Progression-Free Survival in advanced ovarian cancer; safety aligns with expectations.
BioAtla secures $9.2M via direct offering to fund clinical trials for TCE and ADC therapies in solid tumours.
Hikma introduces Indomethacin Suppositories (50mg) in the US for arthritis, gout, and acute painful shoulder.
Novo Nordisk’s REDEFINE 1 trial finds CagriSema achieves significant weight loss and is well-tolerated in obesity treatment.
Organon Korea's Oh So-yun assumes Country Lead role in Malaysia, advancing growth in women's health and chronic care.
VaxCell-Bio collaborates with Bio Design Lab to advance CAR-NK cell therapies, offering safer and cost-effective solutions.
GI Innovation launches a phase 1 trial for GI-102, a subcutaneous immune-oncology drug targeting melanoma.
SK Bioscience partners with Sanofi on next-gen pneumococcal vaccines, targeting children, adults, and unmet global needs.
Celltrion secures Korean approval for Avtozma, its Actemra biosimilar, expanding its interleukin inhibitor portfolio.
RAPT acquires rights to RPT904, a long-acting IgE antibody, promising enhanced allergy treatment with global reach.
The WHO calls for greener pharmaceutical practices, urging sustainability in manufacturing, packaging, and distribution.
AstraZeneca’s Tagrisso is approved in the EU for treating advanced NSCLC with EGFR mutations post-CRT
Tonix's TNX-102 SL, a non-opioid for fibromyalgia, nears FDA approval with promising Phase 3 trial results.
Sanofi and SK Bioscience collaborate on next-gen pneumococcal vaccines, including PCV21, now in phase 3 trials
Luxembourg pledges €47.5M to WHO for health crises, equity, and SDG goals, marking a historic collaboration.
Porton and Dragon Sail join forces to revolutionize ADC development and accelerate drug availability worldwide.
Arrowhead launches clinical trials for ARO-INHBE, an RNAi obesity treatment, with ARO-ALK7 also progressing
GEMTESA earns FDA approval as the first β3 agonist for men with OAB symptoms linked to BPH, now available in the U.S.
OBI Pharma and GlyTech collaborate to advance ADC development, focusing on glycan production and cancer therapies.
AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan but affirm their commitment to progress.
Enanta Pharmaceuticals will appeal a court ruling favoring Pfizer in a patent dispute over COVID-19 antiviral Paxlovid.
Prothix LifeSciences partners with Oviya MedSafe to redefine global drug safety, clinical trials, and regulatory compliance.
Bio-Thera and Tabuk collaborate to bring BAT2206, a Stelara biosimilar, to Saudi Arabia, boosting healthcare accessibility.
Meiji Seika Pharma establishes Taiwan subsidiary, boosting healthcare solutions with REZUROCK and key therapies in Asia.
JR-441, JCR’s therapy for MPS IIIA, gains orphan drug status in Japan, bolstering global efforts for rare disease treatments.
MedMira’s Multiplo® TP/HIV test gains Health Canada approval, providing rapid, dual HIV/syphilis detection nationwide.
Qilu's QLS32015 demonstrates remarkable tumor response and tolerability in Phase I trials for relapsed multiple myeloma.
KIST's peptide-based eye drops for dry AMD reduce retinal degeneration, enhancing safety and patient adherence.
Phase 3 trial reveals gecacitinib's superior spleen reduction, symptom relief, and safety in myelofibrosis patients.
ENCell's new CDMO contract with a pharma leader highlights its GMP-certified excellence in biopharma production.
Axcelead and Astellas unite to leverage the DegLead™ Platform, driving innovation in targeted protein degradation.
Hikma debuts generic Liraglutide, a GLP-1 diabetes treatment, expanding affordable care for adults and children.
Elite Pharmaceuticals introduces a cost-effective generic Vyvanse® for ADHD, offering patients greater accessibility.
Kwality Pharmaceuticals achieves SAHPRA approval for Tamoxifen, advancing quality oncology treatment in South Africa.
Mankind Pharma collaborates with Innovent Biologics to introduce sintilimab, revolutionizing cancer treatment in India.
IDEAYA licenses SHR-4849 from Hengrui Pharma to advance treatment for DLL3-expressing solid tumors like SCLC and NETs.
Hikma's ePHEDrine Sulfate Injection in prefilled syringes treats anesthesia-related hypotension, enhancing care access.
RenovaroCube names Maurice van Tilburg CEO, driving AI-powered cancer diagnostics and multi-omics solutions.
reace launches Percuplasty™, a percutaneous system offering 3D bunion correction with smaller incisions, less pain, and quicker recovery.
Japan approves VYVDURA, a subcutaneous CIDP therapy enabled by Halozyme’s ENHANZE®, for at-home patient convenience.
Radiopharm partners with Lantheus to advance clinical development of Lantheus innovative radiopharmaceuticals in Australia targeting solid tumours.
Autonomix secures key patents for its precision nerve ablation tech, aiming to ease pain and explore cancer treatment potential.
FDA approves Opdivo Qvantig™ co-formulated with Halozyme’s ENHANZE®, offering faster subcutaneous administration and similar efficacy to IV Opdivo.
Polyrizon secures patents for C&C™ and T&T™ platforms, innovating nasal protection and effective drug delivery systems.
Chimerix submits NDA for dordaviprone in treating recurrent H3 K27M-mutant glioma, seeks priority review, and secures up to $30M loan.
Orion and Marinus end the European ganaxolone agreement. Marinus regains commercial rights, and Orion suspends launch preparations.
Axsome’s AXS-05 delays agitation relapse in Alzheimer’s, achieves key endpoints in Phase 3 trials, and earns FDA status.
Galera’s acquisition of Nova Pharmaceuticals adds a pan-NOS inhibitor to its pipeline, targeting resistant breast cancers.
Cocrystal Pharma extends its Phase 2a study for CDI-42344 after low H3N2 infection rates. The trial evaluates safety, efficacy, and PK.
Altamira advances RNA delivery with CycloPhore™, achieving strong circular mRNA transfection and protein expression, also filled a patent.
Oncotelic launches PDAOAI for biotech AI document search, enabling precise answers and decentralised governance via PDAO tokens.
ARsgen launches trial for KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, in relapsed/refractory B-NHL patients.
Yuhan's lazertinib gains European approval, becoming Korea's first anticancer drug authorized in both the U.S. and Europe for NSCLC.
Huons transitions to a single-CEO structure with Song Soo-young, followed by the resignation of Yoon Sang-bae.
HK inno.N files phase 3 IND for obesity drug IN-B00009, targeting weight loss and safety in a 3-year clinical trial
Handok begins local sales of Lipidil, Abbott's hyperlipidemia drug, strengthening its chronic disease treatment portfolio.
Prag Goel joins Alembic Pharma as VP of Sales and Marketing, bringing 30 years of diverse industry experience.
HOOKIPA and Poolbeg plan all-share merger to form a Nasdaq-listed biopharma focused on cancer and unmet medical needs.
Veeda Group becomes Veeda Lifesciences, marking its growth into a full-spectrum partner in global drug development services.
Radius Pharmaceuticals partners with Pharmanovia to bring abaloparatide, an osteoporosis therapy, to the Asia Pacific region.
ANI Pharmaceuticals introduces Prucalopride Tablets, a generic Motegrity® version, following FDA approval, with a $168M U.S. market value.
Innovent and Roche collaborate on IBI3009, an inventory DLL3 ADC, with $80M upfront and $1B in milestones possible.
Karyopharm names Lori Macomber as CFO, leveraging her 20+ years in life sciences finance to drive growth and innovation.
Capricor completes BLA for deramiocel, a DMD cardiomyopathy therapy backed by Phase 2 data and Orphan Drug Designations.
NervGen enrols the final participant in the chronic cohort of its NVG-291 SCI trial, advancing to subacute screening after IRB approval.
Joseph F. McGuire, named NEXGEL's CFO, brings 30+ years of experience as Adam E. Drapczuk will remain as a consultant.
Scott Coiante was named CFO at Lexicon Pharmaceuticals, with 35 years of finance experience in life sciences, previously at Agile Therapeutics and Aprea.
HOPE Therapeutics acquires Kadima Neuropsychiatry, a leader in interventional psychiatry, to drive advanced treatments for CNS disorders.
Eton Pharmaceuticals acquires Galzin®, enhancing support for Wilson Disease patients with treatment access and global expansion.
Chime Biologics and Mabgeek achieved a significant milestone with MG-K10, an anti-IL-4Rα antibody, entering Phase III trials.
Nona Biosciences announces BeiGene's acquisition of global rights to a DualityBio-developed ADC targeting tumours.
GSK's Nucala wins approval in China as an add-on therapy for adults with uncontrolled CRSwNP, easing key symptoms.
Shilpa Medicare advances to Phase III trials for recombinant albumin, revolutionizing treatment for critical conditions.
Vetter appoints three senior leaders as managing directors, reinforcing global growth and commitment to serving patients worldwide.
Dr. Vellaian Karuppiah joins Acme and Immacule Group as COO, bringing 20+ years of expertise in manufacturing, tech transfer, and operations.
JCR and Modalis advance CNS gene therapy, validating proof of concept and entering pre-clinical studies for minimally invasive treatment
China approves first stem cell therapy for transplant complications and a new long-acting HIV drug needing only two shots a year.
NMD Pharma's NMD670 receives FDA orphan drug status to treat Charcot-Marie-Tooth disease, advancing trials for this rare neuromuscular disorder.
Discover cutting-edge pharma solutions, network with global experts, and unlock new business opportunities.
EMA backs Acurx's ibezapolstat Phase 3 trials, focusing on treating CDI and reducing recurrence in global patient populations.
Perspective Therapeutics appoints Juan Graham as CFO. He brings 25 years of finance leadership from FibroGen and Johnson & Johnson.
Tempest Therapeutics’ amezalpat receives FDA Orphan Drug Designation after showing survival benefits in liver cancer trials.
Portage Biotech re-launches Cyncado Therapeutics, with CEO Peter Molloy driving the development of adenosine receptor antagonists for cancer.
ARS Pharma seeks approval for neffy in Canada and UK while advancing global licensing and clinical trials for new indications.
RAPT Therapeutics appoints Lori Lyons-Williams as board chair. Industry veteran succeeds William Rieflin, now a company consultant.
Elutia collaborates with Vizient to offer EluPro™ BioEnvelope to S3P's 993 acute care facilities, providing innovative solutions for post-surgical care.
ImmunityBio secures permanent J-code for ANKTIVA, streamlining access for bladder cancer patients and providers with broad coverage.
Dan Monahan joins Amylyx as Chief Commercial Officer, driving commercialisation and avexitide’s launch for PBH treatment.
Variant Bio joins Novo Nordisk in a $50M genomics venture to develop innovative treatments for metabolic diseases globally.
Recursion advances REC-3565 for B-cell cancers and REC-4539 for SCLC, with regulatory clearances from MHRA & FDA for Phase 1 trials.
Canyon Labs strengthens services with iuvo acquisition, focusing on end-to-end medical and pharmaceutical testing solutions.
Gain actionable insights at the Pharma Project & Portfolio Management 2025 in Goa, with expert sessions and networking.
Bio-Rad introduces 45 cm Foresight Pro Columns, enhancing downstream purification for vaccines, antibodies, and proteins.
Molex completes acquisition of Vectura, enhancing Phillips Medisize’s expertise in inhalation drug delivery and pharmaceutical R&D.
BioInvent reports a complete and partial response in the NHL trial for BI-1206 combo therapy; melanoma CR is nearing a two-year milestone.
ProBioGen enhances its protein and viral vector production with a new 1000L GMP protein line and advanced viral manufacturing facilities.
Island Pharmaceuticals starts Phase 2b trial for ISLA-101, testing its safety and effectiveness in reducing dengue virus symptoms.
Biomea Fusion shares preclinical data showing improved metabolic markers with icovamenib and semaglutide in diabetes models.
Expanded Novo Nordisk-Valo partnership leverages AI to advance 20 drug programs in cardiometabolic care globally.
Agios' PYRUKYND® gains FDA sNDA acceptance for thalassemia treatment. PDUFA decision set for September 7, 2025.
Merck's GARDASIL became the first HPV vaccine approved for males in China, targeting HPV-related cancers, warts, and precancerous lesions.
Silo Pharma receives USPTO patent approval for SPC-15, enhancing its position in PTSD therapy with intranasal drug delivery.
Tonix appointed Gary Ainsworth as VP of Market Access along with the FDA review of TNX-102 SL for fibromyalgia, a chronic pain condition.
Newron and Myung In Pharm join forces to develop and commercialise evenamide, a novel therapy for treatment-resistant schizophrenia in South Korea.
PrecisionLife appoints Bill Keating as CCO to scale Mechanostic® tests, transforming chronic disease diagnostics globally.
Catalyst resolves litigation with Teva, delaying FIRDAPSE generic launch to 2035, ensuring patient access and IP protection.
WHO's new G6PD test helps prevent complications from malaria treatments, ensuring safer care for P. vivax patients.
Evonik and ST Pharm collaborate to enhance RNA and nucleic acid therapies, speeding up treatment development.
Aspyre Lung by Biofidelity and CellCarta enhances NSCLC biomarker detection, accelerating clinical trial enrollment globally.
Jo Marshall joins Coronado as EVP of Data Services, leveraging expertise to enhance drug development and patient safety.
Zentalis secures FDA Fast Track Designation for azenosertib, targeting platinum-resistant ovarian & PROC cancers tied to Cyclin E1.
Bora Biologics partners with DotBio to accelerate DB007, a tri-specific antibody, through advanced manufacturing and development.
Seres' SER-155 data reveal improved gut barrier integrity, reduced bloodstream infections, and enhanced immune balance in allo-HSCT patients.
GSK’s Shingrix prefilled syringe application is accepted by the FDA, offering a more convenient shingles vaccination option for healthcare providers.
Rigel’s R289 granted FDA Orphan Drug Designation, boosting its development for lower-risk myelodysplastic syndromes treatment.
UCB collaborates with XtalPi, using AI-driven XtalFold™ to accelerate antibody design and biologics innovation.
Genenta and AGC Biologics expand manufacturing capacity for Temferon, supporting GBM and metastatic cancer clinical trials.
Telix expands pipeline and innovation with ImaginAb's biologics platform and radiopharmaceutical technology.
Ascendis Pharma outlines 2025 goals, introduces the new TransCon platform, and reports substantial 2024 revenues at the J.P. Morgan Conference.
Telix reclaims Scintimun to enhance diagnostic use, sales, and clinical applications for unmet medical needs.
NMPA approves Sarclisa for relapsed multiple myeloma, offering innovative treatment options in China.
PM Modi praises the completion of the Indian Genome Project, which will boost healthcare and precision medicine through genetic mapping of India’s population.
Merus and Biohaven join forces to co-develop bispecific ADCs, combining platforms to transform cancer therapy.
Caribou initiates the GALLOP Phase 1 trial for lupus, advancing CAR-T therapy programs with key 2025 data milestones.
Molecular Partners and Orano Med expand collaboration to create innovative targeted alpha radiotherapies for cancer.
AbbVie partners with Simcere Zaiming to develop SIM0500, a trispecific antibody targeting multiple myeloma.
Updates on ABBV-RGX-314 clinical programs: advancing gene therapy for wet AMD and diabetic retinopathy.
Tarsus targets ocular rosacea with TP-04, boosts XDEMVY growth, and advances global initiatives for transformative eye care.
ORIC shares 2024 achievements, including Phase 1b data for ORIC-944 and key milestones for oncology advancements.
Regeneron and Truveta announce the Truveta Genome Project, aiming to sequence 10 million genomes to transform genetic research and healthcare delivery.
Interim data from Corvus Pharmaceuticals’ Phase 1 trial of soquelitinib demonstrate safety and significant efficacy in treating moderate-to-severe atopic dermatitis.
GSK acquires IDRx for $1 billion upfront, gaining IDRX-42, a precision therapeutic targeting primary and secondary KIT mutations in GIST.
ORIC Pharmaceuticals to initiate a Phase 1b trial of ORIC-114 and SC amivantamab for first-line treatment of advanced NSCLC with EGFR exon 20 insertion mutations, starting Q1 2025.
Salarius Pharmaceuticals merges with Decoy Therapeutics to advance Decoy's peptide conjugate therapeutics pipeline, targeting respiratory infectious diseases and oncology.
Astria Therapeutics' ALPHA-ORBIT Phase 3 trial of navenibart for hereditary angioedema to evaluate Q3M and Q6M dosing, aiming for global registration and patient-centric treatment options.
Context Therapeutics announces Andy Pasternak as Chairman of its Board, bringing decades of expertise to drive innovation in T cell engagers for solid tumor treatment.
Elutia introduces EluPro™, the first FDA-cleared biomatrix to prevent infections in implantable devices.
Serina Therapeutics appoints Karen J. Wilson to its Board, enhancing leadership for transformative biotech growth.
AskBio’s Phase II gene therapy trial for Parkinson’s disease begins participant randomization, advancing AB-1005 research.
Context Therapeutics has dosed its first patient in a Phase 1 trial for CTIM-76, targeting CLDN6-positive gynecologic and testicular cancers.
Hikma teams up with Emergent for exclusive sales of KLOXXADO® 8 mg naloxone spray, expanding opioid overdose treatment options.
Acadia submits trofinetide for EMA approval as the first Rett syndrome treatment in the EU, supported by positive Phase 3 results.
Vetter's V-OVS® next closure system offers intuitive features and enhanced safety for injectable products, launching in 2027.
Sapio Sciences launches Release 24.12, adding immunogenicity automation, GMP improvements, chemistry tools, and molecular biology updates.
Enhanc3D Genomics introduces integrated 3D Multi-Omic solutions, advancing precision in drug discovery and development.
Moffitt and Cryoport partner at Speros campus, accelerating innovation in cell and gene therapies and patient care.
Keros Therapeutics halts Phase 2 TROPOS trial for PAH due to safety concerns; topline data expected by Q2 2025.
Niktimvo™, approved by the FDA, offers a new treatment option for chronic GVHD, reducing inflammation and fibrosis.
ImmunityBio shares progress with the FDA on bladder and lung cancer therapies, offering new hope for patients with limited options.
TNF Pharmaceuticals announces safety milestone for isomyosamine, advancing trials for sarcopenia, frailty, and GLP-1-induced muscle loss.
Sanabil Investments and Redesign Health team up to boost healthcare innovation in Saudi Arabia.
Piramal Pharma reduces emissions by 24,000 tCO2e yearly with biomass boiler conversion at Digwal facility.
ImmunityBio advances ANKTIVA approval in the EU and UK for bladder cancer, with potential approvals by 2026.
FDA revokes FD&C Red No. 3 for food and drugs after studies showed cancer risks in rats, though no similar effects in humans.
NORSE EIGHT trial supports Outlook Therapeutics' plan to resubmit its wet AMD therapy BLA in 2025, showcasing safety and efficacy.
Kindeva secures $129M contract to produce DuoDote® autoinjectors, aiding U.S. emergency preparedness against chemical nerve agents.
Illuccix gains European approval, revolutionizing prostate cancer imaging with superior accuracy and care.
WHO launches a $1.5B Health Emergency Appeal to address global crises, targeting urgent needs in conflict zones and severe emergencies
IDT Biologika appoints Federico Pollano as Chief Commercial Officer, leveraging his extensive experience in the biotech and CDMO industries.
Caris and Ontada team up to advance cancer research and precision medicine with integrated data solutions.
Scilex strengthens its gout treatment portfolio with ex-US rights to Gloperba®, enhancing global patient care.
Novo Nordisk’s STEP UP trial reveals 20.7% weight loss with semaglutide 7.2 mg in adults with obesity over 72 weeks.
Cormica expands into Germany with the acquisition of Zwisler Laboratorium, enhancing its European footprint in life sciences testing.
Glenmark Life Sciences is now Alivus Life Sciences as Nirma acquires 75% stake, aiming to expand in global healthcare markets.
Disc Medicine to host a call on Jan 21 at 8:00 am EST to discuss FDA updates on bitopertin for severe EPP treatment.
UK advanced therapy trials grew 7% to 187 in 2024, with Phase I trials jumping 70%, per the CGT Catapult database.
Keros Therapeutics and Takeda finalize global license agreement for elritercept, marking a significant milestone in hematologic disorder treatments.
Xilio Therapeutics announces initial Phase 2 data for vilastobart (XTX101) with atezolizumab, showcasing anti-tumor activity in MSS CRC patients.
MaaT Pharma’s PHOEBUS trial progresses with strong safety backing, advancing microbiome therapies in cancer care.
Century teams up with experts for CNTY-101 trials, advancing treatment for autoimmune diseases.
Apollo™ for CRADL® speeds up research onboarding, enhancing drug discovery through digital innovation.
ARS Pharma provides free neffy® nasal sprays to schools, enhancing allergy preparedness nationwide.
Amylyx prepares U.S. and Canadian trials for AMX0114 ALS therapy after FDA hold is lifted.
Catalyst Pharmaceuticals expands access to FIRDAPSE® in Japan, aiding LEMS patients through DyDo Pharma partnership.
Medix Biochemica acquires Germany’s CANDOR Bioscience to strengthen immunoassay solutions and support global IVD manufacturers.
Experience innovation at INTERPHEX 2025, in NYC. Join Pharma Now for expert talks, networking, and industry insights.
Cellipont Bioservices welcomes Brett Reynolds as CFO, bringing over 25 years of financial leadership experience.
AstraZeneca's C$820M investment creates 700+ jobs in Ontario, advancing life sciences and innovative medicine development.
Flagship Pioneering teams up with CUHP and MTI to drive breakthroughs in research, innovation, and biotechnology.
Messe München expands in India, Middle East, and Africa with Bhupinder Singh as President IMEA.
Year-two results from Roche’s EMBARK Phase III trial show Elevidys™ delivers statistically significant and clinically meaningful motor function improvements in Duchenne muscular dystrophy patients.
Pankaj R. Patel, Chairman of Zydus Lifesciences, has been awarded the Padma Bhushan for his transformative contributions to trade, industry, and healthcare in India.
The IACP Leadership Educators’ Summit 2025 in Hyderabad, supported by Pharma Now, united pharmacy educators and students to inspire innovation and excellence in the pharmaceutical sector.
FDA approves LEQEMBI® for Alzheimer’s maintenance treatment, transitioning to every four weeks.
Will Downie joins Touchlight as an adviser, driving innovation in synthetic DNA for genetic medicines.
Telix Pharmaceuticals expands U.S. operations by acquiring RLS Radiopharmacies.
Itovebi delivers significant overall survival benefits in Roche’s Phase III study for advanced breast cancer.
Study shows enobosarm helps older patients preserve muscle and improve body composition during weight loss.
Sage Therapeutics reviews strategic options after rejecting Biogen's acquisition proposal.
Merck's WELIREG sNDA for rare tumors gains FDA priority review; decision expected by May 26, 2025.
Innate Pharma launches Phase 1 trial for IPH4502, a Nectin-4-targeting ADC therapy for advanced solid tumors.
Clinigen collaborates with Tepsivo, combining expertise to enhance global Pharmacovigilance through AI-driven innovation.
The FDA accepts Alvotech and Teva’s AVT05 biosimilar for review, marking a key step in advancing treatment for inflammatory conditions.
PHARMEXCIL declares India and UAE pharmaceutical partnership, hosting the India Pavilion at Arab Health 2025 in Dubai to highlight Indian innovation and exports.
New clinical data shows cebranopadol has significantly lower intranasal abuse potential than oxycodone, reinforcing its promise in pain management.
ProductLife Group acquires Stragen Services, expanding its pharmacovigilance and clinical safety capabilities.
Lupin and Avas introduce NaMuscla® in Italy, offering the first licensed treatment for non-dystrophic myotonia.
Lupin wins FDA approval for Ipratropium Bromide Nasal Spray, a generic Atrovent® alternative for cold and allergy relief.
Argonaut and Akoya expand their partnership to produce IVD assays, advancing precision medicine with superior diagnostics.
Zentalis restructures to advance azenosertib, extending cash runway to support key trial results expected by late 2026.
Lantheus acquires Evergreen for up to $1B, strengthening radiopharmaceutical production and expanding cancer diagnostics.
Zentalis shares promising azenosertib monotherapy results in Cyclin E1+ PROC, with potential for accelerated FDA approval.
Adial Pharmaceuticals finalizes the AD04 study, confirming predictable absorption and FDA submission for AUD treatment trials.
aTyr Pharma will showcase three efzofitimod studies on pulmonary sarcoidosis at ATS 2025, sharing key trial insights.
TME Pharma teams up with Aimed Analytics to leverage AI, accelerating cancer drug research while cutting costs.
Explore cutting-edge biologics innovations, networking, and expert insights at the Biologics Workshop 2025 in Goa.
Julie Kim to succeed Christophe Weber as Takeda's CEO in June 2026, marking a new era for the pharma giant.
Cognizant earns Global Elite status in the ServiceNow Partner Program, reinforcing its leadership in AI-driven solutions.
Vertex’s JOURNAVX™, a non-opioid pain reliever, gets FDA approval, offering effective, addiction-free relief for acute pain.
Cognizant And Gilead Expand Their Partnership
HOOKIPA finishes enrolling 30 participants in its Phase 1b trial for HB-500, testing safety and immunity in HIV patients.
NATCO and Breckenridge launch a generic Everolimus TFOS in the U.S., providing a cost-effective option for TSC patients.
Cognizant deepens its collaboration with Medidata, utilizing AI and expertise to streamline clinical trials and improve patient outcomes.
Experts met in Goa to explore biosimilars, gene editing, and bioprocessing innovations at Biologics Workshop 2025.
Paolo Pozzi joins Steriline as Chief Service Officer, focusing on growth, innovation, and customer satisfaction.
Faisal G. Sukhtian is named chairman of Outlook Therapeutics’ Board, and Randy Thurman continued as lead independent director.
Lupin receives FDA approval for its generic version of Symtuza®, securing first-to-file exclusivity in the U.S. market.
Aplagon secures €7M in funding to advance its APAC therapy for thrombo-inflammatory diseases into Phase 2a clinical trials.
Sandoz announces Francisco Ballester’s retirement, with Peter Stenico succeeding him as President Region International, effective March 1, 2025.
Ocugen’s OCU400 earns EMA ATMP classification, advancing its Phase 3 trial for broad retinitis pigmentosa treatment.
PacBio appoints David Ruggiero as Global Head of Sales & Service to accelerate growth and customer engagement worldwide.
Entrada Therapeutics to begin a Phase 1/2 trial of ENTR-601-44 for Duchenne after securing MHRA authorization.
FDA supports Spur Therapeutics' Phase 3 trial of FLT201, a gene therapy for Gaucher disease, with potential for fast approval.
Serina Therapeutics closes $5M funding from JuvVentures, moving SER-252 into human trials for Parkinson’s in 2025.
uniQure's AMT-191 gene therapy for Fabry disease moves forward as the Phase I/IIa trial enters its second cohort.
Sernova seeks FDA approval to trial its Cell Pouch thyroid therapy, a potential long-term solution for hypothyroidism.
Cosette Pharmaceuticals names Brad Leonard as VP to drive generics commercial strategy and growth.
TriLink teams up with Avantor to enhance access to its nucleic acid technologies across EMEA, improving lead times.
Roche’s Susvimo gains FDA approval, providing a breakthrough treatment for diabetic macular edema with fewer injections.
Astellas Pharma is restructuring its management team, introducing new leadership roles to enhance R&D, commercialization, and compliance.
Outlook Therapeutics presents NORSE EIGHT trial data at the Virtual Investor “What This Means” segment and plans to resubmit ONS-5010 for FDA approval.
Jabil strengthens its Pharmaceutical Solutions portfolio with Pii acquisition, boosting aseptic filling and drug production capacity.
Bhavin Mehta joins Pharmexcil as Vice-Chairman, aiming to expand India’s pharmaceutical exports and MSME growth.
Astellas submits an NDA in Japan for ACP, aiming to bring the first GA treatment to patients facing progressive vision loss.
The Union Budget 2025-26 enhances India's healthcare, pharma, and medical R&D with key investments and reforms.
Eleva secures GMP production with 3PBIOVIAN, advancing Factor H (CPV-104) and expanding its moss-based expression system.
Vaxcyte's VAX-31 vaccine study progresses to Phase 2, bringing hope for preventing pneumococcal disease in infants! Data expected in 2026.
Aprea strengthens IP for ATR & WEE1 cancer therapies, securing patents till 2044, plus added exclusivity.
Amgen & Accumulus launched the first digital CMC dossier, revolutionizing global drug approvals with real-time access.
Myriad & Lumea integrate Prolaris and MyRisk tests into BxLink, cutting errors & delivering results in under 10 days.
Codexis welcomes Arthur Levin, PhD, a pioneer in RNA therapeutics, to its Strategic Advisory Board to support the expansion of its ECO Synthesis™ platform for enzymatic oligonucleotide manufacturing.
Lipella’s LP-310 gains FDA approval for expanded access, providing relief for oral lichen planus patients in need.
Tonix’s TNX-1500 demonstrates strong safety and efficacy in Phase 1, paving the way for Phase 2 kidney transplant trials.
Healthcare and pharma leaders applaud Union Budget 2025-2026; the pharma chiefs also appreciate the step towards healthcare, startups, and medical tourism.
FDA extends PDUFA date for Eton Pharmaceuticals’ ET-400 NDA, with approval expected by May 28, 2025.
BioMed X and Merck complete an oncology project on ecDNA, with findings acquired for potential cancer therapy development.
Senseonics files for CE Mark approval of Eversense 365, the only one-year continuous glucose monitor, aiming to bring long-term CGM benefits to European diabetes patients.
Alumis and ACELYRIN will merge, creating a $737M-backed immunology powerhouse with funding secured through 2027.
Pharma Now partners with PharmaTech Expo 2025, fostering pharma innovation in Bengaluru with 156 exhibitors and 4,000 attendees.
Santhera Pharmaceuticals appoints Catherine Isted as CFO, leveraging her expertise in biotech finance and corporate strategy.
Preliminary HLA data from the FLAMINGO-01 trial strengthens the outlook for GLSI-100 in breast cancer immunotherapy.
Dr. Joshua Bleharski joins IDEAYA as CFO, bringing years of biopharma finance expertise to fuel company growth.
GTx-104 reduced hypotension and improved outcomes in aSAH patients compared to oral nimodipine in Phase 3 trial.
Dr. Douglas Faller joins IMUNON as CMO to advance IMNN-001 for advanced ovarian cancer, with a Phase 3 trial set for early 2025.
Clearside unveils ODYSSEY Phase 2b results, guiding its Phase 3 trials for wet AMD treatment.
Achieve Life Sciences advances its NDA plans as the DSMC confirms strong safety data in its ORCA-OL smoking cessation trial.
Tempest’s amezalpat earns FDA Fast Track for liver cancer, showing strong survival benefits in trials.
ImmixBio’s NXC-201 earns FDA RMAT designation, accelerating development for relapsed AL amyloidosis therapy.
Dan Kirby joins Iovance as CCO, bringing decades of expertise to expand TIL therapy and Proleukin sales globally.
Medera’s CTScreen™ installed at UMC Utrecht, advancing cardiac disease modelling and drug screening with human-based tech.
Ashvattha’s subQ MGB shows promising Phase 2 data, cutting treatment burden in wet AMD & DME with strong safety results.
Palisade Bio’s PALI-2108 reduces UC symptoms in preclinical studies, showing strong potential for clinical use.
Oragenics and BRAINBox Solutions collaborate to create a breakthrough intranasal therapy and diagnostic platform for concussions.
Novartis is acquiring Anthos Therapeutics, strengthening its cardiovascular pipeline with abelacimab, a next-generation anticoagulant for stroke prevention.
PathAI and Rede D’Or collaborate to introduce AI-driven digital pathology, enhancing diagnostics and research in Brazil.
60 Degrees Pharma gains FDA approval to import KODATEF, ensuring continued malaria prophylaxis amid rising ARAKODA demand.
Bolt and Toray's collaboration targets Caprin-1, aiming to improve cancer treatments with innovative therapies.
Kiora Pharmaceuticals' KIO-104 approved for Phase 2 trial, aiming to treat retinal macular edema with fewer side effects.
Voyager shifts SOD1 ALS gene therapy focus, delaying IND filing to explore new payloads; cash runway to mid-2027.
FDA accepts Regeneron’s BLA resubmission for linvoseltamab in relapsed/refractory multiple myeloma; decision due July 2025.
Silo Pharma announces promising preclinical results for SP-26, a ketamine implant for chronic pain and fibromyalgia; final data due March.
Charles River and Deciphex deepen partnership to enhance AI tools, streamline toxicologic pathology workflows, and boost efficiency.
Experts at the 8th Annual Pharma Project & Portfolio Management 2025 explore AI, strategy, and industry innovation.
AbbVie and Xilio collaborate to develop novel tumor-activated immunotherapies, aiming for safer, more effective cancer treatments.
Genentech’s Evrysdi tablet gains FDA approval, providing a flexible and non-invasive treatment option for SMA patients.
MMS expands its expertise with the acquisition of Exploristics, enhancing biostatistics, data science, and clinical trial design.
HEJJE adds Dr. Prabhavathi R., a leading pediatrician specializing in neurodevelopmental disorders, to its expert healthcare team.
Synexa Life Sciences achieves the highest My Green Lab Certification, driving sustainability in lab operations and clinical research.
Robin Kenselaar is Orchard's new CCO, set to drive global strategy as the company advances gene therapies.
UK approves Telix’s Illuccix, a next-gen PET imaging agent that enhances prostate cancer detection and management.
NYBCe researchers identify immune pathways in Sickle Cell Disease, opening doors to innovative treatment approaches.
Theratechnologies has resumed EGRIFTA SV® distribution in the U.S. after FDA clearance, ensuring continued patient access.
Dr. Navin Saxena awarded Russia’s 'Order of Friendship' and 'Memorial Medal' for his contributions to science and Indo-Russian relations.
Lacutamab earns FDA Breakthrough Therapy status for relapsed Sézary syndrome, advancing treatment for rare T-cell lymphoma.
Dupixent gains FDA Priority Review for treating bullous pemphigoid, offering hope for patients with this severe skin condition.
Mukhtar Ahmed joins BC Platforms as CEO, bringing extensive expertise to advance real-world data innovation in life sciences.
AlgoTx’s ATX01 Phase 2 trial for neuropathic pain reports encouraging efficacy signals despite high placebo response.
Zymeworks appoints Oleg Nodelman, Founder of EcoR1 Capital, to its Board of Directors, reinforcing strategic leadership in biotech innovation.
Merck’s WELIREG receives EU approval for treating advanced RCC and VHL disease, bringing new hope to patients.
Biogen teams up with Stoke to develop zorevunersen, a potential first-in-class treatment for Dravet syndrome.
Cabaletta Bio reveals new data on rese-cel, highlighting its potential to treat autoimmune diseases without steroids.
Dr. Vivek Reddy to lead Orchestra BioMed’s BACKBEAT study, advancing AVIM therapy for patients with uncontrolled hypertension.
Opus Genetics doses first pediatric patient in its OPGx-LCA5 trial for Leber congenital amaurosis, with initial data expected by Q3 2025.
Supernus' SPN-820 misses primary and secondary endpoints in Phase 2b trial for treatment-resistant depression but remains safe.
Lexicon's study confirms sotagliflozin reduces MACE, heart attack, and stroke risk in T2D and CKD patients per SCORED trial.
Tiziana doses four more na-SPMS patients in expanded access for foralumab; 10 early patients show stability or improvement.
Queensland advances biotech, AI-driven healthcare, and clinical research partnerships with India at BioAsia 2025.
Acurx Pharmaceuticals earns a Japanese patent for DNA Polymerase IIIC inhibitors, advancing its innovative antibiotic research.
Amneal launches mesalamine tablets for ulcerative colitis and secures FDA approval for generic lenalidomide in the U.S.
ImmunityBio’s FDA-approved EAP offers a new BCG source to tackle bladder cancer drug shortages, effective in EU trials.
Adial wins a U.S. patent for genetic-based addiction treatment, enabling personalised therapy for alcohol and opioid disorders.
Milestone gains a U.S. patent for CARDAMYST’s repeat dose regimen, extending IP protection and awaiting FDA approval.
Chugai Pharmaceutical’s Tecentriq® (atezolizumab) gains Japan’s MHLW approval as the first immune checkpoint inhibitor for treating unresectable alveolar soft part sarcoma.
Terns Pharmaceuticals appoints Robert Azelby to its board, strengthening leadership in oncology and obesity research.
Elixirgen’s gene therapy EXG-34217 gains FDA Orphan Drug Designation for Telomere Biology Disorders treatment.
Roche’s SBX technology sets a new standard in high-speed, high-accuracy sequencing, transforming genomics and disease research.
Neurona advances NRTX-1001 to Phase 3, aiming to revolutionize treatment for drug-resistant epilepsy with cell therapy.
Inventiva and Hepalys launched a Phase 1 trial in Japan to assess the lanifibranor’s safety and support future MASH treatments.
Discover AI-driven drug discovery, compliance trends, and sustainability in Pharma Now’s Feb-Mar 2025 edition.
Dr. Gregory George joins Mesoblast’s Board, bringing expertise in medical innovation and commercial expansion.
Sandoz introduces Pyzchiva®, a biosimilar to Stelara®, expanding treatment access for chronic inflammatory diseases in the US.
Phase 2 trial data reveal Lusvertikimab’s efficacy in ulcerative colitis, achieving key remission and healing milestones.
Cellectis presents a breakthrough CAR T-cell strategy using IL-2 to boost solid tumor treatment at AACR-IO 2025.
Takeda’s new 2 mL pre-filled pen for TAKHZYRO® offers greater flexibility for hereditary angioedema patients in the EU.
NGM Bio’s Phase 2 trial of NGM120 aims to provide a breakthrough therapy for hyperemesis gravidarum by blocking GDF15.
Atea Pharmaceuticals appoints Arthur Kirsch to its Board, enhancing financial strategy for antiviral drug development.
BioMarin adds Timothy Walbert to its Board, leveraging his biotech leadership to advance innovative rare disease treatments.
ElevateBio’s LETI-101 achieves over 80% reduction of mutant huntingtin protein, showing promise for HD treatment.
PDS Biotech’s Versamune® HPV clears HPV16-positive tumor DNA, showing promise for HPV-related cancer treatment.
Calidi Biotherapeutics launches a new trial for CLD-101, aiming to improve treatment for high-grade glioma patients.
Kevin Springman joins Avadel Pharmaceuticals as VP of Sales to expand LUMRYZ’s reach in the sleep medicine market.
Russell Bradley joins CNSide Diagnostics as President to drive growth and market introduction for CNS cancer diagnostics.
Regeneron's DB-OTO trial shows improved hearing in children with genetic deafness, with near-normal results in some cases.
Inhibikase appoints top pharma executives, strengthening leadership in PAH research, development, and corporate strategy.
Bavarian Nordic and Biological E. partner to boost chikungunya vaccine access in LMICs through manufacturing expansion.
Oragenics’ Dr. James Kelly joins The Leigh Steinberg Foundation’s Medical Board to drive concussion research.
Andrew Gengos joins Terns Pharmaceuticals as CFO, bringing 25 years of biotech finance and strategy expertise.
ORIC Pharmaceuticals accelerates clinical plans for ORIC-944 and ORIC-114, extending its cash runway into 2027.
Celularity secures FDA TRG recommendations for Natalin and Acelagraft™, advancing its regenerative medicine portfolio.
Austria approves VAZKEPA® reimbursement, expanding access to cardiovascular care and strengthening Amarin’s European presence.
CAN-2409 trial shows long-term survival benefits for pancreatic cancer patients, offering new hope for treatment.
UZEDY’s sNDA accepted by FDA, marking a step toward long-acting treatment options for bipolar I disorder.
Telix’s TLX250-CDx for kidney cancer imaging gets FDA Priority Review, with a PDUFA date set for August 27, 2025.
Adial gains FDA support for AD04’s bridging strategy, advancing toward Phase 3 trials in 2025 for addiction therapy.
Allogene and Foresight partner to develop an MRD assay as a companion diagnostic for LBCL patients in the ALPHA3 trial.
Actuate enrolls 56 patients in its Phase 2 trial evaluating elraglusib, FOLFIRINOX, and losartan for metastatic pancreatic cancer.
LIXTE adds Lurie Cancer Center as a second site in its trial testing LB-100 and Dostarlimab for ovarian clear cell cancer.
Elixirgen reports the first-ever sustained telomere elongation in TBD patients using EXG-34217, with no safety concerns.
Lucid-MS, a neuroprotective MS drug by Quantum BioPharma, completes Phase 1 trial with no safety concerns.
Silo Pharma secures a new patent for SPC-15, an intranasal PTSD treatment, strengthening its intellectual property portfolio.
Renovaro and BioSymetrics merge to harness AI for biomarker discovery, precision medicine, and faster drug development.
Derm-Biome’s DB-007-5 surpasses top AD drugs in reducing itch and inflammation, showing promise for first-line treatment.
Rakovina and Variational AI strengthen their partnership to accelerate AI-powered cancer drug discovery.
IMUNON’s IMNN-101 vaccine demonstrates safety, strong immune response, and potential for future pandemics.
Humacyte launches Symvess, a bioengineered vessel designed to revolutionize emergency vascular repair and save limbs.
PDS Biotech’s immunotherapy Versamune® HPV shows promising clinical results in HPV-related cancers, per JAMA Oncology study.
Pharma leaders unite in Jordan for ARAB PHARMA MANUFACTURERS’ EXPO 2025, focusing on innovation and industry growth.
Hikma launches the first generic Mercaptopurine Oral Suspension in the US, gaining FDA approval and CGT exclusivity.
Nxera Pharma assigns APAC rights for cenerimod to Viatris, securing $10M and future milestone payments.
Cyclacel Pharmaceuticals names Datuk Dr. Doris Wong Sing Ee as CEO following a major ownership and leadership transition.
Myriad Genetics partners with Gabbi to integrate genetic testing with telehealth breast cancer risk assessment and specialist care.
Alumis unveils new data on A-005, a CNS-penetrant TYK2 inhibitor, with plans for a Phase 2 trial in multiple sclerosis.
Ocugen’s OCU410ST gains FDA backing for a Phase 2/3 trial, offering new hope for Stargardt disease patients.
Medicus Pharma begins a UAE clinical study for its non-invasive BCC treatment, strengthening its global development program.
It will bring together Europe’s top pharmaceutical outsourcing decision-makers, shining a spotlight on this rapidly growing industry.
NYBCe and Human Life CORD partner to advance MSC manufacturing, strengthening regenerative medicine supply worldwide.
AstraZeneca and Daiichi Sankyo’s Enhertu receives CHMP recommendation for EU approval in HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.
Novartis will showcase remibrutinib and Cosentyx® data at AAAAI/WAO and AAD 2025, supporting CSU regulatory filings.
Strand Life Sciences introduces the StrandOmics Portal to enhance rare disease diagnosis with faster genetic insights.
Valneva’s IXCHIQ® receives CHMP support for adolescent use, with EU approval expected in 60 days, boosting access.
Vincerx Pharma cancels reverse merger and explores strategic options, including M&A, asset sales, or winding down.
AbbVie and Gubra sign a licensing deal for GUB014295, a long-acting amylin analogue in Phase 1 trials for obesity.
Roche’s OUtMATCH study confirms Xolair’s effectiveness over OIT for food allergies, with fewer adverse events.
AstraZeneca’s Imfinzi gains EU backing for NSCLC, reducing recurrence risk by 32% in the AEGEAN trial.
Oryzon sets Phase III trial endpoints for vafidemstat in BPD, aligning with FDA standards and planning 2025 regulatory submission.
Australias TGA rejects lecanemab for early Alzheimers, disagreeing on safety for ApoE4 heterozygotes despite Eisais proposals
ACP-711 proves safe in Phase 1 study, prompting plans for further trials in elderly volunteers and higher doses.
Protagonist & Takeda’s rusfertide meets all endpoints in Phase 3 study, offering hope for polycythemia vera patients.
Seres Therapeutics receives FDA feedback on SER-155, planning next study to support allo-HSCT patients.
Pliant Therapeutics halts BEACON-IPF trial due to safety issues but sees early efficacy signs in pulmonary fibrosis treatment.
Genentech's TNKase gets FDA approval for acute ischemic stroke, providing a faster alternative to standard treatment.
Zentalis will showcase azenosertib data at SGO 2025, highlighting clinical updates and biomarker insights in ovarian cancer.
Acurx's ibezapolstat shows reduced gut microbiome disruption in CDI treatment, surpassing VAN and MET in a study.
Ocugen’s gene therapies for vision loss receive EMA backing, showing promise in treating GA and Stargardt disease.
Amneal’s denosumab biosimilars move forward with FDA review, aiming to compete in the $5B osteoporosis drug market.
ANI Pharmaceuticals secures FDA approval for a prefilled Cortrophin® Gel syringe, enhancing convenience for patients.
Adverum launches ARTEMIS Phase 3 trial for Ixo-vec, a gene therapy designed to reduce injections for wet AMD patients.
Baxter introduces Voalte Linq, a voice-activated wearable that enhances hospital communication and workflow efficiency.
FDA accepts Roche’s sBLA for Gazyva in lupus nephritis, based on positive Phase III REGENCY study results.
Nelson Labs introduces Rapid Sterility Testing at three sites, cutting testing time while ensuring regulatory compliance.
Evotec receives $20M from Bristol Myers Squibb as their neuroscience collaboration reaches a key milestone.
J&J names Darren Snellgrove VP of Investor Relations as Jessica Moore becomes CFO of Innovative Medicine.
New research confirms NXP900 boosts osimertinib’s effect in EGFR-mutated NSCLC, reducing resistance and tumour growth.
Tiziana submits IND for Phase 2 ALS trial of intranasal foralumab, aiming to improve treatment for neurodegenerative diseases.
Enzene’s Pune sites receive EU GMP certification, supporting commercial biologics production with advanced manufacturing tech.
Syner-G & Sequoia appoint Chris Erickson as COO, leveraging his 25+ years of experience to drive operational growth.
Aenova upgrades Bad Aibling site with €20M investment, enhancing blister and effervescent packaging capabilities.
Jazz acquires Chimerix for $935M, adding glioma treatment dordaviprone to its rare oncology pipeline.
Tenax increases TNX-103 trial enrollment and prepares for global Phase 3 study, aiming to advance PH-HFpEF treatment.
Certara appoints Adrian McKemey to lead drug development solutions, enhancing biosimulation and R&D strategy.
Vaxart's oral norovirus vaccine shows strong immune responses in older adults, published in Science Translational Medicine.
Circio's circVec platform shows 70x RNA durability vs. mRNA, opening new possibilities for gene and cell therapies.
Oryzon publishes a PMS study, paving the way for vafidemstat trials in precision psychiatry and rare CNS disorders.
Acadia’s DAFFODIL™ study affirms DAYBUE’s safety in Rett syndrome patients aged 2–4, reinforcing FDA-approved use.
aTyr Pharma’s Phase 3 EFZO-FIT™ study on efzofitimod advances smoothly after a positive safety assessment.
Ourvita expands in Asia with Braveiy acquisition, enhancing global manufacturing and innovation in health and wellness.
Sun Pharma expands oncology portfolio with Checkpoint acquisition, bringing FDA-approved UNLOXCYT to global markets.
OMLYCLO® becomes the first FDA-approved interchangeable biosimilar to XOLAIR®, expanding treatment access for allergy patients.
Novo Nordisk’s CagriSema shows major weight loss benefits for obesity and diabetes, with FDA filing expected in 2026.
VIVUS’ QSYMIA® gets UAE approval, expanding treatment options for obesity in adults and children aged 12 and older.
Dr. Mark Frohlich joins Rigel’s Board, adding expertise in oncology and immunotherapy to its leadership team.
Pittcon 2025 in Boston featured groundbreaking lab innovations, expert insights, and global scientific collaboration.
4D Molecular Therapeutics advances to Phase 3 with its 4D-150 gene therapy for wet AMD, aiming to reduce treatment burden and preserve vision.
Biodexa gains FDA guidance for its Phase 3 eRapa trial in FAP, setting the stage for patient enrollment next quarter.
Tevogen Bio patents an AI-powered T-cell vaccine designed to target entire viral genomes and enhance immune response.
CervoMed’s neflamapimod shows promising results in the 16-week extension phase of Phase 2b trial for dementia with Lewy bodies.
LIXTE announces findings on LB-100 activation, identifying a biomarker that may predict patient response to treatment.
Tonix receives MCDC funding for TNX-801, mpox and smallpox vaccine, supporting market analysis and commercialization.
The 9th Biologics Festival & 15th Vaccine World Summit 2025 drive innovation in India's biopharma industry.
Phase 3 results show vepdegestrant improves progression-free survival in ER+/HER2- metastatic breast cancer patients.
Olivia Brown joins Ipsen to drive global neurotoxins strategy, overseeing therapeutic and aesthetic growth initiatives.
Roche and Zealand Pharma collaborate to develop petrelintide, aiming to transform obesity care with innovative therapies.
Madrigal welcomes biotech leader Jackie Fouse to its board as the company expands MASH treatment efforts.
Kane Biotech marks a three-year deal with Best Buy Medical to expand revyve™ Antimicrobial Wound Gel in Canada.
Merck launches a $1B Durham vaccine plant, integrating AI, 3D printing, and digital twin tech for efficiency.
Cognizant and Boehringer launch a unified Veeva-powered platform, enhancing drug development and regulatory workflows.
aTyr Pharma’s efzofitimod study reveals its role in reducing lung inflammation and fibrosis via NRP2 targeting.
Portage Biotech resumes patient enrollment in the final dose escalation stage of its PORT-6 Phase 1b trial after a funding delay.
FDA expands ILUVIEN’s label to include chronic non-infectious uveitis, improving treatment options for patients.
Gradalis' study in Scientific Reports highlights exome sequencing to enhance cancer immunotherapy targeting.
Dyne’s DYNE-251 demonstrates sustained improvement in Duchenne patients, advancing toward potential FDA approval in 2026.
TRYVIO is now fully released from REMS, expanding access to patients with difficult-to-control hypertension.
ASIA LABEX 2025 unites experts, exhibitors, and innovators to showcase the latest lab advancements in Chandigarh.
Argent BioPharma reports positive Phase IIb results for CimetrA®, highlighting its safety, faster recovery, and anti-inflammatory potential.
AstraZeneca's acquisition of EsoBiotec aims to transform cell therapy, making treatments faster and more accessible.
BridgeBio Pharma welcomes Thomas Trimarchi as President & CFO while Brian Stephenson transitions to a consulting role.
Eneboparatide meets key endpoints in a Phase III trial, showing promise for chronic hypoparathyroidism treatment.
Pliant’s PLN-101095, combined with pembrolizumab, shows anti-tumor activity in ICI-refractory cancers in Phase 1 trial.
Telix’s Illuccix® secures ANVISA approval, bringing advanced PSMA-PET imaging to prostate cancer patients in Brazil.
AstraZeneca’s Imfinzi secures EU approval, offering a new immunotherapy option for limited-stage small cell lung cancer.
Perspective Therapeutics doses first patient in a new cohort studying [212Pb]VMT01 with nivolumab for melanoma treatment.
Greenwich LifeSciences’ FLAMINGO-01 trial confirms GLSI-100’s strong safety profile, with no serious adverse events.
Capricor’s HOPE-2 trial data shows deramiocel preserves muscle function, slowing Duchenne muscular dystrophy progression.
Genmab’s Rina-S achieves a 55.6% response rate in ovarian cancer, with Phase 3 trials underway for further evaluation.
AstraZeneca licenses ALT-B4 from Alteogen to develop subcutaneous cancer treatments, improving patient convenience.
SIGA adds General Jack Keane to its board, enhancing biodefense strategy with his national security expertise.
Whitehawk Therapeutics unveils its new name and vision, accelerating next-gen ADCs for cancer treatment.
Chugai introduces LUNSUMIO, a bispecific antibody, as a new treatment for relapsed follicular lymphoma in Japan.
FDA accepts BLA for AVT03, a proposed biosimilar to Prolia® and Xgeva®, developed by Alvotech and Dr. Reddy’s.
Allogenica receives €2.5M to scale its universal CAR-T therapy, offering a cost-effective solution for blood cancer patients.
ANI Pharmaceuticals introduces Nitazoxanide Tablets, offering a cost-effective alternative for patients nationwide.
Auron Therapeutics names Glenn Goddard as CFO, strengthening financial strategy as it advances groundbreaking therapies.
Todd Baumgartner joins Applied Therapeutics as Chief Regulatory Officer to lead global regulatory strategy for rare disease therapies.
Join the London Biotechnology Show 2025 at ExCeL London for cutting-edge insights, networking, and industry advancements.
Recognizing top pharma quality teams for innovation, reliability, and industry leadership. Nominate today!
Join industry leaders in Mumbai for Pharma GMP & Quality 2025, focusing on compliance, AI, and manufacturing excellence.
Merck unveils breakthrough research on PAH & cholesterol management at ACC.25, shaping the future of heart health.
Join top EHS leaders at the 2nd EHS for Biopharma East Summit 2025 to explore safety, sustainability, and compliance trends.
Sanofi strengthens its immunology pipeline by acquiring DR-0201, a novel B-cell depletion therapy for autoimmune diseases.
Alvotech expands R&D with Xbrane’s acquisition, strengthening biosimilar development and establishing a Swedish presence.
Infinitopes welcomes biotech leaders Dan Menichella & Jo Brewer to its board as it moves its cancer vaccine ITOP1 into clinical trials.
Novartis' gene therapy OAV101 IT improves motor function in SMA patients, marking a major step forward in treatment.
Dr. Igor Matushansky joins Immuneering to lead clinical trials for cutting-edge cancer therapies, including IMM-1-104.
Plus Therapeutics secures FDA conditional acceptance for REYOBIQ™, its lead radiotherapeutic for CNS cancers, boosting brand recognition.
CARBIOS names Isabelle Parize as Chairwoman and Vincent Kamel as CEO, following Philippe Pouletty’s resignation.
FDA approves Telix’s Gozellix®, improving PSMA-PET imaging access for prostate cancer patients across the U.S.
Harbour BioMed and AstraZeneca team up on next-gen antibody therapies, with a $105M investment and $4.7B in milestone payments.
CStone applies for EMA approval of sugemalimab in stage III NSCLC, backed by strong GEMSTONE-301 Phase III trial results.
Everest’s EVM14, an mRNA cancer vaccine for NSCLC and HNSCC, gets FDA IND clearance, marking a key milestone.
Junshi Biosciences’ Toripalimab-Bevacizumab Combo Gains NMPA Approval for First-Line Advanced Liver Cancer Treatment
Newronika’s AlphaDBS receives CE Mark, bringing adaptive deep brain stimulation to Parkinson’s patients in Europe.
DBV's Viaskin peanut patch for 4–7-year-olds advances toward FDA approval with VITESSE data, accelerating its launch.
Novo Nordisk secures global rights (ex. China) for UBT251, a next-gen obesity & diabetes drug, in a $2B deal with TUL.
Elicio Therapeutics names Dr. Preetam Shah as CFO, strengthening its leadership in cancer immunotherapy innovation.
PharmAla partners with a U.S. logistics firm to enhance MDMA clinical trial distribution and mitigate import risks.
The FDA is reviewing tolebrutinib to slow MS-related disability, with a decision expected by September 2025.
Tempero Bio starts a Phase 2 trial for TMP-301, an mGluR5 NAM for alcohol use disorder, under a deal with Nxera.
New data from Onconetix’s Proclarix® confirms high accuracy in prostate cancer detection, reducing false positives.
Alumis teams up with Kaken to bring ESK-001, a next-gen TYK2 inhibitor, to Japanese patients with immune disorders.
AstraZeneca’s Tagrisso shows strong results at ELCC 2025, extending survival and quality of life for lung cancer patients.
Hikma strengthens its US portfolio with Cisatracurium Besylate Injection, supporting anesthesia and critical care.
TFS HealthScience appoints Miriam Martin as VP of Business Development, strengthening strategic growth and clinical innovation.
Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal worth up to $1.97 billion.
Charles River and Valo Health’s AI-powered Logica® identifies a potential lupus treatment, accelerating drug discovery.
Elutia’s antibiotic-eluting bioenvelope eradicates bacteria, showing promise in preventing CIED infections.
David Banko joins Tevogen Bio as Global Head of Government Affairs, driving patient access and commercialization strategies.
Sanofi’s mRNA chlamydia vaccine moves forward with FDA fast track, aiming to combat rising global infection rates.
Jane Healy joins Photocure as GM EMEA, bringing decades of expertise to drive growth in uro-oncology across Europe.
Alvotech, Kashiv, and Advanz Pharma announce MHRA acceptance of AVT23, a biosimilar to Xolair® for asthma and nasal polyps.
Shane Olwill joins Asgard Therapeutics as CDO to lead the development of AT-108, a breakthrough cancer immunotherapy.
Avalo Therapeutics welcomes Michael Heffernan as Chairman to drive growth and pipeline expansion in immune-mediated diseases.
Intellia’s NTLA-2001 earns FDA RMAT designation, accelerating its development for transthyretin amyloidosis with cardiomyopathy.
Join biopharma experts in San Francisco for key insights on biotech, biomanufacturing, and future innovations.
Pittcon 2027 brings global scientists back to Pittsburgh, marking 60 years since its last event in the city.
Ajay Royan rejoins Invivyd’s Board to support breakthrough monoclonal antibody treatments for high-risk patients.
Chugai’s Evrysdi tablet offers SMA patients a more convenient treatment option with easier storage and administration.
Alvotech welcomes Dr. Balaji Prasad as Chief Strategy Officer to advance biosimilar innovation and global market expansion.
BridgeBio receives Japanese approval for Beyonttra (acoramidis) to treat ATTR-CM, with Alexion leading commercialization and a $30M milestone payment.
LIXTE Biotechnology updates on LB-100 trials for ovarian and colorectal cancer, progressing with GSK and Roche collaborations.
CPHI Americas 2025 gathers pharma leaders in Philadelphia for three days of networking, innovation, and collaboration.
Merck’s subcutaneous pembrolizumab meets key endpoints in Phase 3 trial, showing promise for lung cancer treatment.
PacBio names Jim Gibson as CFO, tapping into his leadership experience from Tesla, Apple, and Netflix to fuel growth.
Regeneron and Sanofi’s Dupixent receives approval in Japan for COPD, offering new hope for patients with uncontrolled disease.
IASO Bio secures NDA approval in Macau for Equecabtagene Autoleucel, a breakthrough for relapsed multiple myeloma.
Chugai and IFReC uncover FOXP3’s regulatory network, opening doors to innovative autoimmune disease treatments.
Elutia teams up with Advantus to offer EluPro™, an FDA-cleared antibiotic-eluting BioEnvelope, through GPO networks.
Genmab’s TIVDAK gets Japan’s first ADC approval for advanced cervical cancer, cutting death risk by 30% in trials.
FDA flags manufacturing and impurity issues in CARDAMYST review; Milestone to work on resubmission for approval.
Langhua Pharmaceutical passes its fourth FDA inspection, boosting its global CDMO services for small-molecule drug development.
CDMO Live 2025 unites pharma leaders in Rotterdam to discuss outsourcing, innovation, and strategic partnerships.
Novartis promotes Karen Hale to Chief Legal & Compliance Officer as Klaus Moosmayer steps down in April 2025.
AstraZeneca’s Calquence receives CHMP recommendation, showing a 27% risk reduction in MCL progression or death.
Valneva applies for UK approval to extend IXCHIQ® use to adolescents, following EMA’s positive opinion.
AAVantgarde and TIGEM's study in Science Advances highlights a novel AAV-based gene therapy for Stargardt’s disease.
IDEAYA’s darovasertib gets FDA Breakthrough Therapy status for neoadjuvant uveal melanoma treatment, advancing to Phase 3.
Kenan Thompson shares his GERD journey with Phathom to help others find relief and spark conversations on treatment.
Merck’s WINREVAIR™ delivers a 76% risk reduction in PAH mortality & hospitalization in a groundbreaking clinical trial.
TransCon CNP, a weekly treatment for achondroplasia, shows promise in growth, muscle function, and leg straightening.
Nxera Pharma appoints Kiyoshi Kaneko as CCO and promotes Mariko Nakafuji to CLO to support global expansion.
TEV-'749 receives strong patient and provider satisfaction in the SOLARIS trial, presented at SIRS 2025.
LIXTE and NKI launch a pre-clinical study to explore LB-100’s ability to eliminate early cancer-linked cells.
TIVDAK earns EU approval, becoming the first ADC for recurrent or metastatic cervical cancer, improving survival rates.
Telix initiates the ZOLAR trial, exploring TLX300-CDx as a theranostic solution for metastatic soft tissue sarcoma.
TONIX ONE™ integrates telehealth, e-prescriptions, and symptom tracking to simplify migraine management.
The EU grants approval for Valneva’s IXCHIQ® vaccine in adolescents, expanding protection against chikungunya.
Amneal and Shilpa debut BORUZU™, a ready-to-use bortezomib injection for multiple myeloma and lymphoma, simplifying prep.
Apellis’ EMPAVELI® for rare kidney diseases gets FDA Priority Review; intense Phase 3 results support approval bid.
Inventiva enrolls 1,419 patients in Phase 3 trial for lanifibranor, a potential MASH treatment; results expected in H2 2026.
Join experts at Pharma Sterile & Injectables 2025 to explore innovations, regulations, and best practices in manufacturing.
Rilzabrutinib receives FDA orphan drug status for wAIHA & IgG4-RD, marking progress in rare disease treatment.
Novo Nordisk restructures its executive team as Camilla Sylvest steps down, appointing new leaders in key strategic roles.
Roche’s Phase III MUSETTE trial confirms OCREVUS 600 mg as optimal for MS, showing record-low relapse rates.
Algorae welcomes Vishal Shah as CCO, leveraging his 20+ years of pharma leadership to fuel growth and innovation.
Anne Whitaker joins Telix as Non-Executive Director, bringing global pharma and Nasdaq governance expertise.
Globus Medical completes Nevro acquisition, unlocking a $2.5B chronic pain and neuromodulation market.
Argent BioPharma gains approval for CannEpil™ in Germany, expanding access for patients with refractory epilepsy.
GSK partners with ABL Bio for £2B+ deal to develop neurodegenerative therapies using Grabody-B BBB platform.
LIfT BioSciences names Mark Exley CSO to steer clinical launch of its neutrophil-based cancer immunotherapy.
Telix names Dr. Paul Schaffer CTO, boosting its radiopharma leadership with expertise in isotope technology.
SkyCell partners with Microsoft to embed AI in Teams, improving pharma logistics with real-time insights and alerts.
India’s pharma sector gains profit from Trump’s tariff relief on medicines, boosting exports and bilateral trade ties.
Jeune Aesthetics taps BOTOX® leader Marc Forth as CEO to drive growth in skin rejuvenation therapies.
ImmuCell taps IDEXX veteran Timothy Fiori as CFO to strengthen financial strategy and fuel future growth.
The KAFTRIO label expands in the EU to treat younger patients with non-class I mutations, allowing broader access in key countries.
AbbVie's RINVOQ becomes first oral therapy approved in EU for giant cell arteritis, offering new hope to patients.
EC approves subcutaneous RYBREVANT® + LAZCLUZE® for NSCLC with EGFR mutations using Halozyme's ENHANZE® drug delivery technology.
Rhythm’s Phase 3 trial shows major BMI reduction in rare hypothalamic obesity, FDA filing set for Q3 2025.
Troculeucel shows improved cognition and biomarker shifts in small Alzheimer’s study—Phase 2a now underway.
MaaT033 safely passes Phase 2b checkpoint in stem cell transplant patients, trial advances across Europe.
Veranova appoints Dr. Zugel as Global VP of Analytical Ops, boosting R&D with deep industry and GMP lab experience.
Health Canada grants Priority Review to AGAMREE, a potential first DMD treatment in Canada by end of 2025.
J&J’s nipocalimab shows durable gMG benefits, improving symptoms and reducing steroid use in Phase 3/OLE data.
Indivumed unveils novel cancer targets, expands leadership, and accelerates CRC drug discovery with AI and biobank.
Valneva and LimmaTech launch Phase 2 infant trial for S4V2, a vaccine to prevent life-threatening shigellosis.
Artiva appoints Dr. Banerjee as CMO to accelerate AlloNK’s development for autoimmune diseases.
ValoTx appoints Marcella Origgi as CEO to lead PeptiCRAd-1 trials and global immuno-oncology efforts.
The FDA accepted Outlook's ONS-5010 BLA with the Aug 27, 2025, PDUFA goal based on the clinical trial data.
Tolebrutinib delays MS disability in nrSPMS patients, NEJM publishes results; FDA review set for Sep 28, 2025
Cytosurge appoints Simon Egli as CEO; co-founder Pascal Behr to guide strategy as Board Delegate in 2025.
TRYVIO label updated by FDA, removing REMS and enabling broader use for resistant hypertension patients in retail.
Corvus welcomes biotech leader Richard van den Broek to its board, supporting ITK inhibitor clinical strategy.
Tonix and Makana team up to combine TNX-1500 with GE pig organs for xenotransplantation therapy development.
Grace Therapeutics receives FDA guidance supporting NDA submission for GTx-104 IV nimodipine in aSAH treatment.
Tevogen Generics launches to lower drug costs and expand U.S. pharma manufacturing; Sadiq Khan named interim lead.
IDEAYA launches Phase 1/2 expansion of IDE397–Trodelvy combo trial for MTAP-deletion urothelial cancer patients.
Pharma Live 2025 hits Mumbai April 17–19 with 35K+ attendees, 200+ exhibitors & keynotes on AI, diagnostics, APIs.
Pharma Now joined INTERPHEX 2025 in NYC, featuring Learning Labs, tech demos, and key pharma partnerships.
Arcutis CFO David Topper to retire in May; Latha Vairavan steps in to lead financial operations amid company growth.
Circio signs agreement with Lonza to evaluate circular mRNA technology in Lonza's expression system for protein production.
Jennifer Cote steps down as CFO of Harvard Bioscience; Mark Frost named interim replacement with effect in May.
CRL launches Single-Use Gamma Bags, engineered for gamma sterilization to meet pharma and biotech standards.
Icotrokinra shows significant skin clearance and safety in adolescents with plaque psoriasis in Phase 3 trial data.
Baxter introduces Hemopatch with room temperature storage, enhancing access for bleeding control in surgeries across Europe.
Shuttle Pharma advances PSMA-targeted cancer therapy with a new patent for PARP conjugates in metastatic prostate cancer.
Phase 1/2a trial of [212Pb]VMT01 starts monotherapy cohort for metastatic melanoma, including brain metastases.
Sun Pharma appoints Shaik Barak Tulla as SVP to drive commercial excellence and global business growth.
Eyestem reports promising vision improvement and safety in Phase 1 trial for dry AMD cell therapy Eyecyte-RPE™.
Roche's Columvi + GemOx was approved in the EU for relapsed/refractory DLBCL, doubling survival compared to standard therapy.
IDEAYA wins FDA backing to start Phase 3 trial of darovasertib in primary uveal melanoma patients.
Celularity supports CMS move delaying LCD on wound care, preserving Medicare access and enabling reform talks.
Cue and Boehringer collaborate on targeted T-cell therapy to transform autoimmune disease treatment.
Sanofi’s amlitelimab shows efficacy in inflammatory asthma; the pipeline expands with multiple Phase 2/3 studies in respiratory disease.
Lifecore welcomes Tom Salus as Chief Legal Officer, bringing 30+ years of legal and life sciences expertise.
MetaVia's DA-1726 achieves 6.3% weight loss with good tolerability in Phase 1 trial; shows promise for obesity and T2D.
Wiley teams up with Anatek to provide advanced spectral databases and tools to analytical labs across India.
Charlotte Moser joins Parexel as CMO, bringing 25+ years of leadership in clinical development and oncology research.
Vivani and Okava broaden OKV-119 development for ageing dogs, aiming to tackle obesity and diabetes and extend lifespans.
Telix’s TLX101 extends survival in recurrent glioma; early Phase 2 data confirms safety and efficacy at NMN Symposium.
Nobel Prize winner Dan Shechtman joins NeuroNOS’s SAB to support breakthrough ASD and Alzheimer’s research.
Dr. Rebecca Taub becomes advisor; Dr. David Soergel named CMO as Madrigal advances MASH treatment pipeline.
Industry leaders shared practical strategies and insights on aseptic processes at Pharma Now’s 2025 event in Ahmedabad.
Phathom adds Ted Schroeder to its Board to strengthen commercial strategy and expand VOQUEZNA®’s reach.
ACIP recommends Bavarian Nordic’s VIMKUNYA™ single-dose chikungunya vaccine for at-risk travellers and lab workers.
Scilex gains FDA orphan designation for colchicine in pericarditis, expanding beyond pain into rare inflammatory diseases.
Addex regains ADX71149 rights as Janssen exits the epilepsy program; the partnership officially ends with the return of asset rights.
Vabysmo improves vision and retinal swelling in angioid streaks. Patients meet Phase III endpoints with a good safety profile.
Dr. Robert Langer joins Decoy Therapeutics' SAB post-Salarius merger, enhancing innovation in peptide therapeutics.
Werewolf appoints Steven Bloom as CBO to drive growth as it advances breakthrough immunotherapy programs.
Design Therapeutics welcomes Dr. Storgard as CMO to advance clinical milestones for genetic disease treatments.
NewAmsterdam appoints pharma veteran Adele Gulfo to its board, enhancing leadership with decades of industry success.
Tevogen Bio collaborates with CD8 to develop a facility that enables in-house research and GMP cell therapy production.
BVI Medical's FDA-cleared Leos™ system revolutionises glaucoma care with advanced laser and imaging technology.
Africa CDC and WHO updated the mpox plan to boost control, vaccines, and resilience amid the global case surge.
Atea names Dr. Berman as Board observer under new deal with Radoff-JEC Group, who will support nominees at the 2025 vote
Lilly’s oral GLP-1 drug, orforglipron, shows strong results in type 2 diabetes and weight management trial.
Biotech leader Craig Wheeler joins Apellis Board to boost innovation and advance strategic vision in groundbreaking C3 therapies. Read More!
Enhertu plus pertuzumab demonstrates superior progression-free survival compared to THP in patients with HER2+ metastatic breast cancer. Read more!
Medicus expands SKNJCT-003 trial to 90 patients after IRB approval; interim data shows strong efficacy and safety for treating BCC.
Achieve’s cytisinicline Phase 3 results published in JAMA, showing strong efficacy and tolerability for smoking cessation; NDA planned for June 2025.
Jazz completes $935M Chimerix acquisition, gains promising brain cancer drug dordaviprone, under FDA Priority Review with a PDUFA date in August 2025.
NeuroNOS receives FDA Orphan Drug Designation for BA-102, a therapy targeting autism-linked Phelan-McDermid Syndrome.
NeuroNOS receives FDA Orphan Drug Designation for BA-102, a therapy targeting autism-linked Phelan-McDermid Syndrome.
Roche to invest $50B in the U.S. over 5 years, creating 12,000+ jobs and expanding R&D, manufacturing, and diagnostics capabilities.
Sun Pharma & Ambuja Foundation start a 4-year water management project in Dhari, Gujarat, to improve irrigation, farming, and groundwater for 40 villages.
HUTCHMED completes Phase II enrollment for savolitinib in MET+ gastric cancer, aims for China approval in 2025.
Cassava announces Dr. Kupiec’s retirement and Dr. Moore’s appointment as Senior VP of Clinical Development, effective April 2025.
Rob Bancroft appointed CEO of AEON Biopharma, bringing 25+ years of life sciences leadership.
Rona Therapeutics gets NMPA approval for RN1871, an siRNA drug for hypertension, advancing to clinical trials in China.
BiomatiQ inaugurates world-class life science manufacturing facility in Hyderabad to advance life science manufacturing in India.
Abivax adds Dr. Dominik Höchli to Board, strengthening leadership ahead of Phase 3 ulcerative colitis data expected in Q3 2025.
Regeneron to nearly double biologics manufacturing through Fujifilm partnership, boosting U.S. capacity with a $3B+ investment and expanded job creation.
- Charles River reveals new cancer research platforms ahead of AACR 2025, including AI-driven analysis, humanised models, and 3D tumour screening tech.
1Cell.Ai launches OncoIncytes to power next-gen precision oncology with AI and single-cell insights.
- MetaVia’s DA-1726 demonstrates promising weight loss and safety in Phase 1 trial, with follow-up studies planned targeting Wegovy dropouts.
Tagworks starts Phase 1 trial of TGW101, a novel ADC; appoints Keith Orford as Chief Medical Officer.
Ascletis reports strong Phase Ib results for oral GLP-1R agonist ASC30 in obesity and submits 13-week Phase IIa study plan to FDA.
Gannet BioChem appoints Dr. Harry Rathore to its Board, bringing 35+ years of expertise to drive growth in specialty chemicals and CDMO services.
Roche's Chest Pain Triage algorithm earns CE mark, enhancing ACS detection and emergency care with AI-driven diagnostics via navify Algorithm Suite.
Voyager SPAC to merge with VERAXA Biotech, creating a Nasdaq-listed firm focused on next-gen cancer therapies.
DIOSynVax and ACM Biolabs team up on a universal bird flu vaccine, aiming for needle-free, global pandemic protection.